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Summary 
Statins are 3-hydroxy, 3-methylglutaryl coenzyme A (HMG-CoA) reductase 
inhibitors, which block the cholesterol biosynthetic pathway to lower serum total 
and LDL-cholesterol. However, the cholesterol pathway also provides a supply of 
isoprenoids (farnesyl and geranylgeranyl) for the prenylation of signalling 
molecules, which include the Ras and Rho families of GTPases. Prenyl groups 
provide a membrane anchor that is essential for the correct membrane localisation 
and function of these proteins. An alternative explanation for the disruption of 
signalling pathways is that cholesterol depletion disrupts cholesterol and 
sphingolipid rich micro-domains - termed membrane rafts. Rafts playa central 
role in signal transduction in immune effector cells by providing a platform that 
physically concentrates receptors, downstream kinases and adaptor proteins 
involved in signalling pathways. Clustering of raft components upon receptor 
ligation and cross-linking increases the local concentration of signalling molecules, 
facilitating or triggering the generation of signals. 
In this thesis, the pleiotropic effects of statins on the disruption of prenylation and 
membrane rafts were investigated in immune effector cells. T cells and NK cells 
were extracted from various groups of patients treated with statins and 
proliferation and cytotoxicity respectively, measured ex vivo. In a study of patients 
with cardiovascular disease, a 23% reduction in T cell proliferation and 43% 
reduction in NK cytotoxicity were observed. In a normal volunteer study where 
healthy subjects received simvastatin (40mg per day) for 4 weeks, a comparable 
reduction in T cell proliferation was not apparent, however a 30% reduction in NK 
cytotoxicity was observed. In vitro statin treatment further reduced proliferation 
and cytotoxicity whereas addition of farnesyl and geranylgeranyl transferase 
inhibitors had little or no effect. Addition of farnesol and geranylgeraniol groups 
failed to rescue statin inhibited T cell proliferation indicating that inhibition of 
prenylation is likely to have less of an impact than membrane raft disruption. A 
final study of ex vivo NK cytotoxicity was performed in a diverse group of patients. 
It revealed a trend towards higher levels of cytotoxicity at higher cholesterol levels 
and although statin therapy reduced NK cell killing in individuals, statin-treated 
patients had levels of NK cell killing appropriate for their total cholesterol. 
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The effect of statins on prenylation of small GTPases was studied in the U937 
monocyte cell line and primary human T cells. U 937 cells treated with statins were 
separated into cytosolic and membrane components and visualised by western 
blot. Reductions of GTPases were observed in membrane compartments with 
corresponding increases in cytosolic compartments. Unprenylated Ras was also 
observed as a band shift. Ras and Rac activity was reduced in primary human T 
cells treated with statin. Corresponding downstream signalling molecules ERK 
and P38 were also reduced by statin treatment and this was confirmed in the U937 
cell line. 
Cholesterol reduction in membrane rafts by statins were then analysed using the 
U937 cell line and the NK92MI cell line. Both fluvastatin and simvastatin reduced 
membrane raft associated proteins LAT and Lyn in a dose dependent manner in 
U937 cells and NK92MI cells. FTI and GGTls had no effect on rafts and 
mevalonate rescued the statin inhibition, indicating that prenylation did not affect 
rafts and cholesterol depletion within the rafts could be recovered by restoration of 
cholesterol biosynthesis. Similar results obtained from the cholesterol chelator 
MPCD, confirmed that statins reduced cholesterol within the membrane to alter 
the density of rafts. 
The functional effect of statins on Fc receptor signalling in monocytes was 
investigated using the U937 cell line. Tyrosine phoshorylation of cross-linked 
FcyR was time and dose dependently inhibited by statins, as was the corresponding 
downstream signalling molecules ERK and P38. FcyR immune complex 
internalisation and trafficking and release of MMP-l, IL-6, IL-8 and IL-10 
inflammatory cytokines was reduced dose dependently by fluvastatin and 
simvastatin and unaffected by FTI and GGTI. ERK and P38 inhibitors 
demonstrated that IL-6 release involves both the ERK and P38 signalling pathways 
whereas MMP-l release involves the ERK pathway, but not the P38 pathway. 
The functional effects of statins on lymphocytes were finally investigated in human 
T cells and the NK92MI cell line. Primary human T cell proliferation was 
measured in vitro. Fluvastatin reduced proliferation while mevalonate rescued the 
inhibition and FTI and GGTI had no effect. Statins minimally reduced NK cell 
proliferation and dose dependently reduced NK cytotoxicity as measured in the 
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NK92MI cell line. Mevalonate rescued the inhibition and FTI and GGTI had no 
effect. Low concentrations of MpCD in the presence of cholesterol increased NK 
cytotoxicity, but at higher concentrations acted as a chelator to remove cholesterol 
from membranes and reduced cytotoxicity. I concluded that the pleiotropic effect 
of statins was due to raft disruption rather than inhibition of prenylation. 
In conclusion, this thesis has demonstrated that statins have a multitude of 
applications and effects. The pleiotropism of statins due to reduced prenylation 
was observed in vitro by western blot in multiple signalling pathways and 
confirmed with the use of FT and GGT inhibitors in these pathways. However, the 
lack of functional effect of FT and GGTIs indicated that prenylation has a lesser 
impact on the functions of immune effector cells than cholesterol depletion of 
rafts. The comparable results obtained with MPCD indicated that the reduction of 
cholesterol in the membrane by statins was disrupting rafts and therefore 
disrupting signalling pathways to a greater extent than prenylation inhibition. It is 
however likely to be a combination of both processes that contributes to the 
pleiotropic effect of statins. 
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chaffer 1: Introduction 
1.1 Cholesterol pathway 
1.1.1 Products of mevalonate 
Statins are 3-hydroxy, 3-methylglutaryl coenzyme A (HMG-CoA) reductase 
inhibitors that block the cholesterol biosynthetic pathway! (Figure 1.1). 
Cholesterol is required for the synthesis of steroid hormones, vitamin D, bile acids 
and lipoproteins and it is therefore important to maintain intracellular levels. 
Reduction of intracellular cholesterol stores activate sterol-responsive-element-
binding proteins, leading to increased transcription of the LDL receptor gene and 
expression of cell surface receptor and aids the clearance of LDL from plasma, 
therefore restoring intracellular homeostasis. Other products of HMG-CoA 
include, dolichol, haem, ubiquinone and isoprenylated proteins. Cells can also 
regulate mevalonate disposition. Non-sterol pathway enzymes have higher 
affinities for mevalonate-derived substrates than sterol pathway enzymes. The 
first committed enzyme of sterol synthesis, squalene synthetase, is suppressed by 
the presence of sterols, thereby limiting incorporation of mevalonate into further 
sterols and favouring the high affinity non-sterol pathways. 
1.1.2 Biochemistry 
1.1.2.1 HMG-CoA biochemistry 
Conversion of HMG-CoA to mevalonate, catalysed by HMG-CoA reductase, is the 
rate limiting step of the cholesterol pathway and proceeds in three stages, the first 
and third of which are reductive2 (Figure 1.2). 
1.1.2.2 Statin biochemistry 
Statins share a structural component that is similar to, but more bulky and 
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Figure 1.1 The Mevalonate pathway. 
Cholesterol can be produced from two different sources: 1) endogenously by 
synthesis from mevalonate metabolism and 2) exogenously from receptor-
mediated uptake of plasma LDL. The balance of sources is achieved through 
feedback regulation. In the absence of LDL high activities of HMG-CoA synthase 
and reductase are maintained, and decline in the presence of LDL. When 
cholesterol accumulates, LDL receptors are repressed to prevent further uptake. 
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Figure 1.2 The reaction catalyzed by HMG-CoA reductase. 
The reversible four-electron reductive deacylation of HMG-CoA to mevalonate 
involves mevaldyl-CoA and mevaldeyde as enzyme-bound intermediates. 
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hydrophobic, than the HMG portion of HMG-CoA. This interacts with the active 
site (CoA recognition site) of HMG-CoA reductase and competes with HMG-CoA 
for binding. A conformational change in the reductase allows movement of flexible 
C terminal alpha helices to expose a shallow hydrophobic binding site for the bulky 
hydrophobic groups of the statin molecule. The statin side chains mimic 
mevalonate and therefore sterically hinder substrate binding by blocking access of 
the substrate to the enzyme's active site3• The affinity of statins for the active site 
is several orders of magnitude higher than HMG-CoA, which leads to effective 
displacement of the natural substrate and inhibition of endogenous cholesterol 
synthesis4. 
Mevastatin was first identified in the mould Penicillium citrinium5 and Aspergillus 
terreus naturally produces lovastatin. Lovastatin, simvastatin and pravastatin 
have a hydronapthalene ring that interacts with the coenzyme A recognition site 
and a hydroxy acid side chain that mimics mevalonate6 . Simvastatin and 
pravastatin (Type 1 statins) are produced from lovastatin by chemical modification 
(Figure 1.3). Fluvastatin (Type 2 statin) was the first totally synthetic HMG-CoA 
reductase inhibitor and is a mevalonolactone derivative of a fluorophenyl-
substituted indole ring. The fluorophenyl indole portion of fluvastatin mimics CoA 
in interacting with HMG-CoA reductase and the side chain mimics mevalonate 
(Figure 1.3). 
The mean inhibitory concentrations for some statins are shown in table 1.1. 
1.1.3 Statin Pharmacology 
Atorvastatin, cerivastatin, lovastatin and simvastatin utilise the P450 (CYP) 3A4 
pathway for metabolism or biotransformation7 where as fluvastatin metabolism 
occurs via CYP2C98. Pravastatin and rosuvastatin does not use the CYP pathway 
significantly. The concomitant use of 2 drugs that are both metabolised by the 
CYP3A4 pathway compete for that pathway which results in increased serum 
concentrations of both drugs9• Other drugs that may cause concern when used in 
conjunction with atorvastatin, cerivastatin, lovastatin and simvastatin are CYP3A4 
inhibitors cyclosporin, erythromycin, the antidepressants fluoxetine, 
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Figure 1.3 Structures of statins 
Type 1 and type 2 statins contain an HMG-like moiety, covalently linked to a rigid 
hydrophobic group. In addition, type 1 statins contain a decalin ring whereas type 
2 contains a fluorophenyl group and a methylethyl group. 
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Statin ICso Statin ICso 
Cerivastatin 10 
Sirnvastatin 9 Atorvastatin 10 
Pravastatin 7 Rosuvastatin 2 
Cornpactin 23 Fluvastatin 18 
Table 1.1 Median inhibitory concentrations of statins 
Median inhibitory concentrations (ICso) of statins (flM) for inhibition of HMG-CoA 
reductase. 
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fluvaxamine, nefazdone and seraline, the protease inhibitors indinavir, nelfinavir, 
ritonavir and saquinavir, calcium channel blocker mibefradil, conjugated 
oestrogen diltiazem, grapefruit juice. Care should also be taken when combining 
fluvastatin with alprenolol, diclofenac, diazepam and warfarin. 
Pravastatin is more hydrophilic when compared to the other statins. It has a short 
half life and is not affected by food intake6• Hydrophilic statins are distributed 
more selectively in hepatic cells than hydrophobic ones. Hydrophilic statins (i.e. 
pravastatin) cannot penetrate the membrane of extrahepatic cells because they 
consist of lipid bilayers and therefore cannot reach the intracellular enzyme. 
However hepatic cell membranes contain organic anion transporters, which take 
hydrophilic material into the cell. Conversely, hydrophobic statins are lipophils 
and can enter extrahepatic and hepatic cells and not only inhibit cholesterol 
synthesis but also other essential substances of the mevalonate pathway in many 
extrahepatic tissues lO • 
1.2 Isoprenylated proteins 
1.2.1 Prenylation 
The inhibition of mevalonate synthesis also prevents the synthesis of isoprenoid 
intermediates. The is-carbon farnesyl pyrophosphate and the 2o-carbon 
geranylgeranyl pyrophosphate are lipid attachment molecules for the post-
translational prenylation of various important cell-signalling moleculesll • Protein 
prenylation allows the covalent attachment, subcellular localization and 
intracellular trafficking of membrane-associated proteins. Heterotrimeric G 
protein subunits and nuclear lamins are prenylated but the largest group is the 
small GTPase family of molecular switch proteins. The Ras superfamily is 
structurally classified into five major subfamilies: Ras, Rho/Rac, Rab, San/ ARF 
and Ran12• The functions can be broadly classified as follows: Ras mainly regulate 
gene expression; Rho/Rac/Cdc42 regulate cytoskeletal reorganization and gene 
expression; Rab and Dan/ ARF regulate intracellular vesicle trafficking and Ran 
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regulate nucleocytoplasmic transport during the G1, Sand G2 phases of the cell 
cycle12• 
1.2.2 Transferases 
Farnesyl transferase (Frase) catalyses farnesylation, while geranyltranferases 
(GGTases I and II) catalyse geranylgeranylation13• Frase and GGTase I are 
heterodimers of Zn2+ metalloenzymes that share an a subunit and have 
homologous but distinct fJ subunitsll • GGTase II is also a up hetrodimer but is 
distinct from GGTase I and doubly geranylgeranylates proteins of the Rab small G 
protein family that end in CC or CaC. The prenyl groups farnesyl diphosphate and 
geranylgeranyl diphosphate, are added to the thiol group of the cysteine residue in 
the CaaX motif, where 'a' is any aliphatic amino acid and X determines which 
prenyl group is added: if serine, methionine, glutamine or alanine the protein is 
farnesylated and if leucine or phenylalanine it is geranylgeranylated14-16• 
1.2.3 Cleavage of aaX and methylation 
Following prenylation, two further post-translational modifications occur. The 
aaX is cleaved from the s-prenyl protein by the endoprotease Rce-117, resulting in a 
C-terminal prenylated cysteine that is carboxymethylated. The removal of the last 
three amino acids may relieve steric hindrance and allow insertion of the farnesyl 
group into the lipid bilayer18• The final modification is methylation of the new 
carboxy terminus by a carboxymethylase, using s-adenosylmethionine as the 
methyl donor19 (Figure 1-4). Methylation adds hydrophobicity to farnesylated 
proteins by neutralising the negative charge on the ionised carboxyl group, which 
could cause repulsion from the negatively charged head groups of membrane 
phospholipids18• Geranylgeranyl is already more hydrophobic than farnesyl, 
thereby facilitating lipid-lipid interactions16• 
1.2.4 Exceptions to the rule 
The substrate specificity rules for Frase and GGTase noted above are not 
absolutely stringent, with many examples of cross-prenylation14• For example, 
Pi1fJC 8 
~ 
COAAX + 
~ 
Veo Cf~ j 
Melhyl 
Transfl!rase .. AdoM~ t 
.... 
chrlJ'trr 1: l1Itrodll ctiO}l 
I'HNv 
S~COAAX 
!pmt"~~OOH 
Figure 1.4 Isoprenylanonjmethylation pathway for CAAX proteins 
(Adapted from Rando 20) 
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when K-RasB which has an FTase CaaX box is inhibited by FTase inhibitors, it 
becomes geranylgeranylated by GGTase 121. The reaction is made possible by an 
upstream polybasic sequence that alters GGTase I substrate specificity22. 
Furthermore, RhoB contains a GGTase I CaaX box but is found in both 
farnesylated and geranylgeranylated forms in cells, due to the ability of GGTase I 
to both geranylgeranylate and farnesylate this substrate23. 
1.2.5 Palmitoylation, myristolyation and acylation 
A second signal is required for stable membrane association of prenylated 
proteins. Palmitoylation and myristolyation are known to localise proteins to 
membranes24, 25. Palmitoylation of Ras proteins has been shown to stabilize the 
association of prenylated proteins with the plasma membrane16 and may play an 
important role in membrane localization and protein function. However not all 
Ras proteins are palmitoylated (e.g. K-Ras), but instead have a polybasic run of six 
positively charged lysine residues, which may increase the avidity of membrane 
binding through ionic interactions with negatively charged membrane head 
groups26 (Figure 1.5). 
Protein S-acylation has been proposed to be involved in cooperation between 
prenylation and carboxymethylation, regulating cycling between intracellular 
membrane compartments to control signalling activity27. Thus, post-translational 
modifications that follow prenylation may be potential candidates as factors that 
confer membrane-binding or functional specificity to the prenylated proteins. 
By inhibiting HMG-CoA reductase, statins reduce the availability of these 
intermediate metabolites and therefore the activity of key cell-signalling 
molecules. Given the central role these small GTP-binding proteins have in 
determining cell function, it is not surprising that the immune response will be 
modified independently of their plasma lipid-lowering effect. 
The role of some prenylated proteins in mediating immune function are listed in 
Table 1.2 
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Figure 1.5 Palmitoyl and polybasic domains of Ras 
H-Ras is doubly palmitoylated and K-Ras has a polybasic run of six positively 
charged lysine residues, which localise them to the plasma membrane. (Adapted 
from Parton et a128) 
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Prenylated protein 
Leukocyte motility 
CDC42, RACi 
CDC42, RACi, RHOA 
CDC42 
RHOA 
RAP 1 
RACi 
cJuYJtel' I: /lItl'odIlctitm 
- -" -----~~---------~--
Function 
Forward cell movement through formation of membrane protrusions 
Oamellipodia and filopodia) 
Formation of focal complexes and podosomes 
Directional leukocyte migration: macrophage and lymphocyte 
chemotaxis 
Leukocyte tail retraction during transmigration 
Increased leukocyte substrate motility and migration 
LFAi-induced T cell motility 
Antigen uptake, processing and presentation 
CDC42, RAC 
RAB proteins 
CDC42, RHO 
RACi, RAC2 
RAP 1 
Cytoskeleton remodelling for antigen endocytosis and immunological 
synapse formation 
Antigen processing and presentation 
Antigen presentation 
Formation of mature DC dendrites; polarized short-range migration 
to T cells for T cell priming 
Regulation of LFAi avidity for ICAMi 
Leukocyte activation, proliferation andfunction 
RAP 1 
RAS 
RACi 
RAC2 
RHOA 
CDC42, RACi, RAS, RHO 
RAC,RHO 
CDC42, RAC, RHO 
RAB27A 
TCR clustering and increased LFAi avidity for ICAMi after activation 
by TCR ligation; increased integrin-mediated adhesion after 
chemokines activation 
Regulation of transcription factors that control cytokine transcription 
after ligation of TCRs, and some cytokine receptors 
T cell fate in the thymus; regulation of actin cytoskeletal dynamics for 
clustering of TCRs, adhesion molecules and signalling receptors, and 
immunological synapse formation; IL-2 secretion and T cell 
proliferation after TCR ligation 
CD4+ T cell differentiation to Thi cells through activation ofIFNy 
gene expression 
Regulation of BCR signalling and B-cell proliferation 
Cell cycle progression and proliferation 
PKC8-dependent APi and NF-KB activation during proliferation; JNK 
activation in Th cell differentiation; cytoskeletal reorganisation, 
receptor clustering and IL-2 secretion after CD3 stimulation 
Inhibition of CTL- and CD9S-induced apoptosis 
Exocytosis oflytic granules in CTLs 
Continued on next naoe .... 
l'agc 12 
Phagocytosis 
CDC42,RAC1 
RAC 
RHO 
RAP1,RHO 
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.... Continuedfrom previous page. 
Formation of the phagocytic cup 
Induction ofNADPH oxidase production of superoxide-mediated 
phagosome function 
Superoxide formation during phagocytosis 
Complement-mediated phagocytosis 
Leukocyte transvascular migration 
RAP 1 
RAS,RHO 
RHOA 
RAP1, RAP2 
RAP 2 
CDC42,RAC1 
RAC2 
Chemokine-receptor-mediated integrin activation and lymphocyte 
transvascular migration through ICAM1 and VCAM1; PECAM1-
mediated leukocyte signalling to increase integrin adhesion 
Expression of monocyte MMP9 for leukocyte migration 
Induction of high-affinity state of LFA1 
CXC-chemokine-ligand-12-induced B cell migration 
LFA1 and VLA4-mediated B cell adhesion 
Chemokine-induced lymphocyte polarization and directional 
migration 
Neutrophil migration 
Endothelial-cell immune function 
RHO 
RHO,RAC1 
RAC1 
RAPl 
Formation and maintenance of the endothelial cell docking structure; 
ICAM1-mediated endothelial cell signalling for lymphocyte 
migration; endothelial cell actin cytoskeletal reorganization for 
monocyte migration; endothelial cell junction opening; inhibition of 
eNOS and NO production; adhesion-receptor clustering on 
endothelial cell s for monocyte adhesion and spreading; LPS-induced 
ICAMl expression and TNF-induced E-selectin expression by 
endothelial cells 
Induction of IeAM1, VCAM1 and E-selectin expression through 
activation ofNF-KB family members 
VCAM1-mediated endothelial cell signalling for NADPH oxidase 
activation, ROS production, junction opening and monocyte 
transvascular migration 
Increased endothelial-cell junction assembly by reducing leukocyte 
transmigration 
Table 1.2 Role of prenylated proteins in mediating immune function 
(Adapted from Greenwood et a129) 
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1.3 Activation of small G proteins 
1.3.1 GDls 
Monomeric small guanine nucleotide binding proteins (also referred to as GTPase) 
cycle between an inactive GDP-bound state and an active GTP-bound state20 • In 
the resting state, activation is prevented by guanine nucleotide dissociation 
inhibitors (GDIs). GDIs maintain Rho GTPases as soluble cytosolic proteins by 
forming high-affinity complexes in which the isoprenoid moiety of the GTPase is 
shielded from the solvent by its insertion into the hydrophobic pocket formed by 
the immunoglobulin-like fJ sandwich of the GDI. GDIs inhibit the dissociation of 
GDP from Rho proteins, preventing GTPase activation by guanine nucleotide 
exchange factor (GEFs)30 • GDIs are also able to prevent interactions with effector 
targets by interacting with the GTP-bound form of the GTPase31. Through these 
multiple actions, GDIs act as a major regulator of Rho GTPase activity and 
function, but are themselves also regulated by other proteins termed GDI 
displacement factors, or GDFs. (Figure 1.6) 
1.3.2 GEFs 
Following dissociation of GDIs, the small G proteins are activated by guanine 
nucleotide exchange factors (GEFs) which contain a Dbl homology (DH) domain 
that catalyses the exchange of GDP for GTP32 • They also have an adjacent c-
terminal pleckstrin homology domain (PH), which binds to lipid products of PI3K. 
PH domains localize Dbl proteins to plasma membranes, and cooperation between 
DH and PH domains facilitate exchange activity33. The GDP-GTP exchange 
reaction is the rate-limiting step in the GTP-binding/GTP hydrolytic cycle of 
GTPases and the GEFs have therefore been proposed as key regulators of the 
GTPases. 
1.3.3 GAPs 
Inactivation occurs via hydrolysis of GTP, a slow process that is catalysed by 
GTPase-activating proteins (GAPs). GAPs are classified according to their GTPase 
-------------------~~---~-------------------- ----------------- -----------------------------------------
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Figure 1.6 GTPase cycle 
Downstream Effectors 
eg MAPK, PI3 -kinase 
Small G proteins are found in the cytosol bound to GDIs, which are negatively 
regulated by GDFs. Cellular signals stimulate release of GDI and dissociation of 
GDP by GTP binding which is catalysed by GEFs. Farnesylated and 
geranylgeranylated residues bind the active form of GTPase to the cell membrane. 
Intrinsic GTPase activity stimulated by GAPs leads to inactivation. (Adapted from 
McTaggart34) 
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subfamily (Ras-GAP, Rap-GAP, etc) with sequence homology within subfamilies 
but not between families35. GAPs contain a phosphoinositide-binding PH domain 
but also commonly contain a Src homology domain (SH3) that binds proline-
containing peptides36. 
Regulators of G protein signalling (RGS) act functionally as GAPs and interact with 
heterotrimeric G protein a subunits to accelerate the GTP hydrolysis rate of the Ga 
subunit37. 
1.4 Rafts 
Lipid rafts are compartmentalized membrane microdomains into which 
membrane lipids and proteins sort, allowing specific interactions that modulate 
signal transduction, membrane trafficking, cytoskeletal organization and motility, 
polarization and pathogen entry38 . Lipid rafts are highly dynamic, laterally mobile, 
assemblies that float freely within the liquid disordered membrane bilayer. Rafts 
are liquid-ordered domains enriched in sterols (including cholesterol), 
glycosphingolipids and sphyngomyelin that are more tightly packed than the 
surrounding non-raft phase of the bilayer (Figure 1.7). The tighter packing is due 
to the saturated hydrocarbon chains in raft sphingolipids (such as gangliosides) 
and phospholipids compared with the unsaturated fatty acids of phospholipids in 
the non-raft phase39. 
Lipid rafts were initially identified as detergent resistant membrane (DRM) 
fractions. Upon membrane solubilization by some mild non-ionic detergents (such 
as Triton X-100 or Brij) at low temperatures, rafts remain insoluble and because of 
their high lipid content, float to a low density following sucrose gradient 
centrifugation40. Rafts can be visualized by cholera toxin B subunit (CT-B), which 
binds to and cross-links with glycosphingolipid GM1. 
Lipid rafts have been subdivided into caveolar and non-caveolar rafts that co-exist 
in distinct membrane areas. Caveolae are flask-shaped membrane invaginations 
enriched in cholesterol and caveolin. Caveolin is thought to stabilize the 
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Figure 1.7 Lipid raft model 
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Lipid rafts are membrane micro domains that are highly enriched in tightly packed 
sphingolipids and cholesterol. Raft associated proteins include GPI -anchored 
proteins that contain saturated acyl chains (e.g. Lyn and Lck). Transmembrane 
receptors are usually excluded from rafts. (Adapted from Dykstra et a1 41) 
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invaginated structure by its hairpin-like palmitoylated structure. Unlike caveolar 
rafts, non-caveolar rafts are flat and heterogeneous in protein composition42. 
Many cell surface proteins localize to the liquid disordered regions, however some 
proteins selectively partition into the rafts domains. These include 
glycosylphosphatidylinositol (GPI) -anchored proteins because their 
phosphoinositide anchors typically have saturated acyl chains43. Palmitoylated 
and myristoylated proteins (e.g. flotillin), doubly acetylated proteins (e.g. Src-
family kinases)44, phospholipid bound proteins (e.g. annexins), and cholesterol 
bound transmembrane proteins (e.g. caveolins) also associate with ordered 
domains. Prenylated membrane anchors (for example, on Ras superfamily 
GTPases) have a preference for disordered domains because of the unsaturation of 
the isoprenyl groups45,46• However, these preferences on the basis of hydrophobic 
membrane anchors may be outweighed by interactions with other proteins or by 
headgroup interactions. 
To engage in membrane function, rafts usually have to cluster together and can be 
accomplished from both sides of the plasma membrane47. Antibodies, antigens or 
raft-lipid-binding proteins such as cholera toxin B, cluster rafts on the extracellular 
side of the membrane whereas raft-clustering proteins such annexins, flotillins or 
other scaffolding proteins could serve as clustering agents for the rafts in the 
cytoplasmic leaflet. Clustered rafts can sequester specific sets of signalling and 
other proteins and could serve as platforms to execute functions in membrane 
trafficking, signalling and polarisation48. 
Evidence for a functional role of lipid rafts came from studies of haematopoietic 
cells. The high-affinity IgE receptor (FC8RI), the T-cell receptor (TCR) and the B 
cell receptor (BCR) are multi chain immune receptors, which translocate to lipid 
rafts upon crosslinking49. In resting mature T cells, the TCR is excluded from lipid 
rafts. However, upon engagement, the TCR associates with rafts where the S chain 
of the CD3 and Zap-70 become phosphorylated50. Adaptor molecules such as LAT 
and SLP-76 are then recruited. Lck, LAT and certain other proteins constitutively 
associate with lipid rafts at least in part because of their fatty acid modifications. 
When T cells recognise the antigen presented on the surface of antigen presenting 
cells (APCs), polarisation oflipid rafts and raft-associated proteins occurs through 
--------~"-~~-----~----- ---"-------------------
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their association with the immunological synapse, where the T cell contacts the 
APCs1. 
MHC class II molecules colocalize with GMl and partition into insoluble 
membranes following cross-linking with specific antibodiess2. Other studies 
demonstrated that, when disrupted by cholesterol depletion, a constitutive 
association of class II molecules with lipid rafts on APC, diminished antigen 
presentation to T cellss3. 
NK cells express an array of inhibitory and activating receptors that together allow 
NK cells to distinguish normal healthy cells from target cells for lysiss4. A study 
has shown that conjugate formation of NK cells with sensitive tumour cells results 
in the actin-dependent redistribution of the raft marker GMl to the contact site in a 
Src- and Syk-dependent fashionss. Significantly, both the redistribution of rafts 
and cytotoxicity were blocked by the engagement of an inhibitory receptor in a 
SHP-l-dependent fashionss. In another study, photobleaching experiments 
showed that CD94/NKG2A receptors move freely within the plasma membrane 
and accumulate at the site of ligand contact where mobility becomes restricted. 
Lipid rafts are excluded from the site of receptor contact with the ligand, which 
suggests that immobilization of the CD94/NKG2A receptors at ligation sites not 
only promote sustenance of the inhibitory signal, but by lipid rafts exclusion 
prevent formation of activation signalling complexess6. As the integration of 
signals from multiple receptors is essential for NK cell activation, the role of lipid 
rafts in NK cell signalling may be pivotal. 
The major lipid of the membrane, cholesterol, is a critical component that controls 
lipid phase separation and stabilizes lipid rafts. Drugs that modify membrane 
cholesterol concentration and disrupt membrane domain organization include: 
drugs that sequester cholesterol (filipin, nystatin, and amphotericin), form 
membrane pores (saponin, digitonin, and streptolysin 0), deplete cholesterol 
(methyl-~-cyclodextrin (M~CD)), impair cholesterol trafficking (progesterone), 
inhibit cholesterol biosynthesis (statin), or perturb raft stability (exogenous 
addition of cholesterol, gangliosides, or polyunsaturated fatty acids). 
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In general, cholesterol depletion impairs receptor activation and downstream 
signalling, consistent with an important role for lipid rafts in the organization of 
signalling components. 
1.5 Immunology and signalling 
1.5.1 Monocytes and macrophages 
Macrophages participate in the production, activation and regulation of all 
immune effector cells. These cells belong to the mononuclear phagocyte lineage, 
being derived from blood monocytes that terminally differentiate to give rise to 
tissue macrophages. Probably the most significant role of these cells is to engulf 
and destroy foreign and aberrant material, including infectious agents, immune 
complexes, virus infected cells and cancer cells. 
Monocytes and macrophages have central roles in innate and adaptive immunity57. 
Receptors on the surface of these cells directly bind to pathogens and result in 
internalisation and disposal. These cells also express receptors for the 
complement system and C-reactive protein (CRP), which mediate internalisation 
of complement and CRP opsonised pathogens. These innate functions of the 
immune system serve as a first line of defence against pathogens. In the adaptive 
response, production of antigen specific antibodies by B-cells results in either the 
formation of antibody: antigen complexes, known as immune complexes, or the 
opsonisation of pathogens through antibody binding to surface antigens. The 
antibodies are then recognised by Fc receptors and the resultant aggregation of 
these receptors by immune complex or opsonised particle leads to their 
internalisation through the process of endocytosis for immune complexes or 
phagocytosis for opsonised particles. 
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1.5. 1. 1 Monocytes and lymphocyte regulation 
Alongside their central roles in immune complex clearance and inflammation, 
monocytes and macrophages, also interact and coordinate lymphocyte responses. 
Monocytes and macrophages are also a major source of the immune regulatory 
cytokines IL-10 and IL-12 which regulate the type oflymphocyte response. In 
addition, macrophages are able to present internalised antigen to T -cells via MHC 
class II. This receptor is the most effective method of stimulating T-cell 
activations8. 
1.5.1.2 Monocytes and Macrophages are highly heterogeneous 
Mononuclear cells such as monocytes and macrophages are highly heterogeneous, 
attributable to differences in their maturation status and also tissue specific 
variations9. This heterogeneity makes in vitro study of these primary cells very 
difficult. Primary human mononuclear cells provide more difficulty due to genetic 
variation and disease status differences between donors. To overcome this 
difficulty, a number of human monocyte-like cell lines have been established, 
including U937, HL60 and THP-160 and are widely used as models for studying 
human mononuclear cells. U937 cells are widely used as a model for elucidating 
immune response signalling pathways and data from U937 cell-based experiments 
have been applied to cardiovascular models of inflammation61-63. 
1.5. 1.3 Fc Receptors 
Three functionally and structurally distinct classes of Fcy receptors are expressed 
by human monocytes and macrophages64. Fcy RI is a high affinity IgG receptor 
that binds monomeric IgG at low, physiological concentrations, whereas Fcy RII 
and Fcy Rill bind with low affinity and thus interact only with IgG aggregates or 
immune complexes. FcyR are activated when clustered at the cell surface by 
immune complexes, and signal through an immunoreceptor tyrosine based 
activation motif (ITAM)6s. For FcyRI and FcyRIII the ITAM is situated within the 
FcyR associated v-chain subunit, whereas FcyRlla contains an ITAM in the 
cytoplasmic tail. Though the exact mechanism remains unclear, aggregated FcR 
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are recruited to cholesterol and sphingolipid rich plasma membrane rafts as a 
platform for signal transduction66, 67, resulting in phosphorylation of key tyrosine 
residues within associated ITAMs and creating a docking site for recruitment of 
cytoplasmic signalling molecules such as Syk tyrosine kinase, the p8s-pno PI3-
kinase complex, PLC-y and LAT (Linker for Activation ofT-cells). LAT is a 
membrane associated 36-38 kDa adapter protein targeted to rafts by 
palmitoylation initially shown to couple the T cell receptor to calcium flux, ERK 
activation and IL-2 production68. In myeloid cells, LAT is phosphorylated in 
response to FcyR clustering and thus recruits key SH2 domain proteins - Grb-2, 
p8S and PLC-y - to the FcyR signalling complex69. 
1.5.2 Lymphocytes 
Lymphocytes are the principle cells of adaptive immunity with their ability to 
recognize antigens. They arise from bone marrow lymphoid stem cells to defend 
against invading pathogens and to prevent or reduce reinfection70. Lymphocytes 
mature in lymphoid organs: B cells are bursa of Fabricius (or bone marrow) 
derived and T cells migrate from bone marrow to mature in the Thymus. 
1.5.2. 1 T cells 
Unchallenged T cells recirculate between blood and lymph nodes, awaiting antigen 
presentation by antigen presenting cells (APCs)70. T cells are stimulated by contact 
of the T cell receptor with an APC. The T cell rapidly proliferates and differentiates 
into effector cells or mature into memory T cells, which lodge in the spleen and site 
of first infection, ready to respond to re-infection. T helper cells (CD4+ ) interact in 
antigen specific contacts with B cells and provide cell surface and cytokine signals 
that drive the B cells toward antibody production. Thl helper cells activate 
macrophages toward phagocytosis of intracellular microbes by secretion of 
cytokines including IFN-y. Th2 secretes cytokines including IL-4 and IL-S to 
stimulate eosinophil/mast cell-mediated immune reactions and to down regulate 
Thl responses. Cytotoxic T-Iymphocytes (CD8+) recognize virally or microbially 
infected cells (or cancerous cells) and directly induce cellular death by release of 
cytoplasmic granules that contain membrane pore-forming proteins and enzymes. 
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1.5.2.1.1 Adhesion molecules 
Lymphocyte function-associated antigen (LFA-i) is a heterodimeric glycoprotein 
belonging to the ~2 integrin family and consists of a i8o-kDa a-chain (CDna) and 
a 95-kDa ~-chain (CD18)7!. LFA-i is involved in lymphocyte recirculation and 
leukocyte extravasation to sites of inflammation72. It is also important for effective 
T-cell activation by APCs by providing a potent costimulatory signal for TCR-
activated T cells73. T-cells appear to require two signals for activation74, the first 
trigger being from recognition of antigen in the form of antigenic peptide bound to 
cell-surface proteins encoded by the major histocompatibility complex displayed 
on the surface of antigen presenting cells. The second co stimulatory signal, for 
example, ICAM-i (CD 54) on APC binds to LFA-i on the T-cell. Similarly, VLA-4 (a 
~i integrin) binds to VCAM-i and controls the progression ofleukocyte migration. 
Resting leukocytes constitutively express LFA-i, which needs to be converted from 
a low-affinity state to a high-affinity state by activation from either a response to 
chemokines or engagement of the T-cell receptor75. 
Lovastatin, mevastatin and simvastatin but not pravastatin were found to bind 
directly to LFA-i via the "lovastatin site" (L-site), which is located on the inserted 
(I)-domain of the LFA-i a chain, distant from the ICAM binding site. A 
conformational change via an allosteric mechanism independent of HMG-CoA 
reductase activity, stabilizes the low-affinity form of LF A-i and does not allow the 
transition to the high-affinity, ligand binding conformation76, 77. An increase in 
ligand binding can also be brought about by lateral association of integrins into 
clusters on the plasma membrane called lipid rafts, which increases ligand binding 
avidity by providing multiple contact sites78. Inactive LFA-i is excluded from 
membrane rafts by cytoskeletal tethers and upon activation are untethered and 
relocated into rafts79, 80. However LFA-i is not palmitoylated, a characteristic of 
many raft transmembrane proteins, so is thought to be localised to rafts by 
complex formation with other membrane proteins79. The prenylated GTPase -
Rho, regulates receptor clustering into membrane rafts8!. Rac and CDC42 mediate 
the assembly of smaller adhesive complexes associated with lamellipodia and 
filopodia, therefore inhibition of prenylation by statins has the potential to disrupt 
regulation and movement of integrins. 
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Therefore blockade of LFA-1 and VLA-4 interactions with their ligands is a 
potential target for immunosuppression and for controlling inflammation and 
autoimmune diseases. Whether this is achieved by statins binding directly, 
disrupting rafts, reducing prenylation of regulatory signalling molecules or by 
monoclonal antibodies82,83 is equally obtainable. 
1.5.2.2 NK cells 
Natural killer cells constitute approximately 10% of peripheral blood mononuclear 
cells and are bone marrow derived, CDS6+ CD16+ CD3-, large granular 
lymphocytes, that function in innate immune responses, a critical role in early host 
defence against infections and cancers as well as rejection of grafts84. They exert 
their effector function, without prior sensitisation, by direct lytic mechanisms and 
production of immunoregulatory cytokines and chemokines85. A balance between 
activating and inhibitory receptors regulates NK activation. 
1.5.2.2.1 Cytotoxicity 
NK cells store perforin (which creates pores in target cell membranes) and 
granzymes (enters perforin pores and induce apoptosis) in preformed cytoplasmic 
granules86. A tight conjugate between the NK cell and its target is required for 
direct delivery of granule components and cytotoxicity87 and leads to the formation 
of an immunological synapse88. This is a rapid process and can be complete within 
20 minutes89. 
1.5.2.2.1.1 Adhesion molecules 
Adhesion molecules are also necessary for cytotoxicity. NK cells express LFA-1 
(CDna), LFA-2 (CD2), CD44, CCD4ge, LFA-3 (CDS8), ICAM-1 (CDS4) and L-
selectin (CD62L), which interacts with the endothelium, for trafficking to 
secondary lymph organs90. LFA-1 binding of NK cells to target ICAM-1 adhesion 
molecules activates the signal transduction pathway ofVav-Rac1-Erk to rearrange 
the cytoskeleton for cytotoxicity87 and gathers the receptors in lipid rafts91• 
Adhesion molecules therefore not only participate in conjugate formation but also 
trigger the earliest activatory signal transduction events. 
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1.5.2.2.1.2 Activating receptors 
Activating receptors in NK cells lack intrinsic signalling domains, therefore require 
coupling to adaptor proteins that contain ITAM motifs for signal transduction92. 
ITAMs contain the consensus sequence YxxL6-8xYxxL/I (where x is any amino 
acis), with 6-8 amino acids between the two YxxL/I elements. Adaptor protein 
family members containing ITAMs include CD3Y, CD38, CD38, C;, Iga, Ig~, FC8RIy 
and DAP12 of which NK cells express C;, FC8RIy and DAP1293. FC8RIy and C; form 
disulfide-bonded homo or heterodimers and DAP12, homodimers only94. When 
receptor engages its ligand, tyrosines in the ITAM are phosphorylated, usually by 
Src family kinases, which results in recruitment through SH2-domain binding and 
activation of Syk or ZAP-70 cytoplasmic tyrosine kinases. 
1.5.2.2.1.2.1 Antibody dependent cellular cytotoxicity (ADCC) signalling 
FC8RIy and C; associate with CD16 (FcyRIIIA) when crosslinked with IgG-coated 
target cells in antibody-dependent cellular cytotoxicity. This results in the 
association of the receptor complex with Src family PTKs (including Lck, Fyn, Yes 
and Lyn), which phosphorylates FC8RIy and C;. Syk family PTKs (including ZAP-70 
and Syk) then become activated, which induces phospholipase Cyl tyrosine 
phosphorylation and the activation of phosphatidylinositol-3 kinase (PI3K). PI3K 
leads to the formation of critical membrane bound second messengers that are 
docking sites for proteins containing pleckstrin homology (PH) domains, such as 
PLCy and the family of three V A V guanine exchange factors. Ras, Rho and Rac are 
substrates of VA V, which then activate the Rac substrate (PAK) p21-activated 
kinase and mitogen-activated protein kinase (MAPK), extracellular regulated 
kinase (ERK). Shc also becomes phosphorylated and binds Grb2, a Src homology 
2 (SH2) and SH3 domain containing protein. The SH2 domain binds LAT (Figure 
1.8)86 
1.5.2.2.1.2.2 ITAM bearing receptors - non-MHC class I binding 
Natural cytotoxicity receptors (NCR) include NKp30 and NKP46 which interact 
with hetero or homodimers of FC8RIy and C;, are expressed in all resting and 
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Figure 1.8 Signalling events in NK cell mediated cytotoxicity. 
Signalling during ADCC, initiated upon engagement of FcgRIIIA by IgG-target cell 
recognition. (Adapted from Perussia 86 and Leibson 95) 
page 26 
c/ltlytcr !: Ilitrotillctio)l 
".~-~.----.- -- --- - - - - - ------ - .--~~---------------- - -
activated NK cells and provide the most accurate surface markers for identifying 
human NK cells. NKp44 which couples with DAP12 is also NK specific, but is 
expressed only upon long term IL-2 induced activation96. NKp44 and NKp46 
recognize virus specific haemagglutinins and therefore facilitate NK lysis of virally 
infected cells. 
1.5.2.2.1.2.3 ITAM bearing receptors - MHC class I binding 
Activating killer immunoglobulin-like receptors (KIRs) contain two or three 
extracellular immunoglobulin-like domains and lack an inhibitory signalling motif, 
but are highly homologous to the inhibitory members of the KIR family. They also 
bind the same HLA ligands (Table 1.3) with lower affinity than the inhibitory 
counterparts. KIR2DS, KIR3DS belong to this group of receptors and couple with 
DAP12. 
The stimulatory isoforms of the NKG2 receptor family are the NKG2C and E 
receptors. They form heterodimers with CD94 and recognize HLA-E. 
1.5.2.2.1.2.4 ITAM independent receptors 
NKG2D is a C-type lectin expressed on all NK cells97 and differs from other NKG2 
proteins because it only shares 20% amino acid identity, is a homodimeric receptor 
and does not bind HLA-E (Figure 1.9). NKG2D is a receptor for the MHC-like 
molecules MICA/B stress inducible ligands, primarily expressed by epithelial 
cells97 (Figure 1.10). MICA and B differ from MHC class I molecules in that they 
lack the ability to bind proteins or associate with ~2-microglobulin and are not 
induced by IFN-y 98. MICA and B have been considered as cell-stress response 
genes as they are regulated by heat shock promoter elements97. MICA can be 
upregulated during certain infections99, resulting in enhanced recognition by 
CD8+a~ or yo T cells. NKG2D has a charged amino acid residue in the cytoplasmic 
domain and requires DAP10 for function. DAP10 contains a different tyrosine-
based motif - YxxMlOO, 101. Engagement of NKG2D results in tyrosine 
phosphorylation of DAP10, recruitment and activation of PI3K and AKT102 (Figure 
loU). NK cells activated with IL-2 in culture associates with both DAP12 and 
DAP10. DAP12 activates SYK or ZAP70 PTKs whereas DAP10 activates PI3K. 
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Receptor Ligand 
Immunoglobulin-like receptors 
KIR2DSl HLA-C, C2 
KIR2DS2 HLA-C, Cl 
KIR:3DSl HLA-B BW4? 
Lectin-like receptors 
CD94/NKG2C or E 
Cytotoxicity receptors 
NKG2D 
NKp30 
NKP44 
NKP46 
CD16 
DNAM-l 
NKp80 
CDS9 
NTB-A 
2B4 
CD2 
LFA-l 
TLR 
HLA-E 
MICA, MICB, ULBP 
Unknown 
Unknown cellular ligand, viral HA 
Unknown cellular ligand, viral HA 
IgG 
PVR (CD1SS), nectin-2 (CDU2) 
* Unknown 
* Unknown 
*NTB-A 
*CD48 
* LFA-2 
ICAM 
P AMPS, e.g. dsRNA 
* Co receptors as well as activatory receptors. 
Table 1.3 Natural killer cell activatory receptors and ligands 
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NKG2D 
ITAM YXXM 
Activation 
Figure 1.9 NKG2D receptor 
NKG2D receptor is a type 2 transmembrane homodimer that contains charged 
residues in the transmembrane segments and associates with DAPlO and DAP12 to 
provide activating signals. (Adapted from Raulet102 ) 
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MHC class I chain-related protein A and B contain an a3-like domain, but fail to 
bind p2-microglobulin - the light chain of MHC class I molecules. (Adapted from 
Raulet102 ) 
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Figure 1.11 Signalling events in NKG2D activating receptor 
Signalling pathway during spontaneous cytotoxicity, initiated upon engagement of 
NKG2D receptor with MICA ligand is independent of Ras. (Adapted from 
Perussia86) 
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Activation of both leads to killing and cytokine release. 
Toll-like receptors (TLR) are a family of innate immune receptors which recognize 
conserved pathogen-associated molecular patterns (PAMPs), eg LPS103. Ten 
mammalian TLRs have been identified to date, classified as TLR1 to TLR10. While 
individual TLRs bind specifically to one or two ligands, the TLR family as a whole 
will bind a wide range of microbe-derived ligands. These include LPS and LTA, 
bound by TLR4, PGN and lipoproteins, bound by TLR2, and unmethylated 
bacterial DNA, bound by TLR9. TLR:3 has been shown to bind polyinosinic-
polycytidylic acid (polyI:C) which is a synthetic analogue of double stranded RNA 
(dsRNA) 104. 
The TLR family all share a similar structure. Embedded in the plasma membrane 
the typical TLR possesses a large extracellular portion made up of between 12 and 
23 leucine-rich repeat domains with a cysteine-rich domain flanking the 
transmembrane region. The intracellular portion consists of a Toll/IL-1 receptor 
homology domain (TIR). 
TLR activation leads to an immune response mainly through gene regulation via 
the NF-KB transcription factor system. This TLR-mediated immune response is 
available to a wide range of cell types that form the first line of defence against an 
immune challenge. Macrophages, neutrophils and dermal, gut and lung epithelial 
cells all express various TLRs on their surfaces. Upon exposure to microbes they 
are then recruited from the plasma membrane to phagosomes where they help 
facilitate the destruction of invading cells. 
1.5.2.2.1.3 Costimulatory receptors 
Co receptor's ability to signal depends on the simultaneous co-engagement of one 
or another triggering receptor and may help amplify the signal. 2B4 and NTB-A 
are members of the CD2 Ig superfamily and contain an immunoreceptor tyrosine 
based switch motif (ITSM) - TxYxxV /1. ITSM recruits the signalling lymphocyte 
activation molecule-associated protein (SAP) upon activation105. They recruit 
SHP-1 (or 2106), SAP, LAT, PLCy and Grb2107. The ligand for 2B4 is CD48, a GPI-
anchored surface molecule expressed by mainly B cells. 
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A similar co receptor function has been demonstrated for NKpS0108 
1.5.2.2.1.4 Polarisation of granules 
Resting NK cells contain cytotoxic granules scattered around the cytoplasm. 
Activation leads to the reorganisation of the actin cytoskeleton and the polarisation 
of the microtubule organising centre (MTOC) toward the immune synapse88. 
Granule polarisation is triggered by the Src - Syk - PI3K - V A V-I - Rac-l - P AK -
MEK - ERK-2 pathway109• 
1.5.2.2.1.5 Granule exocytosis 
Activated PLCy produces inositol-l,4,5-trisphospate (IP3) which induces Ca2+ 
release from the intracellular stocks and diacylglycerol (DAG), leads to activation 
of protein kinase C (PKC) (Figure l.S). The elevated intracellular free Ca2+ [Ca2+ Ji 
is required for granule release95• 
1.5.2.2.2 Inhibitory receptors 
NK cells are programmed to kill and therefore require inhibitory signals to 
override the activating signals and prevent death of normal autologous cells. Few 
receptor types are expressed by every NK cell, which leads to functional 
heterogeneity based upon the combination of cell surface receptors expressed. 
This is likely to translate into some degree of antigen or pathogen specificity. 
1.5.2.2.2.1 MHC inhibitory receptors 
HLA class I expression normally maintains NK cell tolerance. However, during 
viral infections or cancer, inhibition is removed by reduced HLA class I expression 
(i.e. the 'missing self hypothesisllo). Killer immunoglobulin-like receptor family is 
comprised of 15 receptors of both inhibitory and activatory members. Inhibitory 
receptors are characterized by immunotyrosine-based inhibitory motifs (ITIMs) in 
their cytoplasmic tails, where as activatory receptors recruit adaptor molecules 
(Table 1-4). ITIMs contain the consensus sequence IVLSxYxxL/V. Healthy cell 
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Receptor Ligand 
Immunoglobulin-like receptors 
KIR2DLl HLA-C, C2 
KIR2DL2/3 HLA-C, Cl 
KIR3DLl HLA-B BW4 
KIR3DL2 HLA-A A3, An 
Lectin-like receptors 
CD94/NKG2A HLA-E 
Table 1.4 Natural killer cell inhibitory receptors and ligands. 
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HLA ligands bound to inhibitory KIRs results in the inhibition of NK cell activation 
and protection from lysis. 
Three immunoglobulin-domain KIRS, KIR3DLI recognizes a subgroup ofHLA-B 
molecules expressing the serological BW4 epitope111• It is a 7o-kDa protein 
containing three extracellular immunoglobulin domains (3D) and a long (L) 
intracellular domain that contains two ITIMs. Ligation results in phosphorylation 
of ITIMs and recruitment of phosphatases, SHP-l and SHP-2, that inhibit 
activation pathways112, 113 by dephosphorylation of downstream signalling proteins 
such as Vav1. KIR3DLI is sensitive to the peptide presented by the HLA molecule. 
Unlike T-cell receptors, which display very fine peptide specificity, KIR3DLI shows 
a broader specificity, with several unrelated peptides capable of preventing 
KIR3DLI recognition and thus leading to KIR3DLl+ NK cell activation. This 
allows NK cell detection of viral infection or transformation as a result of 
perturbation in the inhibitory signal to KIR upon presentation of viral or tumour 
derived peptide. Figure 1.12 depicts other KIR. 
CD94/NKG2A heterodimer belongs to the lectin-like family of receptors114, which 
recognize the non-classical class I HLA-E molecule56. HLA-E binds and presents 
the leader peptide of most HLA-A, -B and -C molecules and non-classical HLA-
G115. While KIRs are sensitive to individual HLA changes, they are complemented 
functionally by CD94/NKG2A, which responds to changes in global HLA 
expression. This allows NK cells to respond to both subtle and major alterations in 
HLA-expression caused by different pathological situations. 
LILR family encode inhibitory receptors that bind MHC class I. LILRBI binds 
with low affinity to a conserved region in the a3 domain of essentially all HLA 
class I glycoproteins, including HLA-A, B, C, E, F and G. 
A model for activation of NK cell cytotoxicity was suggested as ligand binding to 
stimulatory receptors leads to tyrosine phosphorylation of Va VI and subsequent 
Vavl-dependent actin cytoskeleton rearrangements forming a stable NK cell 
immunologic synapse. SHP-llocated at the periphery cannot prevent the 
stimulatory activities i.e. VaVl dephosphorylation cannot occur and leads to 
activation. The activating signals responsible for initiating cytotoxicity may 
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Human receptors 
KIR3DL3 
KIR2DL3 
KIR2DL2 
KIR2DLl 
KIR2DL4 
KIR3DLl 
KIR3DSI 
KIR2DL5AiB 
KIR2DS3 
KIR2DS5 
KIR2DSl 
KIR2DS2 
KIR2DS4 
KIR3DL2 
CD94INKG2A 
CD94INKG2C 
E]E] I ~ 
E]E] I ~ 
E]E] I ~ 
E]E] I ~ 
E] ~~  
E]E] I ~ ----{~  
r--1 
L-..J 
I ~ 
-{~  
I J~~ 
I 
------@ ~ 
----4 ~ 
E]E] I ~ 
r--1 r--1 I I 
~ c=J I cx=x=s 
E] I I ~ 
I 
----{c1 1 ~ 
LILRBI r==l r==l r==l r==l l  L-..J L-..J -- -- I 
clli1yta 1: l1It rorillCtiOlt 
Ligands 
? 
HLA_CS77NSO 
HLA_CS77NSO 
HLA_CN77NSO 
HLA-G? 
HLA-Bw4 
? 
? 
? 
? 
HLA_Cweakly 
? 
HLA-A 
HLA-E 
HLA-E 
HLA-A, B, C, E, F 
D ITIM c=:::2 Ig-domain @ Charged residue C C-lectin domain 
Figure 1.12 Human NK cell receptors/or MHC class I 
Inhibitory KIR LILRBI and CD94/NKG2A contain ITIMs in their cytoplasmic 
domains. CD94/NKg2C and the KIR lacking ITIMs and containing a charged 
residue in their transmembrane domains are likely to pair with DAP12 signalling 
adapter. KIR2DL4 is an exception; it possesses an ITIM in its cytoplasmic domain 
and is associated with FCERIy signalling adapter. (Adapted from Lanier116) 
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converge on downstream signalling molecules such as Vav1117. 
1.5.2.2.3 NK cell inactivation and apoptosis 
After an NK cell delivers its lethal hit to a susceptible target, it may either recycle 
to kill again, become inactivated or undergo activation induced cell death. MHC 
class I inhibition is transient where as inactivation induced by NK -sensitive targets 
is more sustained and decreases the capacity to mediate subsequent killing of 
additional targets. Exposure to IL-2 increases NK responsiveness and recovery of 
cytotoxic function, however IL-2 or IL-12-activated NK cells are also more 
susceptible to activation-induced cell death if they subsequently bind to 
susceptible targets or FeR-specific ligands95. FeR-initiated cell death is dependent 
on tyrosine kinase activation and calcium signalling and is due to the induction of 
FasL. 
1.5.2.2.4 Cytokine release 
NK cells express the Tumour necrosis factor (TNF) family ligands; TNFa, Fas 
ligand (FasL) and TNF related apoptosis inducing ligand (TRAIL). These 
molecules bind to death domain containing receptors on target cells leading to 
perforin-independent apoptosis118. NK cells constitutively express receptors for 
IL-2 and IL-15, which markedly enhance the ability ofthese cells to kill ab-coated 
targets, or cells that lack MHC molecules. 
NK cells are a source of cytokines and chemokines including IFNy which can 
control tumour cell proliferation119 or kill infected cells120• IFNy can elicit innate 
and adaptive immune responses by increasing the expression of MHC class I and 
II molecules and by activating macrophages. Various inflammatory cytokines (IL-
12, IL-18 and IFNa/p) or cross-linking of activating receptors induces IFNy 
production by NK cells. NK cells also secrete IL-5, IL-10, IL-13, GM-CSF, MIP-
1a/b and RANTESl21, and chemokines which recruit other effector cells during the 
immune response122• 
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Overall, the combination of various activating receptors and different signalling 
pathways gives multiple choices to NK cells. There are at least two levels of 
redundancy, one at receptor level, with the existence of numerous receptors that 
can trigger cytotoxicity, and the other at the intracellular level with signalling 
molecules that share partially overlapping functions. Moreover, the strength of the 
activating signal, the nature of the receptor-ligand systems and the different 
environmental situations are integrated inputs that participate to decide whether 
to switch on signalling pathways specific for cytotoxicity or IFNy production, or 
both, thus modulating effector functions. 
1.6 Inflammation and Atherosclerosis 
1.6.1 The inflammatory response 
Inflammation is the physiological process which occurs in response to damage 
induced by multiple agents, including pathogens, foreign bodies, complement 
opsonised particles and immune complexes, as well as physical injury123. In the 
inflammatory response, soluble mediators and cellular components act in concert 
to eliminate the cause of damage. While this response is key to host defence, it is 
also clear that inflammation can also result in tissue destruction. In inflammation, 
soluble inflammatory mediators are released which recruit and activate the cellular 
components of inflammation, including neutrophils, monocytes and lymphocytes. 
Many of these proinflammatory mediators are synthesised and released by 
macrophages and monocytes. These include the cytokines TNF-a, IL-l (a and P), 
IL-6 and IL-8 together with other inflammatory mediators such as prostaglandins 
and eicosanoids. Further, in the resolution of inflammation, macrophages are 
responsible for clearing recruited leukocytes, such as neutrophils and for the 
release of anti-inflammatory mediators such as transforming growth factor p 
(TGF-P) and IL-10. Thus, monocytes and macrophages playa key role in the 
initiation, coordination and resolution of the inflammatory response. 
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Other cells also play key roles in the inflammatory response123. Release of IFN-y by 
NK cells and T -cells is important in the priming and activation of monocytes and 
macrophages. Neutrophils are phagocytic cells, which are rapidly recruited in 
response to inflammatory stimuli. These cells playa key role in the clearance of 
foreign materials and cellular debris. They, therefore, express high levels of 
phagocytic receptors, including Fc receptors and complement receptors. 
Eosinophils and mast cells playa central role in inflammation associated with 
allergy. Central to this response are IgE and its receptors (e.g. FCERI and CD23) 
expressed on these cells. 
1.6.2 Atherosclerosis and the immune response 
Atherosclerosis is a major cause of cardiovascular disease and stroke. Plaques 
(focal lesions) in the arterial tree are composed of cell debris, lipid (mainly 
cholesterol), inflammatory cells, such as macrophage foam cells and a fibrous cap 
of smooth muscle cells and collagen124. Rupturing of plaques promotes thrombus 
formation and leads to ischaemia in end organs such as the brain or heart125. 
1.6.2.1 Local responses 
Atherosclerosis is a chronic inflammatory disease in which both cell-mediated and 
humoral immune responses participate. Hypercholesterolemia and hypertension 
initiate the inflammatory activation of the vascular endothelium. Immune cells are 
recruited across the endothelial barrier into the arterial intima. Platelet 
glycoproteins activate endothelium via engagement of surface molecules126. Excess 
LDL penetrates the artery wall, facilitated by proteoglycans of the extracellular 
matrix that bind LDL, where it is prone to oxidation127. Phospholipids released 
from LDL activate endothelial cells, which then express vascular cell-adhesion 
molecule-1 (VCAM-1)128. Haemodynamic strain of oscillating flow changes, 
common at arterial branches, also promotes VCAM-1 expression129. Monocytes 
and T cells display the VCAM -1 receptor, VLA-4 and therefore adhere to the 
endothelium. Chemokines such as monocyte chemoattractant protein-1 (MCP-1), 
RANTES, fractalkine and others, also recruit monocytes and T cells to the lesion. 
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Monocyte-colony stimulating factor (M -CSF) induces monocytes entering the 
plaque to differentiate into macrophages that express pattern recognition 
receptors, such as scavenger receptors and TLRs130 • P AMPs such as endotoxins, 
endogenous molecules such as heat-shock proteins (HSPs), apoptotic cell 
fragments and oxidized LDL (oxLDL) are taken up and destroyed via the scavenger 
receptor pathway. TLRs also bind molecules with pathogen-like patterns, but in 
contrast initiate an activation signal pathway131. Cholesterol contained in the LDL 
accumulates in the macrophage cytoplasm and transform the macrophage into a 
foam cell. TNF produced by neighbouring immune cells and IL-l by immune and 
vascular cells, trigger a signal transduction pathway similar to TLRs132 to produce 
inflammatory cytokines, chemokines, proteases, vasoactive agents, cytotoxic 
oxygen and nitrogen radical molecules. 
Endothelial nitric oxide synthase (eNOS) and thrombomodulin confer anti-
adhesive and anti thrombotic properties to the vessel wall and thereby maintain 
bloodflow, however these favourable factors are reduced in response to 
inflammatory cytokines and oxLipids. 
Antigens such as oxLDL, Hsp-60 and microbial antigens activate T cells in the 
atherosclerotic artery. CD4+ Thl predominate and secrete INFy, which leads to 
activation of macrophages and endothelial cells. INFy improves the efficiency of 
antigen presentation and augments synthesis ofTNF and IL-l synergistically 
instigating the production of inflammatory and cytotoxic molecules in 
macrophages and vascular walls. However, regulatory T cells act to inhibit 
atherosclerosis by producing IL-IO and TGF~133, 134, 
1.6.2.2 Systemic responses 
Systemic reactions include humoral immunity and acute phase reactants135. 
Antibodies reactive to oxLDL are abundant in atherosclerosis. IgM reactive to 
phospholipid epitopes, cross-react with oxLDL, apoptotic bodies and the capsule of 
Streptococus pneumoniae, all of which contain phosphocholine136. These 
antibodies may contribute to the elimination of oxLDL and dead cells as well as 
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defence against pneumococcal infections. Atheroprotective immunity can be 
induced (in animals) by immunization with oxLDU37 or Hsp-6S13B• 
Acute phase reactants include CRP, serum amyloid A, fibrinogen, pentraxin-3 and 
others. CRP is an independent risk factor for coronary artery disease139, and likely 
reflect inflammation in the coronary artery rather than the ischemic 
myocardium140. CRP acts together with complement to eliminate microbes and 
C3, C4 and terminal CSb-C9 complement complexes occur in atherosclerotic 
lesions141. 
1.6.2.3 Plaque rupture 
Activated macrophages, T cells and mast cells at sites of plaque rupture142, 143 
produce several types of molecule - inflammatory cytokines, proteases, 
coagulation factors, radicals and vasoactive molecules - that destabilise lesions. 
Inflammation interferes with the integrity of the interstitial collagen matrix by 
blocking the formation of new collagen fibres and therefore formation of stable 
fibrous caps, and by stimulating the destruction of existing collagen, initiating 
thrombus formation144. TGFp, Platelet-derived growth factor (PDGF) and IL-l 
stimulate smooth muscle cells to produce collagen. However INFy, produced by T 
cells in the plaque, inhibits both basal collagen production and the stimulatory 
effects ofTGFp, PDGF and IL-1145. 
Matrix metalloproteinases (MMPs)146 and cysteine proteases147 have been 
implicated in plaque activation. CD40 ligand and IL-l produced by T cells 
promote the production of collagen-degrading enzymes by macrophages including 
MMP-l, MMP-8 and MMP-1314B. MMP are synthesized and secreted as inactive 
proenzymes, activated by TNFa, tryptase and chymase146. CD40 ligand also 
stimulates the production of tissue factor, when exposed to factor VII, initiates the 
coagulation cascade144. 
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1.7 Anti inflammatory effects of statins 
Statins interfere with the pro inflammatory pathway of adhesion and migration at 
the protein expression and function levels. For example, Lovastatin and 
cerivastatin have been shown to reduce expression ofthe ICAM-1ligand - CDllb 
on monocytes and inhibit adhesion of leukocytes to endothelial cells149, 15°. Table 
1.5 summarizes the inflammatory pathways and mediators affected by HMG-CoA 
reductase inhibitors. Reduction in adhesion molecule synthesis also occurs in 
other cell types e.g., E-selectin and VCAM-1 on EC149, 15°. 
Statins diminish the expression and function of proatherogenic cytokines such as 
IL-6, IFN-g and TNFa in macrophages151. Stains may also repress the activation of 
T lymphocytes by inhibiting MHC class II antigen expression152. 
Statins regulate expression of chemokines MCP-1, IL-8 and RANTES in cultured 
monocytes, ECs and SMCS153, 154. Inhibition of sterol synthesis via squalestatin was 
not comparable in a study, suggesting that the in vivo regulation of 
cytokine/ chemokines production by statins depends on the biosynthesis of 
nonsterol compounds arising from mevalonate155. MCP-1 induction (as well as IL-
1P and TNFa) reduced by statins is related to a decrease in NFxB activation156. 
Statins may mediate apoptosis. Concentrations as low as 10 nM induce the 
expression of proapoptotic enzymes caspase-3 and -9 and limit the expression of 
Bcl-2, an inhibitor of apoptosis157, 158 . Reduced prenylation OfP21-RhoB, a central 
regulator of apoptosis, by statins in SMCs, promotes apoptosiS159. In atherogenesis, 
apoptosis promotes the formation if the lipid core by the death of foam cells and 
influences the SMC content in the fibrous cap160. 
Statins lower the expression and function of a broad range of MMPs including 
interstitial collagenases, MMP-1 and MMP-13, gelatinases MMP-2 and MMP-9, 
and stromelysin MMP-3 in most cell types involved in atherogenesis including 
macrophages161,162. Statins also augment the expression ofTIMP-1 in SMCs and 
macrophages, which limits extracellular matrix breakdown, and thus render 
lesions less prone to rupture163. Mechanisms regulating MMP /TIMP expression 
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Process/pathway Mediator Cell type 
Adhesion D 
• 
CDllb, LFA-l (also via direct M~ and T cells to 
binding) endothelium; 
• 
ICAM-l (and sICAM-l), peripheral blood 
VCAM-l (and SVCAM-l) 
• 
E-selectin, L-selectin 
Migration D • 
MCP-l, IL-8, RANTES EC, SMC, M~, T cells 
Proliferation D 
• 
SMC, EC(via 
D t 
p2l[Wafl/Cipl]) 
Endothelial function eNOS EC 
• 
LDL oxidation, Endothelin-l 
Matrix degredation D 
• 
Interstitial collagenases 
MMP-l/-l3 
• 
Gelatinases MMP-2/-9, 
Stromelysin MMP-3 
t TIMP-l 
Apoptosis D t Caspase-3, Caspase-9 EC,SMC,M~ 
• 
Prenylation of P2lRhoB, Bcl-
2 
Thrombosis D 
• 
Tissue factor, Factor VIla, t- EC, M~, platelets; 
PA, TX2, TxB2 peripheral blood 
• 
Platelet aggregation 
t Fibrinogen, PAI-l,PGI2 
Inflammatory mediators 
• 
CD40/CD40L, sCD40L 
D IL-lf3, IL-6, TNF-a, CRP, 
• 
cyclooxygenase 2, Serum 
amyloid A 
• 
MHC II, Thl (IFN-y, IL-l2) 
t PPAR-g, Th2 (IL-4, IL-lO, TGF-(3) 
Table 1.5 Inflammatory pathways and mediators affected by HMG-CoA 
reductase inhibitors. 
Arrows indicate enhanced or diminished activation/ expression of 
pathway/mediator after statin administration. (Adapted from Schonbeck et al164) 
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may involve NF-KB activity and prenylation of Rho proteins165. 
Statins modulate lesional procoagulant activity and platelet activity. They reduce 
tissue factor expression166, the primary initiator of the extrinsic pathway in 
macrophages and ECs. They also promote fibrinolytic activity by diminishing 
plasminogen activator inhibitor-1 expression and enhancing tissue-plasminogen 
activator in EC and SMCS167. Statins inhibit fibrinogen expression and thrombin 
formation, and reduce platelet aggregation and deposition in diseased vessels168. 
Reduced expression of COX -2, TxA2 or TxB2 and enhanced synthesis of 
prostacyclin by statins contribute to diminished platelet activation169, 170 • 
Statins reduce the susceptibility of LDL to oxidation by lowering the amount of 
substrate available for oxidation171 and reducing macrophage superoxide formation 
thereby decreasing oxygen production172. Fluvastatin and lovastatin bind to 
phospholipid on the surface of LDL and thus prevent diffusion into the lipoprotein 
core, of free radicals, generated under oxidative stress173. Atorvastatin has also 
been shown to have direct antioxidant effects by protecting LDL, VLDL and HDL 
from oxidation174. 
Statins can directly upregulate eNOS expression and prevent its down regulation by 
oxidized LDU75. Endothelium dependent vasodilation is increased by simvastatin 
after four weeks treatmentI76. 
1.8 Clinical trials and the effects of statins 
Several clinical trials have suggested that benefit of statin therapy is greater than 
that expected on the basis of LDL reduction alone. 
1.8.1 Scandinavian Simvastatin Survival Study (4S) 
The secondary prevention trial, Scandinavian Simvastatin Survival Study (4S)177 
established the importance of treating the hypercholesterolaemic patient with 
cardiovascular disease. A total of 4444 patients with serum cholesterol 212-
------------ - --------------~-------------- ---------~~-- ----
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309mg/dl (5.5-8.ommol/l) and angina or prior myocardial infarction (i.e. stable 
coronary disease) were given either simvastatin (dose range 10-40mg) or placebo 
and followed up for a median of 5-4 years. LDL cholesterol was reduced by 35% 
and total cholesterol by 25%, in the simvastatin group. Treatment with 
simvastatin significantly reduced the total mortality primary end-point (RR 0.70, 
95%CI 0.58-0.85), as well as major coronary events (defined as coronary death, 
myocardial infarction, or resuscitated cardiac arrest, RR 0.66, 95%CI 0.59-0.75), 
and coronary mortality (RR 0.58, 95%CI 0-46-0.73). Statin therapy also reduced 
the need for coronary revascularization with bypass surgery or angioplasty (RR 
0.63, 95%CI 0.54-0.74). There was no difference between the treated and placebo 
groups in noncardiovascular deaths. This study established that hypolipidaemic 
therapy was safe and reduced morbidity and mortality in hypercholesterolaemic 
patients with IHD. It concluded that all patients with elevated cholesterol levels 
and known previous cardiovascular heart disease should receive statins to limit 
future adverse events. 
Post hoc analysis of the 4S study suggested that the benefit provided by 
simvastatin was indeed related to the change in LDL cholesterol178 . 
1.8.2 West of Scotland Coronary Prevention study 
(WOSCOPS) 
The primary prevention trial, The West of Scotland Coronary Prevention study 
(WOSCOPS)179 investigated whether hypolipidaemic therapy was beneficial in 
hypercholesterolaemic men without a prior history of myocardial infarction. 6595 
men aged 45-64 years, at high risk of coronary events were enrolled i.e. middle-
aged men with high lipid levels - mean total cholesterol 27222mg/dl (7.03 
±0.57mmol/l) and elevated BMI (26 ±3.1kg/m2), and over a third were current 
smokers. They were treated with either 40mg/ day of pravastatin or placebo, and 
followed up over an average of 4.9 years. LDL cholesterol was reduced by 26% and 
total cholesterol by 20% with pravastatin. Pravastatin therapy reduced the 
primary end-point of non-fatal myocardial infarction or coronary deaths by 31% 
(95%CI 17-43%), revascularization procedures by 37% (95%CI 11-56%) and 
cardiovascular mortality by 32% (95%CI 3-53%). The reduction in total mortality 
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of 22% was of barely significant (p=0.051) and there was no difference in non-
cardiovascular mortality. This suggests that in subjects with no previous heart 
disease, treatment of elevated lipid levels does not achieve as great a benefit as it 
would in a group with known cardiovascular disease, (such as in the 4S 
population). The reduction of coronary events in WOSCOPS was profound, and 
high-risk hypercholesterolaemic patients not previously known to have IHD would 
still benefit from treatment of hyperlipidaemia. 
Post hoc analysis of the WOSCOPS study180 applied the Framingham coronary 
heart disease model and accurately predicted the risk in the placebo group but 
underestimated the risk reduction in the pravastatin group by 31%. The benefits of 
LDL reduction with statins also appear to occur earlier than observed with other 
cholesterol lowering therapies such as cholestyramine and ileal bypass surgery181, 
182, although they did provide long term risk reduction. It was concluded that LDL 
reduction alone might not account for the observed benefits of statin therapy. 
1.8.3 The Cholesterol and Recurrent Events (CARE) study 
Data from The Cholesterol and Recurrent Events (CARE) study suggests that 
pravastatin, in a process independent of LDL lowering, directly attenuates the 
adverse effects of inflammation183. Subjects examined had average cholesterol 
levels of 209 ±17mg/dl (5-4±0-4mmol/l) and a history of myocardial infarction. 
4159 patients had follow-up for a median five years. LDL cholesterol was reduced 
by 28% and total cholesterol by 20%. Pravastatin treatment compared to placebo 
reduced the primary end-point (defined as coronary death or non fatal myocardial 
infarction) by 24% (95%CI 9-36%). There was no significant difference in 
cardiovascular, non-cardiovascular or total mortality. However, the significant 
reduction in the primary end-point could be accounted for by the marked 
reduction in myocardial infarction. Pravastatin therapy also lowered the need for 
revascularization procedures and the incidence of strokes were significantly 
reduced. Patients with a prior myocardial infarction (secondary prevention), 
hypolipidaemic therapy is important even if cholesterol levels are not highly 
elevated. However, the absence of coronary mortality reduction, and the lower 
percentage reduction of major coronary events in the CARE study compared to 4S, 
~ _.- ._--------------------------- - --------
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suggests that it is the patient who is both hyperlipidaemic and high-risk who will 
benefit most from therapy. 
In a stratified analysis, patients with persistent inflammation, measured by 
elevation of hs-CRP and serum amyloid A, were at increased risk of recurrent 
cardiovascular events184. This was shown in the placebo study group who's risk of 
recurrent events were: relative risk=2.81, P=0.007 compared to in the pravastatin 
group: relative risk=1.29, P=0.5. Although the two groups had identical LDL 
baseline levels, the proportion of recurrent cardiac events prevented by pravastatin 
was 54% among those with high CRP levels and 25% without inflammation. 
Pravastatin therapy also reduced median hs-CRP over five years, compared with 
placebo185. Taken together the data suggests pravastatin has clinically important 
anti-inflammatory properties in addition to LDL cholesterol lowering. 
1.8.4 Long Term Intervention with Pravastatin in Ischemic 
Disease (UPID) study 
The placebo-controlled, Long Term Intervention with Pravastatin in Ischemic 
Disease (LIPID) study enforced the importance of hypo lip ida ernie therapy in 
secondary prevention 186. Subjects enrolled had a broad range of initial total 
cholesterol levels, from 155 to 271mg/dl (4.0-7.ommoljl) and a history of 
myocardial infarction or unstable angina with. After a mean follow-up of 6.1 years 
9014 patients were enrolled. Pravastatin reduced LDL cholesterol by 25% and 
total cholesterol by 18%. The primary end-point was coronary mortality and 
pravastatin treatment reduced this by 24% (95%CI 12-35%). Total mortality was 
reduced by 22% (95%CI 13-31%). There was also a 24% reduction of major 
coronary events (coronary death and non fatal infarction), 20% reduction in 
coronary revascularization and 19% reduction in strokes. Subgroup analysis of 
LIPID showed the benefit of hypolipidaemic therapy over all ranges of total 
cholesterol levels, however benefit was seen most in those with the highest LDL 
cholesterol. 
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1.8.5 Air Force/Texas Coronary Atherosclerosis Prevention 
Study (AFCAPS/TEXCAPS) 
The placebo controlled, randomised trial, Air Force/Texas Coronary 
Atherosclerosis Prevention Study (AFCAPS/TEXCAPS)187 investigated the effects 
of lovastatin on a healthy population with average risk and normal cholesterol 
levels of 221 ±21mg/dl (5.71 ±0.54mmoljl) but having low HDL cholesterol: <45 
mg/dl for men (1.16mmoljl) and <47mg/dl (1.22mmoljl) for women. Treatment 
with lovastatin significantly reduced LDL cholesterol by 25%, total cholesterol by 
18%, and increased HDL cholesterol by 6%, after a year. 5608 men and 997 
women received a mean follow-up of 5.2 years, the primary end-point of first 
major coronary event, defined as myocardial infarction, unstable angina or sudden 
death, was highly significantly reduced (RR 0.63, 95%CI 0.50-0.79). A similar 
marked improvement was seen in risks of myocardial infarction, unstable angina 
and coronary revascularization. There was no difference in total mortality between 
the two groups188 with 80 deaths in the lovastatin group, and 77 in the placebo 
group (RR 1.04, 95%CI 0.76-1.42). Over two-thirds (115) were from non-
cardiovascular causes, which highlight the fact that in a group of people not at high 
risk of coronary deaths, therapy to lower cholesterol cannot do much to lower 
mortality. Non-statin hypocholesterolaemic drugs have revealed similar findings 
of a reduction in cardiac end-points without total mortality reduction in primary 
prevention trials. AFCAPS/TEXCAPS concluded that patients at high risk of 
adverse cardiovascular events should be treated with statin even though their 
cholesterol levels are not elevated. 
1.8.6 Myocardial Ischemia Reduction with Aggressive 
Cholesterol Lowering (MIRACL) study 
The Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering 
(MIRACL) study189 looked at the acute coronary syndromes (ACS) and the effect of 
early use of atorvastatin. 3086 patients with unstable angina or non-Q-wave 
myocardial infarction were randomly assigned to atorvastatin 80 mg/ day or 
placebo at 24-96 h of admission. Atorvastatin treatment reduced LDL cholesterol 
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by 52% and total cholesterol by 34%. After a follow-up of 16 weeks, atorvastatin 
therapy produced a significant reduction in the primary end-point, defined as 
death, non-fatal myocardial infarction, cardiac arrest or recurrent symptomatic 
ischaemia (RR 0.84, 95%CI 0.70-1.00). Unfortunately, there was no significant 
change in death, non-fatal myocardial infarction or cardiac arrest, and the benefit 
was seen in the reduction of recurrent ischaemia. This study concluded that more 
benefit from other therapeutic interventions would arise when dealing with 
unstable angina and myocardial infarction190, i.e. quick, increased, coronary flow 
which is not obtainable with hypolipidaemic therapy. 
1.8.7 Atorvastatin Versus Revascularization Treatment 
(AVERT) study 
The Atorvastatin Versus Revascularization Treatment (AVERT) study investigated 
the value of aggressive cholesterol reduction in comparison with coronary 
angioplasty191. 341 patients with stable angina recommended for percutaneous 
intervention were studied. 177 were advised to have angioplasty and 164 were 
given 80 mg/ day atorvastatin instead of angioplasty. Atorvastatin treatment 
reduced LDL cholesterol by 46% and total cholesterol by 31%. After a follow-up of 
18 months, 13-4% of patients assigned to the aggressive lipid-lowering therapy had 
had an ischaemic event, compared to 20.9% in the angioplasty group (risk 
reduction 36%, P=0.048, not significant after adjustment for interim analysis). It 
took significantly longer to reach an ischaemic event in the atorvastatin group (RR 
0.64, 0.33-0.95, P=0.03). The study confirmed the safety of aggressive lipid 
reduction therapy, and suggested that it may be as effective as angioplasty in 
managing patients with stable angina pectoris. It has been shown that angioplasty 
does not reduce the incidence of MI or coronary mortality192, as MIs are not due to 
the progression of previously narrowed plaques, but the sudden disruption of 
mildly stenotic lesions125. 
1.8.8 Heart Protection (HPS) study 
The Heart Protection (HPS) study established the benefit of statin therapy in 
patients at high risk of atheromatous disease, regardless of initial lipid levels, in 
-~-----------------------------~-~-------------------------------------
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preventing adverse events193. 20 536 patients at high risk of coronary mortality 
due to prior coronary disease (secondary prevention), presence of non-coronary 
atheromatous disease or diabetes were recruited and followed-up for a mean of 
five years. Patients were randomised to receive simvastatin 40 mg/ day or placebo. 
Simvastatin reduced LDL cholesterol by 1.0mmoljl (29-4%) and total cholesterol 
by a mean of 1.2mmoljl (20.3%). Primary end-point was total mortality. 
Simvastatin produced a highly significant reduction in total mortality (RR 0.87, 
95%CI 0.81-0.94, P=0.0003), in major coronary events (RR 0.73, 95%CI 0.67-
0.79, P<O.OOOl), in strokes (RR 0.75, 95%CI 0.66-0.85, p<O.OOOl) and in 
revascularization procedures (RR 0.76, 95%CI 0.70-0.83, P<O.OOOl). There was 
no effect on noncardiac mortality and no increase in non-haemorrhagic stroke. 
Women, the elderly, and patients with prior non-cardiac atheromatous disease saw 
a benefit. The value of statin therapy in diabetic patients was seen in the reduction 
of cardiovascular disease in the 5963 diabetics recruited194. The proportional 
reduction in adverse events was the same in all categories of lipid levels, even in 
those with initially low LDL and total cholesterol. 
1.8.9 The Lescollntervention Prevention Study (UPS) 
The secondary prevention Lescol Intervention Prevention Study (LIPS)195 assessed 
the efficacy of fiuvastatin treatment and supported the view that the protective 
effect of statins is a class effect. 
1.8.10 The Prospective Study of Pravastatin in the Elderly at 
Risk (PROSPER) trial 
The mixed secondary and primary prevention study, The Prospective Study of 
Pravastatin in the Elderly at Risk (PROSPER) trial assessed hypocholesterolaemic 
therapy in older patients. 5804 patients aged 70-82 years were randomised to 
either pravastatin 40 mg/ day or placebo. Patients recruited either had a history of 
existing vascular disease (coronary, cerebral or peripheral) or were at risk because 
of smoking, hypertension or diabetes. Pravastatin therapy reduced LDL 
cholesterol by 34%, and increased HDL cholesterol by 5% after three months. The 
primary end-point was composed of coronary death, non-fatal myocardial 
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infarction, and fatal or non-fatal stroke. After mean follow-up of 3.2 years, the 
primary end-point was significantly reduced (RR 0.85, 9S%CI 0.74-0.97, 
P=0.014), due to the lowered risk of coronary death and non-fatal myocardial 
infarction (RR 0.81, 9S%CI 0.69-0.94, p=0.006). There was no significant change 
in stroke incidence (RR 1.03, 9S%CI 0.81-1.31, p=0.8). However, there were more 
frequent new cancer diagnoses in the pravastatin group (RR 1.25, 9S%CI 1.05-1.51, 
P=0.02), supporting the previous concern about the potential carcinogenic 
dangers of statin therapy196. Meta analysis was performed on previous statin trials, 
and showed no overall increase in cancer occurrence whether patients were on 
pravastatin or other statin drugs. 
1.8.11 The Anti-hypertensive and Lipid-Lowering Treatment 
to Prevent Heart AHack Trial-Lipid Lowering Trial 
component (ALLHAT -LLT) 
The mixed primary and secondary prevention trial, Anti-hypertensive and Lipid-
Lowering Treatment to Prevent Heart Attack Trial-Lipid Lowering Trial 
component (ALLHAT-LLT) randomised patients aged >55 years with hypertension 
and one other risk factor to either pravastatin 20-40 mg/day (n=S170) or usual 
care (n=SI8S)197. With pravastatin, LDL cholesterol was reduced by 17% and total 
cholesterol by 10%. There was no difference in the primary end-point of all-cause 
mortality between the pravastatin and usual care groups (RR 0.99, 9S%CI 0.89-
1.11, p=0.88) after a mean follow-up of 4.8 years. With 86% of patients having no 
prior coronary disease it was not surprising that there was no difference in 
coronary heart disease events (RR 0.91, 9S%CI 0.79-1.04, p=0.16). Generally 
healthy patients are at risk of dying from non-cardiovascular causes, and therefore 
any benefit from statin therapy in reducing coronary mortality is obscured. The 
unexpected failure of ALLHAT -LLT to show a reduction in coronary heart disease 
events was attributed to the use of hypolipidaemic therapy in the 'usual care' 
patients. 26.1% of the 'usual care' patients were on statins, 2-4% were on other 
hypolipidaemic drugs and 16.2% of the pravastatin group ended up receiving no 
lipid-lowering therapy at all, after six years198 • 
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1.8.12 Higher dose statin trials (PROVE-IT, REVERSAL and 
ALLIANCE) 
Patients in The Pravastatin or Atorvastatin Evaluation and Infection Therapy-
Thrombolysis in Myocardial Infarction (PROVE-IT)199 were randomised to 
standard therapy with 40 mg/ day pravastatin, or to aggressive therapy with 
atorvastatin 80 mg/day as were phase Z of the A to Z trial2oo. In showing a trend 
favouring early and intensive statin therapy that was more pronounced over a 
longer follow-up period, the A to Z trial supports the findings of MIRACL and 
PROVE-IT which similarly studied ACS patients. Although ACS patients will 
benefit clinically from high-dose statin therapy, liver and muscle enzymes should 
be carefully monitored given the increased incidence of adverse effects. The 
PROVE-IT trial also showed that statin therapy decreases CRP levels in association 
with better clinical outcomes, regardless of cholesterollevels201. 
Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial202 
addressed whether intensive statin therapy would be beneficial in the stable non-
acute coronary patient and successful halt to atheroma progression was 
demonstrated. 
The Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE) 
study suggested that aggressive statin treatment was safe and significantly reduced 
cardiovascular events in patients with known coronary disease, without elevation 
of liver enzymes, rhabdomyolysis or increased cancer 
The treating to New Targets (TNT) recruited patients with stable IHD already 
receiving lomg/day of atorvastatin and either continued with that level or 
increased to 80mg/ day atorvastatin. High dose statin reduced cardiovascular 
outcomes but also increased adverse events. It is therefore important to treat the 
correct patient with high doses of statin to maximize the risk-benefit ratio. 
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1.8.13 The Anglo-Scandinavian Cardiac Outcomes Trial -
Lipid Lowering Arm (ASCOT -LLA) 
The primary prevention study, The Anglo-Scandinavian Cardiac Outcomes Trial -
Lipid Lowering Arm (ASCOT -LLA)203 recruited 19,342 hypertensive patients with 
at least three other cardiovascular risk factors, thus at higher risk of cardiovascular 
event than those in ALLHAT-LLT. Patients were randomised to either 10 mg/day 
atorvastatin or placebo, with a primary end-point of nonfatal myocardial infarction 
and fatal coronary heart disease. In the atorvastatin group, 100 events occurred 
and in the placebo group, 154 events (HR 0.64, 95%CI 0.50-0.83, p=0.0005 ) 
after a median follow up of 3.3 years. Incidence of chronic stable angina, strokes, 
and total coronary and cardiovascular events and procedures, were all significantly 
reduced. Statistical significance was not reached with reduction in total mortality 
(HR 0.87, 95%CI 0.71-1.06, p=0.16). ALLHAT-LLT and ASCOT-LLA suggest that 
the high-risk hypertensive patient will benefit from statin therapy, while the 
hypertensive with no previous cardiovascular disease and at low risk will not. 
1.8.14 A Study to Evaluate the Effect of Rosuvastatin on 
Intravascular Ultrasound-Derived Coronary Atheroma 
Burden (ASTEROID) 
A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-
Derived Coronary Atheroma Burden (ASTEROID)204 assessed whether very 
intensive statin therapy (40mgjday rosuvastatin) could regress atherosclerosis. 
The percent atheroma volume was measured by Intravascular ultrasound. Average 
LDL cholesterol achieved was 60.8mg/dL (53.2% reduction) and HDL cholesterol 
increased by 14.7%. Treatment to LDL cholesterol levels below currently accepted 
guidelines accompanied by significant HDL cholesterol increases, regressed 
atherosclerosis in coronary disease patients. 
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1.9 Non statin lipid lowering trials 
Low levels of HDL-C have long been associated with an increased cardiovascular 
events risk205, 206. Elevated HDL-C levels are protective as they drive reverse 
cholesterol transport (RCT) which results in the net delivery of systemic 
cholesterol back to the liver for disposal as bile salts or to steroidogenic organs for 
conversion to steroids (e.g. adrenalin)207. Atherosclerotic disease is prevented as 
long as RCT outpaces accumulation of cholesterol in vessel walls. HDL reduces 
oxidation of LDL via activity of paraoxonase208 and platelet activating factor acetyl 
hydrolase209, rendering it less atherogenic. HDL stimulates eNOS activity and 
increases NO and arterial vasodilation21O. HDL decreases VCAM-l expression 211 
and decreases platelet aggregability212. 
1 .9. 1 Fibrates 
The peroxisome proliferator-activated receptors (PPARs) (i.e., PPAR-a, -~ and -y) 
form the steroid nuclear receptor superfamily213• All PPARs are activated by fatty 
acids and derivatives. When PPAR-a binds a hypolipidemic fibrate, the activated 
complex interacts with the retinoid X receptor (RXR). The PPAR-RXR 
heterodimer regulates the transcription of a variety of genes involved in 
inflammation, as well as lipoprotein and fatty acid metabolism by binding to the 
peroxisome proliferator response elements within the promoters of these genes. 
Fibrates stimulate lipoprotein lipase and apolipoprotein (apo)A-Vand inhibits 
apoC-III expression (which is a lipoprotein lipase inhibitor) and drives metabolism 
oftriglycerides in VLDL and chylomicra214. Hepatic uptake and esterification of 
free fatty acids is increased, and mitochondrial free fatty acid uptake and the 
resulting free fatty acid oxidation is increased. Plasma HDL-C increases are 
dependent partly on hepatic overexpression of apoA-I and apoA-II and 
upregulation of HD L-C proteins215, 216. PP ARs are also expressed in atherosclerotic 
lesions and fib rates reduce serum CRP levels217. 
PPAR-alpha activators; bezafibrate, fenofibrate and gemfibrozil, reduce 
triglycerides and increase HDL-cholesterol, without significantly affecting LDL-
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cholesterol, to slow down coronary artery luminal narrowing and decrease 
coronary artery disease mortality in secondary prevention trials. 
1.9.1.1 Helsinki Heart Study 
The Helsinki Heart Study found a 34% reduction in the combined CVD endpoint in 
the gemfibrozil treatment group that was independently related to an HDL-C 
increase of 10%218. 
1.9.1.2 Veterans Affairs High-Density Lipoprotein Cholesterol 
Intervention Trial (VA-HIT) 
Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (VA-
HIT) study219 found an 11% decrease in CVD events for every smg/ dL increment in 
HD L-C when treated with gemfibrozil. 
Fibrate use did not confer an independent risk reduction in CVD in patients with 
low baseline HDL-C and High TG levels. Reductions of 30% in triglycerides were 
not independently predictive of a reduction in CVD risk in both studies. 
1.9.2 Niacin 
Niacin (Nicotinic acid, Vitamin B3) is a precursor for nicotinamide adenine 
dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphatase (NADP). 
The reduced coenzyme forms participate in red-ox reactions of many metabolic 
processes220. Chronic deficiency causes pellagra. 
Niacin (at doses of 1-3g/day) is also effective at increasing HDL levels221. 
Mobilization of fatty acids and triglyceride levels are decreased by inhibition of 
lipolysis in adipose tissue. Niacin inhibits triglyceride production at two synthetic 
sites: fatty acid synthesis from acetate and esterification of fatty acids to form 
triglyceride222. Niacin inhibits directly and non competitively microsomal 
diacylglycerol acyltransferase (DGAT), a rate limiting enzyme in triglyceride 
synthesis, which limits apoB lipidation, resulting in delayed translocation of apo B 
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across the ER membrane. The result is increased intracellular apoB degradation 
and subsequent decreased VLDL/LDL and inhibition of the formation of 
atherogenic small dense LDL particles. Niacin does not stimulate hepatic 
biosynthesis of HDL. Instead, the HDL subfraction containing ApoA-I without 
ApoA-II (LP-AI) which acts as a cholesterol acceptor, is increased in the serum223. 
1.9.2.1 The Cholesterol-lowering Atherosclerosis study (CLAS) 
The Cholesterol-lowering Atherosclerosis study (CLAS) randomised patients to 
niacin (3-12g/day) combined with bile acid sequesterant colestipol (30g/day) or to 
diet/placeb0224. LDL decreased by 39%, triglycerides by 16% and HDL rose by 
35%. After two years follow up Quantitative coronary angiography showed 
regression of lesions in 16% of patients compared to 2% on diet/placebo. 
1.9.2.2 sAfety and tolerability stUdy of a modified-release 
nicoTinic acid formuLation in sUbjects with dySlipidaemia 
and low HOL-cholesterol (NAUTILUS) 
The multiceNtre, open, uncontrolled sAfety and tolerability stUdy of a modified-
release nicoTinic acId formuLation in sUbjects with dySlipidaemia and low HDL-
cholesterol (NAUTILUS) recruited 566 patients with dyslipidaemia where lipids 
were inadequately controlled by four weeks of diet treatment and had low HDL-
cholesterol « 1.03mmoljL [< 4omg/dL] in men and < 1.29mmoljL [< 50mg/dL] 
in women), and had triglycerides < 9.o3mmoljL ( < 8oomg/ dL)225. Prolonged-
release nicotinic acid was well tolerated, and the study supports its use in the 
management of patients with low HDL-cholesterol at elevated cardiovascular risk. 
1.9.2.3 ARBITER 2 study 
The ARBITER 2 study recruited patients on stable treatment with statins, average 
LDL cholestero12.3mmoljL, mean duration of statin treatment five years226. They 
all had CHD and low HDL cholesterol and were randomised to placebo or 19/day 
PR nicotinic acid (Niaspan) in combination with statin treatment for one year. 
Niacin increased HDL cholesterol by 21%. Carotid intima-media thickness 
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progressed in the placebo/statin group but remained unchanged in the nicotinic 
acid/ statin group, showing a beneficial effect of Niacin. 
1. 9.3 Infusion of HDL 
Intravenous infusion of HDL or bioengineered HDL induces the regression of 
atheromatous plaques227. 
1.9.4 Ezefimibe 
Ezetimibe binds to Niemann-Pick C1-like 1 (NPC1L1) receptors to dose 
dependently inhibit cholesterol absorption. Ezetimibe localizes at the brush 
border of the small intestine228 and does not affect the absorption of triglycerides, 
fatty acids bile acids or fat soluble vitamins229. Ezetimibe is glucuronidated in the 
intestine and undergoes enterohepatic recirculation, repeatedly returning to its 
site of action and minimizing systemic exposure, explaining its long half life230. 
1.9.4. 1 Ezetimibe Monotherapy trials 
Ezetimibe reduced LDL cholesterol in patients with hypercholesterolaemia in two 
randomised, placebo-controlled phase 3 trials. 892 patients treated with 
1omg/day ezetimibe decreased LDL-C by17.7% compared with placebo (P<O.01) 
and increased HDL-C by 1.3% compared with 1.6% decrease with placebo 
(p<O.01)231• In another trial 827 patients treated with 10mg/day ezetimibe 
decreased LDL-C by 18.2% and increased HDL-C by 1% compared with 1.6% 
decrease with placebo (p<O.01)232. 
1.9.4.2 Ezetimibe plus statin trials 
Ezetimibe was combined with four different statins in randomised double blind 
placebo controlled studies. Patients were randomised to Ezetimibe at 10mg/ day 
alone or with statin at various concentrations or placebo (Table 1.6). Ezetimibe 
with statin lowered LDL-C more effectively than statin alone in each study. 
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Change in concentration (%) 
No of TC LDL-C HDL-C TG ApoB Ref 
patients 
Atorvastatin 248 -32 -44 4 -25 -36 
+ ezetimibe 255 -41 -56 7 -33 -45 233 
Simvastatin 263 -26 -36 7 -17 -30 
+ ezetimibe 274 -37 -51 9 -24 -41 234 
Pravastatin 205 -17 -25 7 -8 -20 
+ ezetimibe 204 -27 -39 8 -18 -30 235 
Lovastatin 220 -18 -25 4 -11 -21 
+ ezetimibe 192 -29 -40 9 -22 -33 236 
Table 1.6 Percent changes in serum lipids:Statin monotherapy versus Ezetimibe 
plus statin 
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CRP was also significantly reduced with combination of statin plus ezetimibe 
compared with statin plus placebo (9.7% v 0%, p<o.OS) in another study237. 
1.9.5 Program on the Surgical Control of the Hyperlipidemias 
(POSCH) trial 
The Program on the Surgical Control of the Hyperlipidemias (POSCH) trial refuted 
a special benefit of statins beyond lipid changes238. Ileal bypass surgery lowered 
LDL by 38% and reduced major CHD events by 3S%, which was almost identical to 
statins. 
1.10 Other uses of Statins 
The anti-inflammatory and immunomudulatory nature of the pleiotropic effects of 
HMG CoA reductase inhibitors239 on prenylation allow a wide variety of uses. 
1.10.1 Immunomodulation 
1.10. 1. 1 Transplant Rejection 
Hyperacute rejection begins within minutes, with intravascular thrombosis 
initiated by binding of pre existing antibodies to HLA and complement to the 
endothelium. Secretion of von Willebrand factor mediates platelet adhesion and 
aggregation. Acute rejection, tissue injury mediated by T cells, macrophages and 
antibodies, follow within the first week. T cells respond to MHC molecules and 
antigens. Activated CD8+ T cells cause direct lysis of graft cells and CD4+ T cells 
produce cytokines that recruit and activate inflammatory cells to cause necrosis. 
Antibodies made during the humoral response bind to vessel walls and activate 
complement. Chronic rejection is characterised by fibrosis and graft 
arteriosclerosis, occurring over a prolonged period. Remodelling of the graft 
extracellular matrix produces scarring which leads to progressive graft dysfunction 
and loss240. 
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1.10.1.2 Current Immunosuppression 
1.10.1.2.1 Corticosteroids 
Glucocorticoids were the first immunosuppressants used in transplantation. They 
affect gene expression of many cytokines on T and B cells, macrophages, 
granulocytes and monocytes240 • 
1.10.1.2.2 Antimetabolites 
Azathioprine and Mycophenolate mofetil inhibit DNA and RNA synthesis by 
blocking de novo synthesis of purine and therefore clonal expansion of T and B 
cells2 41• 
1.10.1.2.3 Calcineurin inhibitors 
Cyclosporin is the most commonly used immunosuppressive agent. As it is T cell 
selective, the incidence of infection is lower. Cyclosporin binds to cyclophillin and 
inhibits the calcium/calmodulin-activated protein phosphatase calcineurin. 
Calcineurin activates the cytoplasmic component of the transcription factor, 
nuclear factor of activated T cells (NFAT). Cyclosporin blocks NFAT and therefore 
the transcription of cytokines such as IL-2 and the growth and differentiation of T 
cells240 • Cyclosporin also induces the synthesis of the immunosuppressive 
cytokine TGF_~57. 
Tacrolimus binds FK binding protein 12 which also inhibits calcineurin. 
1.10.1.2.4 Target of rapamycin inhibitors 
Rapamycin (sirolimus) also binds FK-binding proteins, but does not inhibit 
calcineurin. It binds the kinase, target of rapamycin, preventing the translation of 
cell cycle regulation mRNA and T cell proliferation242 • 
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1.10.1.2.5 Monoclonal antibodies 
The monoclonal antibody OKT3, against CD3 causes non specific T cell depletion. 
CD3 facilitates T cell receptor signalling which is critical in CD4+ activation by 
antigen and in CD8+ cells to bind and lyse target cells243• 
Daclizumab is a humanised mAb and basiliximab a human/mouse chimeric mAb 
against CD25, a key unit of the IL-2 receptor and therefore inhibits T cell 
proliferation244• 
1.10.1.2.6 Statins 
Statins reduce isoprenylation of proteins, such as Ras and Ras-related proteins, 
which are important in T-cell activation and effector function and are pivotal in the 
development of allograft rejection during organ transplantation245• 
Statins have been reported to effectively repress the induction of MHC-II 
expression by interferon-y in a dose-dependent manner. Messenger RNA 
experiments established that the specific mechanism by which MHC-II induction 
inhibited by statins was a selective, repressive effect on the induction of expression 
of the promoter IV region of the MHC-II transactivator (CIITA) gene. Inhibition of 
inducible expression of MHC-II molecules, in the considerable variety of cells that 
normally become MH C-II -positive by the effect of interferon -y I has multiple 
functional consequences. Such conditions include repression of the activation of 
endogenous CD4 + T lymphocytes and recognition of MHC-II molecules by CD4 + T 
lymphocytes in an allogeneic context after organ transplantation152• 
In response to several stimuli, including the T-cell receptor cross-linking with 
MHC-II complex, LFA-l binds to intercellular adhesion molecule-l (rCAM-l) and 
provides a potent costimulatory signal for activated T cells. Statins bind directly to 
a novel allosteric site within LFA-l (see section 1.5.2.1.1) thus inducing 
immunosuppression. CD40 is also a costimulatory molecule and its signalling, via 
an activation of vascular cells, has been shown to induce inflammatory responses 
with expression of adhesion molecules and secretion of proinflammatory 
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cytokines, chemokines, matrix metalloproteinases, and tissue factor246 and been 
implicated in allograft rejection after organ transplantation247. 
Pravastatin has been reported to decrease coronary artery intimal lesions while 
depressing IgG alloantibody levels, suggesting a role for the humoral immune 
response in the development of cardiac allograft vasculopathy248 . 
Given these beneficial effects, early statin therapy (regardless of cholesterol level) 
should be an integral part of the immunosuppressive regimen in transplantation. 
1. 10. 1.3 Statin transplant trials 
A number of studies confirmed the benefit of statins in cardiac transplantation249, 
250 and showed not only a decrease in the development of cardiac allograft 
vasculopathy and improved survival, but also a surprising reduction in the number 
of rejection episodes. The "effect of pravastatin on outcomes after cardiac 
transplantation" trial involved 97 cardiac-transplant patients treated with or 
without pravastatin. Cholesterol levels, survival, rejection with haemodynamic 
compromise, the development of cardiac allograft vasculopathy, and decreased 
natural-killer-cell cytotoxic effects were significant first-year benefits seen in the 
statin-treated patients and suggested an immunomodulatory effect250. The 
pravastatin-treated group had greater 10-year survival than the control group 
(68% versus 48%; P = 0.026) and greater 10- year freedom from the combined 
endpoint of angiographic graft vasculopathy, death, or both (43% versus 20%; P = 
0.009)251• A similar effect was found in a study with simvastatin249. 
A randomised open label renal transplant study of 48 patients randomised to 
treatment with or without pravastatin together with cyclosporin, azathioprine and 
corticosteroids, showed after four months a significantly lower incidence of 
rejection252. However, a multicentre randomised trial of 346 patients double blind 
randomised to fluvastatin with cyclosporin, corticosteroids and azathioprine 
showed no effect on rejection rate, severity of rejection or graft function during the 
first three months after renal transplantation. Nevertheless, the lipid profiles were 
altered beneficially with a trend toward a smaller number of mild rejection 
biopsies in the fluvastatin group. 
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The Assessment of LEscol in Renal Transplantation trial (ALERT) was a large 
multicentre, randomised, double blind, placebo-controlled trial in 2102 renal 
transplant patients with total cholesterol 4.0-9.0 mmoljL (154.7-348 mg/dl)253. 
The reduction in the primary endpoint (total major adverse cardiac events) of 17 % 
was not significant despite a favourable result for the fluvastatin group [risk ratio 
0.83 (95% CI 0.64-1.06), P=0.139]. The rates of cerebrovascular events, 
noncardiovascular deaths, all-cause mortality, and the renal composite endpoint of 
graft loss or doubling of serum creatinine were similar in both groups. This could 
have been due to the stability of the renal patients at entry, comprising of long 
term survivors with good graft function. An alternative primary endpoint such as 
in the WOSCOPS study of cardiac death or definite nonfatal MI would have been 
significant. The absence of an effect on graft loss or doubling of serum creatinine 
was unexpected because chronic allograft nephropathy shares pathophysiological 
mechanisms with atherosclerosis. 
The Study of Lescol (fluvastatin) in Acute Rejection (SOLAR) trial was another 
multicentre, randomised, double blind, placebo-controlled trial in 364 patients 
receiving 40 mg fluvastatin or placebo in combination with cyclosporin254, 255. 
There was no difference in the primary endpoint - treated first acute rejection rate 
[86 (47.3%) fluvastatin vs. 87 (47.8%) placebo] and no significant difference in the 
secondary endpoints - severity of rejection, steroid resistant rejection or mean 
serum creatinine at three months. 
The beneficial effect of statins is more prominent in heart transplant recipients 
where there is established evidence of arterial injury to the donor heart. Although 
there is a lack of immunosuppressive effect in kidney transplant recipients, the 
patients still derive a cardiovascular benefit from statins, similar to the general 
population256. 
1.10.2 Stroke 
The relationship between dyslipidaemia and stroke is less clearly documented than 
CAD. However, the LIPID and CARE trials demonstrated a relative risk reduction 
of stroke of 19% and 31%, respectively in subgroup analyses183, 186. In the primary 
prevention setting of WOSCOPS, the relative risk reduction was 11%. The 
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beneficial effect in these studies resulted from a reduction in non-haemorrhagic 
strokes257• No data exist on statin benefits in the secondary prevention of stroke in 
patients without known CAD. PROSPER focused on a high-risk elderly population 
but showed no reduction on stroke rate perhaps due to the low stroke incidence in 
the study population and short follow-up of 3.2 years2 58 . The relative reduction in 
ischaemic strokes (28%) in the HPS paralleled that of major coronary events193. 
CARDS even reported a 48% risk reduction for strokes in diabetics, higher than 
that for acute coronary events2 59. Taken together, there is clear support of a 
beneficial effect of statins on ischaemic stroke risk, which is comparable to that on 
coronary events. 
1.10.3 Angiogenesis 
HMG-CoA reductase inhibition has a biphasic, dose-dependent effect on 
angiogenesis that is lipid independent and related to geranylated proteins. The 
effect of prenylation inhibition alters endothelial apoptosis and vascular 
endothelial growth factor signalling. Statins have pro angiogenic effects at low 
therapeutic concentrations but angiostatic effects at high concentrations that are 
reversed by geranylgeranyl pyrophosphate26o• 
1.10.4 Rheumatoid arthritis 
Rheumatoid arthritis, a chronic inflammatory disease that destroys synovial joints, 
is associated with systemic as well as local inflammation and with an increased risk 
of cardiovascular disease not fully explained by traditional cardiac risk factors. 
Statins influence multiple steps in the inflammatory process, including leukocyte 
migration and adhesion, T-cell stimulation, nitric oxide bioavailability, generation 
of free radicals, and angiogenesis. Recent studies show that statins may provide 
mild anti-inflammatory benefit in rheumatoid arthritis261, 262. 
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1.10.5 Osteoporosis 
Lovastatin inhibits osteoclasts in vitro by interference with isoprenylation263• 
Statins may therefore have a therapeutic potential in osteoporosis prevention 
and/ or treatmenP64. 
1.10.6 Dementia 
Studies have suggested reductions in risk of dementia and Alzheimer's disease 
with statin treatment26s, 266. There is evidence to suggest a relation between lipids 
and vascular changes involving the brain in dementia. These associations include: 
the e4 apolipoprotein allele (APOEe4) is a risk factor for Alzheimer's disease; the 
effect in cell culture of cholesterol on degradation of the amyloid precursor 
protein; the abnormal appearance of microvascular endothelial cells in affected 
brain areas in Alzheimer's disease; and a possible role of the LDL receptor-related 
protein in Alzheimer's disease. The precise mechanisms by which any of these 
factors might be associated with dementia are poorly understood. 
1.10.7 Psoriasis 
Psoriasis is thought to involve dendritic cells and T cells becoming activated 
through the formation of an immunological synapse which results in NF-KB 
activation, and release of cytokines (e.g. TNF-a), chemokines, proteases and other 
inflammatory mediators, which induce a wound-healing-like phenotype in the 
epidermis that is characterized by keratinocyte proliferation267• T cells migrate 
into the epidermis, which involves interactions between LF Al on T cells and 
ICAMl on endothelial cells and also between VLAl on T cells and type 4 collagen 
basement membrane constituents. In a chronic psoriatic plaque, it is thought that 
there is a continuous cycle of T-cell and dendritic-cell activation. The 
immunomodulatory activities of statins may therefore be useful in the treatment of 
psoriasis76• It has been shown that pharmacological doses of orally administered 
lovastatin do not worsen the course of psoriasis268 and though gemfibrozil, has 
been reported to exacerbate psoriasis, statins do nop69. The condition of some 
psoriatic subjects improves when a statin is administered193. Disruption of the 
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skin barrier as the result of decreased production of cholesterol by keratinocytes 
can be reversed by application of cholestero1270 • It is most likely that the beneficial 
effects of statins on immunocytes outweigh their untoward effect on surface lipids. 
Topical or systemic use of statins, either alone or in combination with topical 
cholesterol, may thus prove beneficial against psoriasis. 
1.10.8 Multiple sclerosis 
MHC class II genes are associated with susceptibility to MS271. Induction of MHC 
class II in the CNS during the pathogenesis of MS is at the centre of a destructive 
cascade of inflammatory events targeting the white matter and the underlying 
axon in this disease. Statins inhibited MHC class II upregulation on antigen 
presenting cells, reducing the activation of pro-inflammatory CD4 T cells152. 
Statins also downregulated ICAM-1 and bind directly to LFA-1, preventing the 
movement of lymphocytes into the brain. INOS and TNFa playa role in MS and 
were suppressed by statins. MMP-9 is upregulated in MS and reduced by 
statins272. MMP-9 is involved in migration ofT cells across the blood brain barrier, 
disruption of the blood brain barrier and degradation of extracellular matrix and 
myelin in MS273. 
1.10.9 Adverse effects 
Statins are generally well tolerated, however measurement of transaminase levels 
are necessary to determine liver and muscle toxicity. Myopathy (muscle pain or 
weakness) is associated with raised levels of creatine kinase, usually greater than 
10 times the upper limit of normal. Rhabdomyolysis and acute renal failure may 
result if myopathy is not recognised, but is reversible if the drug is stopped 
promptly. Symptoms can also include fever and nausea and occurs in about 1 in 
1000 patients, but is dose related274. 
Cerivastatin is 16-80 times more likely to cause fatal rhabdomyolysis than any 
other statin275. Rhabdomyolysis, which lead to kidney failure, was responsible for 
52 deaths worldwide and 385 non-fatal cases reported among 700,000 cerivastatin 
users required hospitalisation. Drug-drug interactions were implicated as 12 out of 
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31 fatalities were using gemfibrozil concomitantly. This lead to the withdrawal of 
cerivastatin from the world market in 2001 and highlights the importance of 
pharmacological aspects in statin toxicity276• 
1.11 Aims and hypothesis 
Statins have revolutionised the treatment of cardiovascular disease. Several 
studies have shown that long-term statin therapy reduces mortality of patients 
with hyperlipidaemia and ischaemic heart disease. A prospective meta-analysis of 
14 randomised trials found that there was a 12% proportional reduction in all-
cause mortality per mmoljL reduction in LDL cholesterol277. This reflected a 19% 
reduction in coronary mortality and 21% in combining myocardial infarction or 
coronary death, in the need for coronary revascularisation, in fatal or non-fatal 
stroke and in any such major vascular event. Statin therapy can safely reduce the 
5-year incidence of major coronary events, coronary revascularisation, and stroke 
by about one fifth per mmoljL reduction in LDL cholesterol, largely irrespective of 
the initial lipid profile or other presenting characteristics. 
Although primarily developed to reduce cholesterol there is increasing evidence 
that statins have cholesterol independent actions. These pleiotropic effects are 
believed to be mediated by reduction of isoprenoid intermediates, farnesyl and 
geranylgeranyl, in the cholesterol biosynthetic pathway239, 278. Thus, statins may 
inhibit prenylation of signalling molecules including the Ras and Rho family of 
GTPases and the y-subunit of G-proteins that is essential for the correct membrane 
localisation and function of these proteins. An alternative explanation is that 
statins reduce the density of cholesterol-rich membrane micro-domains or rafts66, 
279, thus limiting the function of receptors that are localised to membrane rafts. 
Both of these mechanisms are involved in lymphocyte activation and may explain 
the reported immunosuppressive actions of statins152, 280. 
The aims of this thesis were to explore the potential mechanisms of the anti-
inflammatory and immunosuppressive effects of statins specifically using in vivo 
and in vitro methods to measure the effect of statins on prenylation and rafts. I 
examined the effects of statins on lymphocyte functions of T cell proliferation and 
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NK cytotoxicity in vivo and hypothesized that the pleiotropic effects of statins 
would reduce these functions by the disruption of signalling pathways either by 
reduced prenylation of small G proteins or disruption of membrane rafts. I 
demonstrated in vitro that statin reduced the prenylation of small GTPases such as 
Ras and Rac and therefore activation of downstream signalling molecules such as 
ERK and P38 in monocytes and T cells. An alternative mechanism for inhibition of 
signalling pathways was also demonstrated by disruption of cholesterol lipid rafts 
by statins. Functional effects of statins on; monocyte trafficking and endocytosis, 
cytokine release and MMP-l production; T cell proliferation; and NK cytotoxicity 
was shown to be reduced by statin treatment and concluded, by the lack of effect of 
farnesyl and geranylgeranyl transferase inhibitors, that this was most likely due to 
disruption of lipid rafts, rather than inhibition of prenylation. 
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2.1 Materials 
2.1.1 Biochemicals 
Unless otherwise stated, all chemicals were purchased from Sigma (Poole, UK). 
Tissue culture products including foetal calf serum (FCS), L-glutamine, RPMI 
1640 penicillin and streptomycin were purchased from Gibco, (Paisley, UK). 
2.1.2 Immunochemicals 
The commercial antibodies used in this study are listed below in table 2.1. 
2.2 Cell biology techniques 
2.2.1 Cell culture 
2.2.1.1 U937 eel/line 
The human haematopoietic cell line U937 was derived from a patient with 
generalized histiocytic lymphoma281. U937 cells were routinely cultured in RPMI 
1640 medium supplemented with FCS (10% v/v), glutamine (2 mM), penicillin (10 
U/ml) and streptomycin (10 /lg/ml). They were maintained at 37°C in a water 
saturated atmosphere containing 5% carbon dioxide at a density of between 5 x 105 
and 2 x 106 cells/ml, as measured using a Neubauer haemocytometer. They were 
routinely sub-passaged twice weekly by centrifugation for 5 min at 400 x g and 
resuspended in fresh complete medium. Typically, cells were maintained in 75 
cm2 tissue culture flasks in a volume of 10-20 mls. 
page 69 
1 Specificity (clone) Species 2 Usage 3 Source 
Anti-human CD19 IgG-l (SJ2S-Cl) Mouse IP Caltag 
Anti-mouse IgG:magnetic beads Goat IP Biomag 
Anti-mouse Ig Rabbit T cell prolif Dako 
Anti-human CD3 IgG Mouse T cell prolif Serotec 
Anti-human LFA-l (CD11a) Mouse FACS R&D 
Systems 
Anti-human VLA-4 (CD49) Mouse FACS Merck 
Anti-human LCA (CD4S) Mouse FACS Dako 
Anti-mouse: FITC rabbit F ACS 2ndry Abs Sigma 
pTyr IgG2b(4GlO) Mouse W Upstate 
pERK P44/42 MAP Kinase (Thr202/ Tyr204) Rabbit W NEB 
ERK Rabbit W NEB 
PP38 MAP Kinase (Thn8o/Tyn82) Rabbit W NEB 
P38 Rabbit W NEB 
Ras (RASlO) Mouse W Upstate 
monoclonal 
HumanIgG Human IP, FACS, X-link Serotec 
125I-labelled anti-human IgG Sheep TIE Amersham 
LAT Rabbit W Upstate 
Lyn Rabbit W Santa Cruz 
Fyn Rabbit W Santa Cruz 
FcyRI IgGl (lO.l) Mouse IP, FACS Calbiochem 
FcyRI IgGl (22) Mouse IP, FACS, X-link Medarex 
FcyRII IgGl (KB61) Mouse IP, FACS, X-link DAKO 
FcyRII IgG2a (IV3) Mouse IP, FACS, X-link Medarex 
FcyRIII IgGl (3G8) Mouse FACS Medarex 
CD89 IgGl (A3) Mouse IP, FACS, X-link Serotec 
y-chain rabbit W NEB 
SHIP goat W,IP Santa Cruz 
Syk rabbit W Santa Cruz 
anti-mouse:HRP Sheep W2ndryAb Amersham 
anti-rabbit:HRP Donkey W2ndryAb Amersham 
anti-goat:HRP Rabbit W2ndryAb Sigma 
on next page ..... 
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..... Continued/rom previous page 
Table 2.1 Antibodies 
1 Clone number andlor species in which antibody was raised. 
2 FACS; fluorescent activated cell scanning. IP; immunoprecipitation. TIE; 
trafficking and endocytosis. W; western blotting. X-link; crosslinking studies. 
3 manufacturer: -
Amersham, Amersham, UK 
Biomag; Polyscience, Warington P A, USA 
Calbiochem, Beeston, UK 
Caltag laboratories, Towcester,UK 
DAKO Ltd, Cambridgeshire, UK 
Medarex, NJ, USA 
Merck, (VWR International Ltd), Lutterworth, UK 
NEB, New England Biolabs, MA, USA 
R&D Systems, Abingdon, UK 
Santa Cruz, Santa Cruz Biotechnology, Santa Cruz, CA, USA 
Serotec, Oxford, UK 
Sigma, Poole, UK 
Upstate, Upstate Biotechnology, Lake Placid, USA 
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2.2. 1.2 K562 cell line 
The human erythroleukemic cell line Ks62 was established from the pleural 
effusion of a 53-year-old female with chronic myelogenous leukaemia in terminal 
blast crises282. The cell population has been characterised as highly 
undifferentiated and of the granulocytic series283. Ks62 cells were cultured in the 
same way as the U937 cell line and maintained in 25 cm2 tissue culture flasks in a 
volume of 10 mls. 
2.2.1.3 NK-92MI cell line 
NK-92MI is an interleukin-2 (IL-2) independent Natural Killer Cell line derived 
from the NK-92 cell line by stable transfection with human IL-2 cDNA in a 
retroviral vector by particle-mediated gene transfer. The parental NK-92 cell line 
was an IL-2 dependent cell line derived from peripheral blood mononuclear cells 
from a 50 year old Caucasian male with rapidly progressive non-Hodgkin's 
lymphoma284. NK-92MI cells were routinely cultured in Alpha minimum essential 
medium without ribonucleosides and deoxyribonucleosides and containing 2 mM 
L glutamine, 1.5g/L sodium bicarbonate, 0.2mM inositol, o.lmM 2-
mercaptoethanol, 0.02mM folic acid, 12.5% horse serum, 12.5% foetal bovine 
serum, penicillin (10 U /ml) and streptomycin (10 /lg/ml). They were maintained 
at 37°C in a water-saturated atmosphere containing 5% carbon dioxide. 
2.2.1.4 Human peripheral blood mononuclear cells 
Peripheral blood mononuclear cells (PBMC) were isolated typically from 40mls of 
freshly drawn human blood into lithium heparin tubes then centrifuged on a 
Ficoll-Hypaque gradient (1.077g/ml) (Histopaque-1077, Sigma). The cells at the 
interface were removed and washed with HBSS supplemented with 2% FCS, 
25mM HEPES, lOoU/ml penicillin and 100/lg/ml of streptomycin (HBSS+). The 
cellular pellet was resuspended in 20 ml of HBSS+ and incubated on a 15cm plate 
at 37°C for 45 min, to allow monocytes to adhere. Non adherent cells were 
collected from the plate and incubated independently with Mouse IgG-1 
monoclonal antibody to human CD19 then Goat anti-mouse IgG magnetic beads to 
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remove B cells and leave a cell population of T cells and NK cells. The enriched 
T /NK cells were counted and resuspended at a concentration of 2 x106/ml in 
complete RPMI 1640 medium. The plate ofmonocytes was washed thoroughly (up 
to 10 times) with HBSS+ to remove non-adherent cells. 
2.2.2 Proliferation assays 
2.2.2. 1 T cell proliferation assay 
Flat-bottomed 96 well immulon 4 plates (Dynatech, Billingshurst, UK) were coated 
with Rabbit anti-mouse Ig in o.lM sodium hydrogen carbonate (pH 8.2) for 2 
hours at 37 °C and washed with PBS (0.07 M Sodium Chloride, 75 mM disodium 
hydrogen orthophosphate, 5 mM sodium dihydrogen orthophosphate). Mouse 
anti-human CD3 Ig was cross-linked, to stimulate T-cell proliferation. Replicates 
of six wells were seeded at a density of 2 x 105 cells/well in 0.2ml of medium with 
either complete medium, simvastatin (Merck (VWR International Ltd), 
Lutterworth, UK), geranylgeranyl transferase inhibitor (GGTI-286), farnesyl 
transferase inhibitor I (FTI I) (Calbiochem-Novabiochem, Beeston, UK), or a 
combination of inhibitors with concentrations as indicated in individual 
experiments. Cells were incubated at 37°C for 72 hours and pulsed with 1 IlCi 
[3H]thymidine (Amersham International pIc, Amersham, UK) for a further 18 
hours. Cells were harvested onto glass fibre filtermats (Wallac EG & G 
Instruments Ltd, Milton Keynes, UK) and the [3H]Thymidine incorporated into 
replicating DNA counted by Betaplate (1205) flatbed liquid scintillation counter 
(Wallac, Milton Keynes, UK). 
2.2.2.2 Alamar blue assay 
The AlamarBlue assay incorporates a fluorometric/colourimetric growth indicator 
based on metabolic activity. A 96 well plate with 1-2 x 104 cells per well were 
treated with various preparations in replicates of 6 for 24 hours. 22 III of 
AlamarBlue was added for a further 24 hours and fluorescence determined in a 
PerkinElmer LS55B fluorimeter (Aexe = 530nm, Aem = 590nm). 
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2.2.3 Natural Killer cell cytotoxicity assay 
Enriched T /NK cells or NK-92MI cells were seeded at a density of 1 x 106 cells/ml 
in 2.oml of medium with either 1 /-1m simvastatin, 10 /-1m GGTI -286, 10 /-1m FTI I, 
or a combination of inhibitors, for 48-72 hours. The human Caucasian chronic 
myelogenous leukaemia cell line, Ks62, was used as a target for NK cells as they 
lack MHC class I and II antigens285. Briefly, 2 x 106 cells/ml were incubated with 
5MBq of 51chromium at 37°C for one hour and washed thoroughly. Effector cell 
concentration was established and equalised in all samples. Target cell 
concentration was then adjusted to 12.5:1 and 25:1 E/T ratio. One hundred /-11 of 
effector cells and 100 /-11 of target cells were mixed in V-bottomed plates in 
replicates of six. A negative control of 100 /-11 of target cells plus 100 /-11 of media 
and a positive control of 100 /-11 of target cells plus 100 /-11 of 10% Triton X-100 lysis 
buffer were also prepared. After a four hour incubation at 37°C, plates were 
centrifuged at 400g (1000 rpm) for five minutes and 100 /-11 of supernatant 
collected and radioactivity counted by gamma counter (Packard Cobra gamma 
counter). Percentage killing was calculated: (sample - negative control)/(positive 
control- negative control) x 100286. 
2.2.4 Flow cytometry. 
2.2.4.7 T INK cells 
Enriched T /NK cells at a density of 1 x 106 were incubated with either 0.2% BSA in 
PBS, or 1 /-1g of primary antibody: anti-human LFA-1 (CDna), anti-human VLA-4 
(CD49), anti-human LCA (CD45), or the isotype control mouse IgG1 negative 
control - human, to control for non specific labelling, for 45 mins on ice. After 2 
washes with PBS, fluoroscein isothiocyanate (FITC) labelled anti-mouse secondary 
ab was incubated for 45 mins on ice and in darkness. After a further two washes in 
PBS, at least 10,000 cells were analysed by FACScan using System II software 
version 3.0 (Coulter, High Wycombe, UK). 
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2.2.4.2 U937 cells 
Typically 1X106 cells were washed and resuspended in 1ooI-L1 ice cold PBS with 1I-Lg 
of relevant monoclonal antibody (mAb). Where appropriate, 3 I-LM monomeric 
human IgG was added to block non-specific interactions of monoclonal antibodies 
with Fc receptors. Following 45 mins incubation on ice cells were washed twice 
and incubated for a further 45 mins with a fluoroscein isothiocyanate (FITC) 
conjugated goat anti-mouse IgG secondary antibody (1:100 dilution). Irrelevant 
isotype control antibodies were used to control for non-specific labelling. 
2.2.5 Determination of apoptosis in U937 cells 
To exclude a significant pro-apoptotic effect of statins, U937 cells were treated 
with 10 I-Lg/ml puromycin or 1mM H20 2287 as positive controls and various 
concentrations of simvastatin and fluvastatin. 
2.2.5.7 Caspase flow cytometric apoptosis kit 
The caspase activity assay (Oncogene, Beeston, UK) detected activation of caspases 
by flow cytometry in living cells. The assay was based on the cleavage of 
(aspartyl)2 - Rhodamine 110 (D2R), a reported substrate for members of the 
caspase family proteases. The caspase substrate D2R is non fluorescent, however 
upon cleavage by cellular caspases, the released Rhodamine 110 gives rise to 
fluorescence that can be measured at excitation of 488nm and emission of 530nm. 
A pellet of 1X105 cells was resuspended in 0.3 ml of D2R incubation buffer with 
10mM DTI and 1 I-Ll D2R reagent. After 10-20 mins incubation at 37 oC in the dark, 
cells were analysed by flow cytometry using FL-1 channel (Ex/Em=488/530 nm). 
2.2.5.2 Morphology of apoptotic cells 
Cells were cytospun onto gelatin/chrom alum coated slides at 50 x g (500rpm) and 
their morphology scored by counting nuclear condensation (performed by Lorna 
Murray, Centre for Inflammation Research, University of Edinburgh). 
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2.3 Serum measurements 
2.3.1 Lipid Profiles 
A 7 ml tube of blood was allowed to clot then centrifuged at 2000 x g (3000 rpm) 
to collect serum. One ml of serum was used in a rapid semi- micro method for the 
separation of lipoprotein fractions that uses a bench top ultracentrifuge288• 
2.3.2 C-Reactive Protein Measurement 
CRP concentrations were determined using a high sensitivity latex-enhanced 
immunoturbidimetric assay, CRP-UL (Wako Chemicals GmbH, Neuss, Germany) 
on a Cobas Fara centrifugal analyser (Roche Diagnostics, Lewes, East Sussex, UK). 
Six fll of serum was mixed with 270 fll of the kit buffer solution and incubated for 5 
mins at 37°C. Sixty fll of latex reagent was mixed and measured at a wavelength of 
700 nm after a further 5 min incubation. 
2.4 Biochemical Assays 
2.4.1 Cell lysate preparation 
For general lysate preparations, cells in suspension were lysed by the addition of 
ice-cold lysis buffer (1% (v/v) Triton X-100, 50 mM Tris-HCl, pH 7.5,0.25% (w/v) 
sodium-deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mMvanadate and 1 mM NaF) 
containing protease inhibitors (1 mM phenyl methyl sulfonyl fluoride and 1 flg/ml 
each chymostatin, leupeptin, antipain and pepstatin). Following 30 min tumbling 
at 4°C lysates were clarified at 15,000 x g (13,000 rpm) for 15 mins to remove 
insoluble cell debris. Lysates were either used immediately or stored at -20°C 
prior to electrophoresis. 
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2.4.2 Determination of protein concentration 
Protein concentrations were routinely determined for all celllysates and 
membrane preparations. Protein concentrations were estimated using the Bio-
Rad protein assay system (Bio-Rad Laboratories, Hemel Hempstead, UK), which is 
based on the Bradford Coomassie brilliant blue dye binding system. A range of 
bovine serum albumin (BSA) concentrations were used to construct a standard 
curve and samples were suitably diluted to allow their protein level to fall within 
the linear range of this curve. Protein concentrations of all samples and standards 
were routinely measured in duplicate on a Beckman DU640B spectrophotometer 
at a wavelength of 595 nm. 
2.4.3 Sodium dodecyl sulphate- polyacrylamide gel 
electrophoresis (SDS-PAGE) 
SDS-PAGE was carried out using the NuP AGE Pre-Cast Gel System (Invitrogen, 
Paisley, UK). The NuPAGE system works with bis-tris buffered (pH 6-4) 
polyacrylamide gels, available at 3 different acrylamide concentrations (10% (w/v), 
12% and 4-12% gradient gels) allowing different separation ranges to be selected. 
By varying the running buffer used, the separation range can be altered further. 
Samples were denatured in NuPAGE LDS (Lithium Dodecyl Sulphate) sample 
buffer by heating to 70°C for 10 min. For reduced proteins, 50 mM dithiothreitol 
was added prior to sample denaturing. For a detailed protocol, including gel 
separation ranges, please refer to the manufacturers instructions. 
2.4.4 Western blot analysis 
Proteins were transferred to nitrocellulose (Schleicher and Schuel GmbH) using 
the Novex XCell II blotting apparatus. Transfer efficiency was ascertained by 
staining with Ponceau S solution for five minutes followed by washing with dH2 0. 
Ponceau S was removed by washing with TBS (20 mM Tris.HCl, pH 7.6, 136 mM 
NaCl) containing 0.1% (v/v) Tween 20 (TBST). Nitrocellulose membranes were 
blocked in TBST with 4% (w/v) non-fat powdered milk (e.g. Marvel) for at least 1 
hour at RT. Typically, blots were incubated with primary antibodies at a final 
~-"-~-----~-
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concentration of 0.1-1 flg/ml in 4% milk-TBST overnight at 4°C. Blots were then 
washed vigorously three times for five minutes with TBST and incubated with a 
HRP conjugated secondary ab diluted 1 in 2000 for 2 hours at RT. Blots were 
washed extensively with large volumes of TBST (typically 5 x 5 min washes) 
followed by a final wash in H2 0 prior to developing. Blots were developed using 
the enhanced chemiluminescence (ECL) detection system (Amersham, Amersham, 
UK). To strip blots for reprobing, blots were washed in acid strip buffer (100 mM 
glycine, 150 mM NaCI, pH 2.6) for 20-45 minutes. 
2.4.5 Detection of phosphotyrosine containing proteins by 
Western blot 
Proteins phosphorylated on tyrosine residues were detected by Western blot using 
the monoclonal antibody, 4G10 (Upstate Biotechnology). This antibody gave a 
very poor signal and high background using the standard blotting protocol 
outlined above (section 2.4-4) so the following modified protocol was developed. 
Following membrane blocking with TBST 4% milk, blots were incubated with a 
1:1000 dilution of 4G10 (Upstate Biotechnology) overnight at 4°C in TBS with 0.05 
% (v/v) Tween 20 and 0.5 % (w/v) milk. Membranes were washed 3 x 5 minutes 
with TBST and incubated for two hours with donkey anti-mouse IgG: HRP 
(1:4000, Amersham) in TBST with 4% (w/v) milk. Membranes were then rinsed 
four times with large quantities of dH2 0, washed 5 x 5 min with TBST with 
vigorous agitation followed by four further rinses with ddH2 0. Blots were 
developed as described above (section 2-4-4). 
2.4.6 Detection of activated MAPK by Western blot (ERK and 
p3S) 
To detect activated forms of the MAPKs, lysates were prepared as described in 
section 2-4.1. Typically, 10 flg of total cell lysate were electrophoresed and blotted. 
Activated forms of ERK, P38 and JNK were detected by Western blot using rabbit 
polyclonal antibodies raised against peptides corresponding to the dual 
phosphorylated active sites of the different MAP kinases. All blots for activated 
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MAPKs were stripped and reprobed with polyclonal antibodies, which recognise all 
forms of the MAPK being assayed to ensure comparable loading of celllysates 
between samples. For antibody specificities see table 2.1. 
2.4.7 ERK and p38 activation in human T cells. 
Human T cells prepared from PBMC (section 2.2.1.4) were stimulated on anti CD3 
coated 96 well plates for 24, 48 and 72 hours. A shorter time course of 10, 30 and 
120 minutes was examined by first incubating the cells with fluvastatin and 
mevalonate before being stimulated. All samples were then lysed with ice cold 
Lysis Buffer (section 2-4.1). Samples were western blotted and probed for ERK or 
P38 with phospho specific P44/42 MAP Kinase antibody and phospho specific P38 
MAP Kinase antibody. 
2.4.8 Fc receptor aggregation 
2.4.8. 1 Fc rRl aggregation with human IgG 
U937 cells were harvested by centrifugation (5 min, 400 x g), washed and 
resuspended in ice cold RPMI, and incubated with l).!M monomeric IgG for 45 
mins at 4°C to occupy surface FcyRI. Cells were then washed twice with RPMI to 
remove unbound ligand. Following this cells were resuspended in RPMI, 25 mM 
HEPES, 1% FCS and a 1:50 dilution of goat anti-human IgG was added to crosslink 
FcyRI bound IgG. Cells were then warmed to 37°C for the times specified. 
2.4.8.2 Fc receptor aggregation with heat aggregated IgG 
2.4.8.2.1 Preparation of heat aggregated IgG 
IgG was heat aggregated by heating human IgG at a concentration of 50mg/ml to 
65°C for 20 mins. The aggregated IgG was pelleted by micro centrifugation at 
15,000 x g (13,000 rpm) for 30 mins, then washed 3 or 4 times with PBS. The 
protein concentration was measured by Bradford's assay as in section 2-4.2 with 
the ratio - 22-4 mg/ml of protein measured is equal to 50mg/ml of IgG. 
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2.4.8.2.2 Fc receptor aggregation with heat aggregated IgG 
Heat aggregated IgG was added to cells at concentration of 100 /-lg/ml and heated 
for the times indicated. 
2.4.9 Membrane preparation 
Cells were washed twice in cold nuclear preparation buffer (10 mM Tris-HCI, pH 
7-4,2 mM magnesium chloride, 140 mM sodium chloride). Cells were then lysed 
by three liquid nitrogen freeze-thaw cycles in nuclear preparation buffer 
containing 2% (v/v) Tween 40, protease inhibitors (1 mM phenylmethylsulfonyl 
fluoride and l/-lg/ml each chymostatin, leupeptin, antipain and pepstatin) and 
phosphatase inhibitors (lmM vanadate and 1mM NaF). Cell debris and nuclei 
were removed by centrifugation at 15 000 x g (13,000 rpm) for 5 min and 
membranes were precipitated by ultra centrifugation (Beckman Instruments, High 
Wycombe, UK) of the supernatant at 100000 x g (55,000 rpm), 4°C for 1 hour289, 
290 • Following ultra centrifugation, the supernatant represents the cytosolic 
fraction. Membrane pellets were resuspended in cold nuclear preparation buffer. 
2.4.10 Endocytosis and trafficking 
FcyR mediated internalisation and degradation of IgG immune complexes was as 
described by Harrison2 91 • Briefly, cells were loaded with IgG as above (2-4.8) and 
after removal of unbound IgG, Fcy R bound IgG was aggregated with 1251 -labelled 
sheep anti-human IgG (Amersham, Buckinghamshire, UK) for 20 minutes on ice. 
Unbound crosslinking antibody was removed by washing and cells warmed to 37°C 
for specified times to allow internalisation and trafficking of immune complexes. 
At time 0, duplicate aliquots of cells were counted to provide a measure of total cell 
activity. After incubation at 37°C, immune complex (IC) internalisation was then 
determined by washing the cells in ice cold acidified PBS (pH 2) to remove surface 
bound IC and non-acid releasable radioactivity used as a measure of 
internalisation. Duplicate cell aliquots were removed and acid washed at each 
time point and internalisation expressed as a fraction of total cell activity. After 
warming to 37°C internalised cell radioactivity falls, accompanied by the 
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appearance of trichloroacetic acid (TCA) soluble radioactivity in the supernatant, 
representing IC degradation. To determine the rate of degradation, TCA (20% 
w /v) soluble radioactivity in the supernatant was determined in duplicate at each 
time point and expressed relative to total cell activity. 
2.4.11 Lipid raft isolation 
Cells were lysed with MNE (25mM MES, pH6.5, 150mM NaCI, 2mM EDTA) 
containing 1% Triton X -100 (v /v) plus protease and phosphatase inhibitors and 
subjected to sucrose gradient centrifugation40 at 287,500 x g (45000 rpm) for 18 
hours in a SW60 ti rotor (Beckman Instruments, High Wycombe, UK). The 
samples were mixed (1 in 2) with 80% sucrose MNE (lmI), with 30% (2mI) then 
5% sucrose MNE (1.3mI) layered on top. 
2.4. 11. 1 Lipid raft fractions 
Ten 450111 samples were collected from the top and analysed by western blot. 
2.4.11.2 Lipid raft samples 
The top 1ml was removed and discarded; while the next 1.5ml (corresponding to 
fractions 3-5) was collected, with the sucrose content diluted at least 1 in 2 by 
MNE. Raft pellets were collected by microcentrifuging at 15,000 x g (13,000 rpm) 
for 15 mins at 4°C and resuspended in lysis buffer prior to western blot analysis. 
LAT, Lyn or Fyn abs were used as markers for rafts. 
2.4.11.3 Lipid raft densitometry 
PBMC were extracted (as in section 2.2.1.4) from 35mls of blood collected in 
lithium/heparin tubes from normal volunteers before and after taking 40mg of 
simvastatin per day for 28 days. Lipid rafts were collected (as in section 2-4.11 and 
2-4.11.2) with the exception that the PBMCs were lysed in 1.5 mls of MNE 1% 
Triton X-100 and split into 3 separate samples before being centrifuged. The 
triplicate raft samples were resolved beside duplicate total samples (diluted 1 in 5) 
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and probed for LAT, Lyn and Fyn. Protein levels were measured by densitometry 
(Quantity One 4.2.1, Bio-Rad, Hemel Hempstead, UK). A ratio was calculated 
between total protein levels and raft protein levels, to assess whether statin 
treatment could reduce raft levels in vivo. 
2.5 Molec ular biology 
2.5.1 RNA preparation 
Total cellular RNA was isolated by TRIzol (Invitrogen, Paisley, UK) extraction. 
Cells were lysed by resuspending cell pellets in 1ml TRIzol per 107 cells for 5 
minutes at RT. Tubes were shaken vigorously with 0.2ml of chloroform then left at 
RT for 3minutes. Samples were centrifuged at 12000 x g (13,000 RPM) in the cold 
room. The aqueous layer, which contains the RNA, was then removed to a fresh 
tube and the RNA precipitated with 0.5ml of isopropanol followed by 
centrifugation (12 000 x g, 10 min, 4°C). RNA pellets were washed with 75% 
ethanol, resuspended in an appropriate volume of diethylpyrocarbonate (DEPC) 
treated water and stored at -70°C. RNA concentration was determined by 
measuring absorbance at 260 nm and purity was estimated by checking the 260 
nm:280 nm absorbance ratio (RNA has a ratio of roughly 2:1). 
2.5.2 RT -peR 
For reverse transcriptase PCR (RT-PCR) cDNA was prepared from total RNA using 
an Invitrogen cDNA cycle kit with oligo dT primers. Briefly, reactions were carried 
out in 20 III containing 11lg total RNA, RNase inhibitor, 5 mM dNTPs, 4 mM 
sodium pyrophosphate, 4 III Invitrogen 5 x RT reaction buffer and 0.5 III AMV 
reverse transcriptase. Reactions were carried out at 42°C for 1 hour followed by 
phenol chloroform extraction and ethanol precipitation. cDNA was aliquoted and 
frozen at -70°C until used in PCR reactions. Aliquots of cDNA were amplified by 
PCR as follows. To amplify FcyRIIa and FcyRIIb mRNA, a single crossreactive 
forward primer was used (FcyRII-FOR) with reverse primers specific for either 
----------------------------------------------------------~-~"~ 
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FcyRIIa (RIIa-REV - Table 2.2) or FcyRIlb (RIIb-REV - Table 2.2). For FcyRIlb 
these primers flank the alternative FcyRIIb2 splice site to allow identification of 
different splice variants by PCR product size. PCR reactions were carried out in 
SO/-Ll containing 20pmole of each primer, 2.smM MgC12, S/-Ll Promega Taq lOX 
reaction buffer and 2 units Promega Taq polymerase. PCR reactions were 
continued for 20 to 40 cycles with each cycle comprising 1 minute at 93°C 
(denaturing), 1 minute at 50°C (primer annealing) and 1 minute at 72°C (product 
extension). 
2.5.3 Agarose gel electrophoresis of DNA 
PCR DNA products were typically electrophoresed at 100 V through 1-2% (w/v) 
agarose in TAE buffer (40mM Tris-acetate, 1mM EDTA) containing 0.5 /-Lg/ml 
ethidium bromide. Bands were visualised on an ultraviolet transilluminator and 
photographed with a Polaroid instant camera. 
2.6 Manufactured kits 
2.6.1 Ras Assay. 
The Ras small GTPase was assayed using an Upstate biotech Ras activation assay 
kit (TCS Biologicals, Claydon, Buckingham, UK). The kit comprised of glutathione 
agarose bound GST fusion proteins of the Ras binding domain (RBD) of Raf-1, 
which binds Ras:GTP. Briefly, cells were stimulated and then lysed with Mg2+ lysis 
buffer (MLB - 2smM HEPES, pH 7.5, lsomM NaCl1% Igepal CA-630, 10mM 
MgCI2, 1mM EDTA and 2% glycerol). Typically, S00/-Lg cell lysate at a 
concentration of 1 mg/ml was used for each assay sample. Active Ras was 
precipitated with 5 /-Ll Raf-1 RBD agarose for 30 minutes. Precipitates were washed 
three times with 500 /-Ll MLB followed by SDS-PAGE (section 2-4.3) and Western 
blotting (section 2-4-4). Ras was detected with specific mAb. 
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Target 
~ actin 
FcyRI 
FcyRIla 
FcyRIlb 
FcyRIlI 
FcaR 
Fca/).!R 
PIGR 
FcRn 
Name 
~ actin-for 
~ actin-rev 
I-for 
I-rev 
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Sequence (5' -) 3') I Product size 
GGG GTA TGC CCT CCC CCA TGC CAT CCT GCG 
482bp 
TTG GCG TAC AGG TCT TTG CGG ATG TCC ACG 
CAT GTG GTT CTT GAC AAC TCT GCT CC 
876bp 
TGA AAC CAG ACA GGA GTT GGT AAC TGG 
II-for I GCA CAG GAA ACA TAG GCT ACA CG 
II a-rev GGT ATC TTC TTA GAA AGT CCC 
II-for I GCA CAG GAA ACA TAG GCT ACA CG 
lIb-rev 
III-for 
III-rev 
CD89-F2 
CD89-R2 
amr-forl 
amr-rev 
PIGR-for 
PIGR-rev 
FcRn-for 
FcRn-rev 
GGT GAT TGT GTT CTC AGC CCC 
ATG TGG CAG CTG CTC CTC CCA ACT G 
GGT GAT GTT CAC AGT CTC TGA AGA CAC 
CGC TTA AGA TGG ACC CCA AAC AGA CCA C 
GCT CTA GAT TAC TTG CAG ACA CTT GGT G 
GAC AAC TAC CAA GGC TGA TAG G 
TCT GTC CCT CAG GGT CCT GGA T 
GCC CGA GCT GGT TTA TGA AG 
AGC CGT GAC ATT CCC TGG TA 
CAA AGC TTT GGG GGG AAA AG 
TGC AGG TAA GCA CGG AAA AG 
717 + 594bp 
287bp 
567bp 
880bp 
702bp 
694bp 
359bp 
Gamma I GAM3-for GCC CAA GAT GAT TCC AGC AG 
chain GAM3-rev 
458bp 
CCG TAA ACA GCA TCT GAG C 
Table 2.2 Oligonucleotide sequences 
~ ----~------ -------------------
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2.6.2 MMP-l ELISA 
MMP-1levels from the supernatant of U937 cells treated with statin or prenyl 
inhibitors for 48 hours, crosslinked as in section 2-4.8.1 or with heat aggregated 
IgG (section 2-4.8.2) overnight were measured by an Oncogene ELISA kit 
(Calbiochem, Beeston, UK). The MMP-1 ELISA assays was a "sandwich" enzyme 
immunoassay employing two monoclonal antibodies. A monoclonal antibody, 
specific for human MMP-1 protein, was immobilised onto the surface of the plastic 
wells provided in the kit. The samples and standards were pipetted into the wells 
and the capture antibody bound any MMP-1 protein present. Unbound material 
was washed away and monoclonal horseradish peroxidase (HRP)-conjugated anti-
MMP-1 antibody added. Following incubation and washing, the chromogenic 
substrate tetra-methylbenzidine (TMB) was catalysed from a colourless solution to 
blue by the HRP, then yellow by 2.5N sulphuric acid. The intensity of colour was 
proportional to the amount of MMP-1 protein present. Absorbance was measured 
at 450 nm within 30 mins and concentrations determined from the standards. 
2.6.3 CB array 
IL-8, IL-1~, IL-6, IL-10, TNF-a and IL-12P70 levels from the supernatant of U937 
cells treated with statin or prenyl inhibitors for 48 hours, crosslinked as in section 
2-4.8.1 or with heat aggregated IgG (section 2-4.8.2) overnight or LPS overnight 
were measured by cytometric bead array kit (BD Biosciences, Oxford, UK). Six 
bead populations with distinct fluorescence intensities, coated in antibodies 
specific for the proteins above were mixed with PE detection reagent and 50 f.!l of 
sample supernatant (or standard). After 3 hours incubation and a wash with 1 ml 
wash buffer, the beads were resuspended by vortexing with wash buffer. The F ACS 
machine with Cell Quest software installed was prepared with the cytometer setup 
beads provided in the kit. Samples were then analysed by the F ACS and calculated 
from standard curves by the software. 
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3.1 Introduction 
Inhibition of HMG-CoA reductase by statins lowers serum total and LDL-
cholesterol and is of proven benefit in the treatment of patients with a spectrum of 
cardiovascular diseases177, 179, 292• However, actions independent of serum lipid 
lowering may play an important role in the beneficial effects of statins in 
atherosc1erosis128 and in vivo effects on lymphocytes may provide a readily 
accessible model for the in vivo actions of statins on other cell types. 
I therefore carried out three separate in vivo studies of patients receiving statin 
therapy. The first (Study 1) was a sampling exercise of patients with 
cardiovascular disease in which the lymphocyte functions of T cell proliferation, 
NK cytotoxicity and cell adhesion molecules (CAMs) were measured to investigate 
the potential lipid independent, immunomodulatory effects of statins which play 
an important role in atherosclerosis. The second study (Study 2) was an 
interventional study, which investigated the effects of 40mg per day of simvastatin, 
on leukocyte functions of T cell proliferation and NK cytotoxicity in normal human 
subjects. The aim of this study was to confirm the known benefit of statins in 
lowering lipids in patients with elevated cholesterol, to translate this effect to 
normal subjects without elevated cholesterol and to assess the effect of statins on 
immune cell functions without the interference form other medications. The final 
study (Study 3) was another sampling study of a diverse variety of patients and 
concentrated on natural killer cell activity as this cell type showed the most in vivo 
evidence of a statin effect. 
I hypothesised that the pleiotropic effects of statins would reduce lymphocyte 
functions of T cell proliferation and NK cytotoxicity, in vivo by the disruption of 
signalling pathways either by reduced prenylation of small G proteins or reduced 
raft cholesterol. Statins would also reduce the amounts of CAMs reaching the 
membrane by reducing the pro inflammatory cytokines which stimulate 
production of CAMs2 93 as well as by exclusion from lipid rafts which retains LFA-1 
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in an inactive form79. Simvastatin also binds directly to LFA-1 causing an allosteric 
change which blocks the binding of I CAM -1 to LF A -176 • 
3.2 Results 
3.2.1 Study 1: Study of patients with cardiovascular disease 
Blood samples were collected from hospital in-patients and out patients, targeting 
patients admitted for coronary angiography and with angina pectoris or 
myocardial infarction. Renal transplant recipients receiving cyclosporin 
immunosuppressive therapy in conjunction with or without statin treatment were 
also targeted. Recruitment was not restricted to the dose of simvastatin taken 
which ranged from 10 to 80 mg of simvastatin per day. Samples were obtained 
from 16 patients who were not receiving statin therapy (13 men; median age 54 
years (range 35 to 83 years)); 17 patients receiving statin therapy (16 men; median 
age 62 years (range 40 to 76)); 18 patients receiving cyclosporin (15 men; median 
age 42 years (range 28 to 64)) and 8 patients receiving both cyclosporin and 
simvastatin (4 men; median age 46 years (range 38 to 71)). 
3.2. 1. 1 T cell proliferation (Figure 3. 1) 
Lymphocytes were extracted and T cell proliferation measured by tritiated 
thymidine incorporation. A 23% reduction in ex-vivo T cell proliferation was 
observed between the statin treated and untreated group (Figure 3.1). The 
cyclosporin group was reduced by 12% compared to untreated (but was statistically 
insignificant) and cyclosporin plus statin reduced by 51%. In vitro, addition of 
If.lm simvastatin resulted in significant reductions in all four groups: no treatment 
34 ±17% (mean ±SD), statin 23 ±18%, cyclosporin 53 ±3S%, and cyclosporin plus 
statin 37 ±41%. In vitro addition of FTI and GGTI had no significant effect in any 
group. 
3.2. 1.2 Natural Killer cell cytotoxicity (Figure 3.2) 
From the same pool of lymphocytes extracted for T cell proliferation, NK 
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Figure 3.1 Ex vivo and in vitro comparisons ofT cell proliferation/rom groups of 
cardiovascular patients before receiving statin therapy, after starin therapy, 
receiving cyclosporin therapy or cyclosporin and statin therapy. 
Blood samples were obtained from the 4 groups of patients in study 1 and T cell 
proliferation stimulated by anti-CD3 ab was measured by thymidine incorporation. 
Control cells compared ex vivo, showed a reduction in proliferation of 23% 
between the untreated group and the statin group. Addition of 1 flM simvastatin in 
vitro resulted in significant reductions of proliferation in all groups: 34 ±17% no 
treatment, 23 ±18% statin, 53 ±35% and 37 ±41% plus statin. GGTI and FfI had no 
effect on T cell proliferation. [* ( p < 0.05, **( P<0.005. # P<O.OOI vs no 
treatment, control. ~ P<0.005 vs statin, control. + P<O.OOI vs CyA, control. /\ 
P<0.05 vs CyA + statin, control. Students two sample t test.] 
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cytotoxicity was measured by 51Cr release. Statin treated patient's NK cytotoxicity 
was 43% lower than untreated patients and cyclosporin patient's was 54% lower 
(Figure 3.2). In vitro addition of 111M simvastatin resulted in significant 
reductions in all groups: no treatment 76 ±15%; statin 87 ±10%; cyclosporin 80 
±38%. As with T cell proliferation, FTI and GGTI had no significant effect on NK 
cytotoxicity in vitro. 
3.2.1.3 Cell Adhesion Molecules (Figure 3.3) 
Again from the same pool of lymphocytes, F ACS analysis was performed to 
measure changes in levels ofLFA-1 and VLA-4 cell adhesion molecules. VLA-4 
levels remained unaffected by in vivo statin or cyclosporin (Figure 3.3). LFA-1 
levels appear to have been reduced by in vivo statins and increased by cyclosporin 
+ / - statin. However, these results were statistically insignificant. 
3.2.2 Study 2: Normal Volunteer Study 
Thirteen healthy subjects were recruited to the study, 8 men and 5 women, median 
age 36 years (range 26 years to 46 years). Treatment with simvastatin, 40mg per 
day, resulted in a predictable effect on plasma lipid sub-fractions in normal 
subjects without hyperlipidaemia (Table 3.1). Total cholesterol was reduced by 23 
±12% (mean ±SD) during treatment and LDL cholesterol by 36 ±16%. HDL 
cholesterol was increased by 13 ±20%. Triglyceride levels were not reduced 
significantly. I also measured CRP, as an inflammatory marker that could 
potentially follow changes in immune cell function. Although there was a trend 
towards reduced levels during active treatment, the measured levels were low in 
keeping with the absence of illness in the study population and the reduction did 
not achieve statistical significance. 
3.2.2. 1 T cell proliferation (Figure 3.4) 
Lymphocytes extracted from volunteers before and after simvastatin treatment, 
were assayed for proliferation by CD3 stimulation (Figure 3-4). There were no 
significant differences in proliferation of T cells isolated from the pre- and post-
~------------------ - -- - - - -- ------ -- -----------------------~- --~~-------------
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Figure 3.2 Ex vivo and in vitro comparisons of natural killer cell cytotoxicity 
from groups of cardiovascular patients before receiving statin therapy, after 
statin therapy, receiving cyclosporin therapy or cyclosporin and statin therapy. 
NK cytotoxicity was measured by 51Cr release. Control cells compared ex vivo, 
showed a reduction in cytotoxicity of 43% between the untreated group and the 
statin group. Addition of l)..tM simvastatin in vitro resulted in significant 
reductions of cytotoxicity in all groups: 76 ±16% no treatment, 87 ±10% statin, and 
80 ±38% cyclosporin. GGTI and ITI had no effect on NK cytotoxicity. 
[ *( P<0.05, **( P<0.005. # P<O.OOl vs control, ~ P<0.003 vs control, + P<O.Ol vs 
control. Students two sample t test.] 
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Figure 3.3 Ex vivo flow cytometry analysis of adhesion markers on T 
lymphocytes from cardiovascular patients. 
VLA-4 and LFA-l adhesion molecules were unaffected by the patients' treatments. 
LFA-l changes were statistically insignificant compared to the normal group. 
[*p<o.Os. Students two sample t test.] 
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Control 1 Simvastatin Control 2 p-value 
Cantrall Statin v 
v Statin Control 2 
----------------------~----------------------... 
Triglycerides Mean (±SE) l.11 (±0.09) 1.22 (±O.l7) 1.0S (0.14) 0.45 0.67 
mmollL Median 1.10 l.10 0.95 
Total Cholesterol Mean (±SE) 5.02 (±0.15) 3.85 (±0.16) 5.03 (±0.21) <0.001 0.002 
mmollL Median 4.94 3.93 4.97 
VLDL Cholesterol Mean (±SE) 0.32 (±0.05) 0.25 (±0.03) 0.32 (±.OS) 0.27 0.35 
mmollL Median 0.30 0.24 0.25 
LDL Cholesterol Mean (±SE) 3.45 (±O.IS) 2.12 (±O.l2) 3.35 (±0.21) <0.001 0.001 
mmo!/L Median 3.41 2.16 3.15 
HDL Cholesterol Mean (±SE) 1.26 (±0.09) 1.43 (±0.11) 1.35 (±.07) 0.022 0.006 
mmollL Median 1.29 1.44 1.34 
hs-CRP Mean (±SE) 1.33 (±0.5S) 1.27 (±0.54) 1.17 (±0.70) 0.79 0.73 
mg/L Median 0.45 0.2S 0.35 
Table 3.1 Simvastatin treatment reduced cholesterol and LDL levels in normal 
volunteers. 
Lipid profiles were measured before and after taking simvastatin. Total 
cholesterol and LDL cholesterol were significantly reduced by simvastatin (24% 
and 39% respectively). HDL cholesterol levels increased by 12%. The changes in 
other lipids and CRP levels were not significant. 
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Figure 3.4 Simvastatin reduced T cell proliferation in vitro. 
T cell proliferation was measured by [3H]Thymidine incorporation into 
lymphocytes extracted from normal volunteers before and after taking simvastatin 
(Study 2). Kruskal-Wallis analysis showed no significant differences between the 
three groups. Addition of 111M simvastatin in vitro resulted in significant 
reductions of proliferation in all three groups (control 1 - 39 ±18%, stat in - 33 
±24%, control 2 - 43 ±20%) and 1OI1M simvastatin (control 1 - 95 ±3%, statin - 97 
±2%, control 2 - 97 ±3%). GGTI produced a statistically significant reduction in 
proliferation only in the control 1 group - 14 ±15%. [# P < 0.005 vs control 1, 
untreated, stimulated. ~ p < 0.005 vs statin, untreated, stimulated. /\ p < 0.005 
vs control 2 untreated, stimulated.] (Data sets are the mean ±SE, n=13.) 
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treatment control phases, or the simvastatin treatment phase of the study. I then 
added simvastatin, in vitro, to examine the hypothesis that cells from statin-
treated subjects would be more susceptible to the in vitro effects of statins even in 
the absence of an obvious in vivo effect. Addition of 111M simvastatin caused a 39 
±18% reduction in T-cell proliferation and lOI1M simvastatin, a 95 ±3% reduction, 
confirming the well-established in vitro effects oflymphocyte proliferation294• 
Oral simvastatin therapy did not influence the response ofT cells to in vitro statin 
therapy. Addition of a gerany1gerany1 transferase inhibitor in vitro also reduced 
lymphocyte proliferation, by 14 ±15%, whereas addition of a farnesy1transferase 
inhibitor produced a non-significant reduction of 10 ±19%. Addition of both 
preny1 inhibitors together reduced proliferation by 20 ±22.7% (P < 0.001). Oral 
simvastatin therapy did not influence the in vitro response to preny1 transferase 
inhibitors, either alone or in combination. 
3.2.2.2 Natural Killer cell cytotoxicity (Figures 3.5 and 3.6) 
NK cell cytotoxicity was measured in lymphocytes extracted from volunteers 
before and after taking simvastatin. Simvastatin reduced NK cytotoxicity ex vivo 
by 30 ±33% in untreated cells, the levels returning to normal following cessation of 
therapy (Figure 3.5). Addition of simvastatin or preny1 transferase inhibitors in 
vitro resulted in a reduction in NK cytotoxicity. Thus, addition of 111M simvastatin 
to control (period 1) cells reduced NK cytotoxicity by 56 ±24%. Farnesy1 and 
gerany1gerany1 transferase inhibitors had a lesser effect, producing reductions of 9 
±10% and 21 ±18% respectively. Combinations of inhibitors did not show 
increased or additive effects. Similar reductions, although less significant, were 
observed in the statin treatment and washout phase (Contro12) in response to ex 
vivo treatment with simvastatin and preny1 transferase inhibitors. Overall, there 
was a close relationship between reduction in LDL and inhibition of NK cell killing 
(Figure 3.6). 
3.2.2.3 Simvastatin and membrane rafts (Figures 3.7 and 3.B) 
An alternative mechanism for the pleiotropic actions of statins is through the 
disruption of membrane cholesterol-rich rafts. I performed western blot analysis 
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Figure 3.5 Simvastatin reduced NK cytotoxicity ex vivo and in vitro. 
Natural killer cell cytotoxicity was measured by their ability to lyse Ks62 target 
cells and release [sl]chromium. NK cytotoxicity in untreated cells was reduced by 
30 ±33% after taking simvastatin. Adding simvastatin or prenyl transferase 
inhibitors in vitro also resulted in statistically significant reductions. One)lM 
simvastatin added to control group 1 was enough to reduce NK cytotoxicity by 56 
±29%. Farnesyl and geranylgeranyl transferase inhibitors were less effective, 
producing reductions of 9 ±10% and 21 ±18%) respectively. Combinations of 
inhibitors did not have any additive effects. Similar reductions in vitro were 
observed in the statin groups and control group 2. (*{ P < 0.05. # P < 0.005 vs 
control 1, untreated. ~ p < 0.005, vs statin, untreated. /\ p < 0.008 vs control 2 
untreated.) (Data sets are the mean ±SE, n=13.) 
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Figure 3.6 Simvastatin treatment reduced NK cytotoxicity in line with LDL 
levels. 
NK cytotoxicity was plotted against LD L cholesterol levels to show the reduction 
by statin was in line with the reduction in LDL cholesterol. (Data sets are the 
mean ±SE, n=13) 
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of human leukocytes obtained from normal volunteers and treated them in vitro 
with 5JlM simvastatin. I then probed with antibodies against the known raft 
associated proteins, LAT and Lyn. Figure 3.7 shows the results ofthis experiment, 
with reduction of the raft fraction of treated cells. Having established this 
technique, I examined cells from subjects before and after simvastatin treatment to 
identify changes in raft fractions of the cell membrane. 
Leukocyte preparations were made from peripheral blood of normal volunteers 
before and after taking simvastatin 40 mg/ day. The samples were subjected to 
sucrose gradient centrifugation and the presence of raft-associated proteins 
measured in the raft fraction by western blot. The intensity of Lyn and Fyn bands 
was determined by densitometry and a ratio calculated between whole cell levels of 
protein and raft levels. The ratios were plotted on a bar graph and the general 
trend was for a reduction in rafts (Figure 3.8). Although there was a clear trend 
towards reduction of the raft fraction during treatment this failed to achieve 
statistical significance. 
3.2.2.4 Farnesol and geranylgeraniol fail to rescue simvastatin 
inhibition (Figure 3.9) 
To further investigate the effect of simvastatin on prenylation and its role in 
immunomodulation, I attempted to rescue simvastatin inhibition of T cell 
proliferation by addition of excess prenyl groups, farnesol and geranylgeraniol 
(Figure 3.9). Farnesol and geranylgeraniol individually or in combination did not 
significantly rescue simvastatin inhibition where as mevalonate, which is further 
upstream of the cholesterol pathway, did. 
3.2.3 Study 3: Human NK study (Figure 3.10) 
A total of 146 patients and normal subjects had samples taken for measurement of 
NK cytotoxicity using standard methodology. The population sampled was 
deliberately diverse. The average age was 56.3 ± 16.7 years (mean ±SD), 58.9% 
were male, 20.9% were cigarette smokers, 12% had diabetes, 31% had treated 
hypertension, 16.5% had coronary heart disease and 33.5% were on 
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Figure 3.7 Simvastatin treatment reduced raft levels in leukocytes. 
Western blot of leukocytes treated in vivo with 5/J.M simvastatin showed a 
reduction in LAT and Lyn levels and therefore rafts. 
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Figure 3.8 Simvastatin treatment reduced the western blot band intensities of 
raft levels in leukocytes 
Band intensities of Lyn and Fyn on western blots were measured by densitometry. 
A ratio between whole cell levels and raft content was calculated and plotted on a 
bar graph. The general trend was a reduction in raft levels, however the small 
number of samples used made the figures statistically insignificant. (Data sets are 
the mean ±SE, n=7) 
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Figure 3.9 Farnesol and geranylgeraniolfailed to rescue simvastann inhibited T 
cell proliferation. 
Mevalonate, farnesol and geranylgeraniol were added 24 hours after initial 
stimulation. Mevalonate partially rescued proliferation where as farnesol and 
geranylgeraniol did not significantly. (Data sets are the mean ±SD, n=6. 
*{ p=o.o6, **{ P<O.os, ***{ p<o.OOS) 
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immunosuppressive therapy. 30-4% of subjects were on statin therapy; the type 
and dose were not recorded. In this population the average non-fasting total 
cholesterol was 4.76 ±1.08 mmol/L, weight was 77.38 ±15.93 kg, and blood 
pressure was 134.6 ±20.9/74.9 ±11.7 mmHg. In the normal subjects the average 
non-fasting total cholesterol was 4.77 ±1.06 mmoljL, weight was 77-4 ±15.9 kg, 
and blood pressure was 134.8 ±20.3/75.0 ±11.3 mmHg. Overall, in all subjects and 
patients, the proportion of target Ks62 cells lysed, when incubated in a 1:25 ratio 
with a crude plasma lymphocyte preparation, was 52.9 ±19-4% (range 10-89%). 
The relationship between total cholesterol and NK cell killing is shown in Figure 
3.10. There was a trend towards higher levels of cytotoxicity at higher cholesterol 
levels and although statin therapy reduces NK cell killing in individuals, statin-
treated patients have levels of NK cell killing appropriate for their total cholesterol. 
The possible determinants of NK cell function were investigated by regression 
analysis. These data are shown in Table 3.2. The best-fit model identified total 
cholesterol and weight as the main factors associated with cytotoxicity; whereas 
statins, immunosuppressive therapy, gender, age or blood pressure were not 
independently associated. 
3.3 Discussion 
The involvement of inflammatory mechanisms in atherosclerosis is now well 
established where both T lymphocytes and NK cells have been implicated in 
experimental and human atherosclerosis295, 296• Statins are known to inhibit 
proliferation and to modulate function oflymphocytes and NK cells in vitro. 
However, in vivo, statins appear to inhibit NK cell function in transplant recipients 
receiving concomitant immunosuppressive therapy but there is little evidence of 
impaired T cell or NK cell function in other groups (Study 1). Since the prevailing 
view is that these, potentially immunosuppressive, effects are in vitro effects with 
limited in vivo or clinical relevance, I sought to determine the effects of 
simvastatin in normal subjects. 
Study 2 was not randomised. All patients were studied before and after treatment 
-------~-----------------------"---------------------------~~-
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Figure 3.10 Relationship between total cholesterol and NK cell cytotoxicity. 
Crude lymphocyte preparations were extracted from peripheral blood samples 
from a mixed group of patients and normal subjects. NK cytotoxicity was 
measured by lysis of 51Cr labelled Ks62 target cells. NK cytotoxicity (% killing) is 
shown on Y axis vs., random total cholesterol concentration (mmoljL) on the X 
axis. The corresponding multivariate analysis is shown in Table 3.2. 
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Variable Beta (SD) Significance 
Constant 8.09 (17.69) 
Age (years) -0.03 (0.11) 0.90 
Sex (F Ys., M) -2.24 (3.09) 0.44 
Smoker (Y Ys., N) 2.23 (4.33) 0.61 
Statin (Y Ys., N) -2.33 (3.85) 0.55 
TC (mmollL) 4.82 (1.66) <0.01 
Weight (Kg) 0.22(0.12) 0.07 
SBP (mmHg) 0.05 (0.10) 0.59 
ImRx (Y Ys., N) -2.26 (3.68) 0.54 
(ii) Stepwise Model (r=0.29, r2 = 0.09, F=7.23, P=O.OOI) 
Variable 
Constant 
TC (mmoI/L) 
Weight (Kg) 
Beta (SD) Significance 
10.72 (1l.41) 
4.80 (l.54) 
0.25 (0.l1) 
<0.01 
0.02 
Table 3.2 Relationships with NK cytotoxicity - linear regression analysis. 
The best-fit model identified total cholesterol and weight as significant 
independent predictors of cytotoxicity; statins, immunosuppressive therapy, 
gender, age or blood pressure were not independently associated. 
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with simvastatin for four weeks, and once more at least four weeks after the 
cessation of therapy. Reassuringly, a significant reduction in LDL cholesterol of 36 
±16% and a similar reduction in total cholesterol were observed. HDL-cholesterol 
was increased by 13 ±20.2% and, despite the fact that the lipid levels in this study 
were normal and much lower than the majority of patients enrolled in clinical 
trials I observed a quantitatively similar, beneficial effect on plasma lipid levels177, 
179,193,203 (Table 3.1). 
Study 2 sought to determine whether or not, T cell proliferation was affected by 
oral statin therapy. A standard lymphocyte proliferation assay, using CD3 cross-
linking for specificity was utilised. There was no significant difference in the in 
vitro proliferation of T lymphocytes isolated from subjects during statin therapy. 
Moreover, although in vitro treatment with simvastatin (at concentrations in the 
micromolar range that are consistent with the peak levels achieved during 
simvastatin treatment) inhibited T cell proliferation, cells isolated during 
simvastatin treatment were no more susceptible to subsequent in vitro exposure. 
The absence of an in vivo effect of statins on T cell proliferation is consistent with 
the absence of an effect of statins on infection and malignancy rates in large scale 
trials177, 179, 193, 203. Alternatively this may reflect either the insensitivity of the assay 
system or the fact that T cell proliferation is such an important biological response 
that it may bypass inhibition of a single signalling mechanism. 
Natural Killer cell function is more sensitive to in vivo statin use250, 285. A clear 
reduction in NK cell cytotoxicity during statin treatment was observed and was 
reversed following withdrawal of simvastatin. The changes in NK cell function 
paralleled those changes in LDL-cholesterol, reflecting the influence of statin 
therapy (Figure 3.6). As with lymphocyte proliferation, there may be differences in 
sensitivity of the assay so that it is easier to detect a reduction in NK cell killing 
than in lymphocyte proliferation. Alternatively, NK cell activation and killing may 
be more susceptible to blockade of statin dependent signalling pathways, whether 
they be dependent on isoprenoids or membrane rafts56• 
Having shown that simvastatin inhibits NK cell cytotoxicity in normal subjects 
during short-term treatment, I sought to investigate the influence of statins in 
patients receiving statin therapy for conventional indications. In this preliminary 
~-------------- ---- ~"~-.-------------------~------~------
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study (Study 3) I did not restrict sampling to patients without concomitant disease 
or to those on statin therapy alone. However, it is unusual in the clinical practice 
for patients to receive statin monotherapy, or to have an indication for statin 
treatment in the absence of co-morbid disease. Thus, the patients sampled are 
typical of the patients receiving statin therapy in the practice. Although statin 
treated patients were older, there was no significant relationship between age and 
NK cell cytotoxicity (p=o-418). The fact that statin recipients had reduced NK cell 
cytotoxicity, is consistent with the findings in normal subjects and also previous 
reports that NK cell cytotoxicity is reduced in transplant recipients on statin 
therapy250 • Although T cell proliferation was reduced in statin recipients, this does 
not match the findings in normal subjects and should be viewed with caution. 
Overall, the pattern of in vitro effects of statins, and prenyl transferase inhibitors 
in these patients (whether or not they received statin therapy) is similar to the 
findings in normal subjects. 
I examined the potential importance of isoprenoids by the use of isoprenyl 
transferase inhibitors in the first two studies. In vitro, these agents inhibit the 
proliferation of lymphocytes and NK cell cytotoxicity to a more limited extent than 
statins. Both agents together are more effective than either agent alone, suggesting 
that geranylgeranylation and farnesylation may offer alternative pathways, either 
for individual proteins or for physiological processes. FTI and GGTI plus statin 
therapy had no greater effect than statin alone in vitro, consistent with the ability 
of statins to block the common pathway to isoprenoid generation. There was no 
additional effect of these agents (alone or in combination) on cells isolated from 
subjects during oral statin therapy. Although these observations are interesting 
and confirm the efficacy of both farnesyl and geranylgeranyl transferase inhibitors 
in vitro, the effects of these inhibitors are limited in comparison to statins. Whilst 
the specificity and potency of these prenyl transferase inhibitors may differ, and 
are likely to be less than that of commercially available statins, these observations 
are also consistent with the notion that mechanisms other than inhibition of 
prenylation are involved. 
To investigate the effect of the prenylation process on the immunomodulatory 
effect of simvastatin I have shown that addition of excess prenyl groups failed to 
rescue T cell proliferation. However, addition ofmevalonate (which is further 
-------- -- -""~---- -----~---" 
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upstream in the cholesterol pathway and could therefore restore cholesterol 
synthesis) did recover T cell proliferation. Providing prenyl groups to restart the 
prenylation of signalling molecules could not rescue proliferation, demonstrating 
the importance of cholesterol and raft structure over prenylation in the mechanism 
of proliferation. 
This alternative explanation for the actions of statins on lymphocytes is the 
disruption of membrane rafts. These cholesterol rich membrane microdomains 
act as cell membrane platforms for receptors and signal molecules. The raft 
fractions in the cell membrane were separated by sucrose gradient centrifugation 
and probed for the presence of known raft associated proteins, specifically Lyn and 
Fyn in lymphocytes. Lyn is of particular interest as its translocation to the cell 
membrane is independent of prenylation. The data from study 2 show a reduction 
in raft-associated proteins in the samples from seven subjects, during statin 
therapy. Although the failure to achieve statistical significance reflects the fidelity 
of methodology that is seldom subjected to statistical analysis, it is consistent with 
an effect of oral simvastatin to deplete membrane rafts in circulating cells. 
Blockade of LFA-1 and VLA-4 interactions with their ligands is a potential target 
for immunosuppression and for controlling inflammation and autoimmune 
diseases. Statins can prevent these interactions by disrupting membrane rafts. 
Inactive LFA-1 is tethered to the cytoskeleton, and if unable to move into lipid rafts 
where it would normally become activated, it would therefore remain inactive. 
Rho, Rac and Cdc42 are prenylated GTPase signalling molecules which regulate 
receptor clustering81 and treatment with statins would prevent them controlling 
and moving the integrins. Some statins have been found to bind directly to LFA-
176 preventing the conformational change to a high affinity state. I measured the 
adhesion markers LFA-1 and VLA-4 on T cells from the cardiovascular group of 
patients (Study 1) by F ACS. Statin treatment however had no statistically 
significant effect on the amount of either of these markers perhaps due to the 
highly variable levels on normals. The anti-LFA-1 and anti-VLA-4 antibody used 
was not specific enough to distinguish between activated and inactive forms, 
therefore could not distinguish between the forms within or outwith lipid rafts. 
Treatment with statins would only alter the position on the membrane not the 
overall amount. The type of statin used could also have affected the results as 
-----------"- ------------------------------
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some statins bind directly to LFA-l. This could have sterically prevented the FACS 
antibody from binding and as the patients were not all on the same statin, makes 
the results difficult to interpret. 
In conclusion, these preliminary studies demonstrate that a short oral course of 
simvastatin has a detectable effect on NK cell cytotoxicity. Accumulating evidence 
indicates a multifactorial mode of action for statins in the reduction of morbidity 
and mortality from cardiovascular disease. Thus, in addition to lowering LDL-
cholesterol levels, statins block leukocyte recruitment to atherosclerotic lesions, 
inhibit monocyte antigen processing and production of inflammatory mediators, 
and reduce NK functions. NK cells have been implicated in atherosclerosis and are 
known to target cells that do not express HLA class I on the cell surface, including 
cells that have been infected by viruses285, 295. Whether this effect on NK cells 
contributes to the overall beneficial effects of statin therapy in cardiovascular 
disease is not clear and will require further investigation. However, the 
mechanism by which statins inhibit NK cell killing is likely to provide an insight 
into the signalling mechanisms disrupted by statin therapy and that contribute to 
their pleiotropic effects in other cell types86, 239. 
The possibility that reduced NK cytotoxicity may reflect an underlying relationship 
between cholesterol synthesis, membrane cholesterol and cell function has not 
been considered297. In the human NK study (Study 3), I found that statin treated 
patients did not have lower NK cell cytotoxicity than non-statin treated patients 
but that the overall relationship was with total cholesterol (Figure 3.10; Table 3.2). 
The patient selection for this study was not focused on one particular group but 
was deliberately wide-ranging to provide a spectrum of age, underlying disease 
and drug therapy to allow comparison of potential influences. The analysis is 
preliminary and will require further investigation in larger, more homogeneous 
groups. However, the findings concur with the previous study in normal subjects 
where there was a close relationship between reduction in NK cell cytotoxicity and 
lipid levels in normal subjects receiving statins. Thus, rather than being directly 
due to statin treatment this change may be a consequence of changes in cholesterol 
levels, both in the circulation and in the cell membrane. 
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Although this was a small-scale, pilot study that recruited normal subjects and 
patients over a wide age range, a range of drug therapy and underlying pathology, 
it poses questions about the relationship between circulating lipids and membrane 
lipids, and the wider effects on cell membrane structure and signalling. NK cells 
may simply provide an accessible cell type and the relationship between lipids and 
immune cell function297-299 may be applicable to all cells. 
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4.1 Introduction 
Chapter 3 confirmed the effectiveness of statins in reducing LDL cholesterol and 
reducing lymphocyte functions in vivo and in vitro179,300 • These pleiotropic effects, 
independent of cholesterol reduction, are believed to be mediated by reduction of 
isoprenoid intermediates, farnesyl and geranylgerany1239, 278 • Addition of these 
isoprenoids to a variety of signal molecules301 by specific transferases, promotes 
the membrane association of otherwise hydrophilic proteins. Hence, inhibition of 
prenylation (by statins or specific prenyl transferase inhibitors) may lead to 
functional inactivation of signalling proteins, such as those of the Ras superfamily, 
involved in lymphocyte function. The Ras superfamily of small GTPases can be 
subdivided into five major families (Ras, Rho/Rac, Rab, Arf and Ran)302, 303; the 
Ras family, are farnesylated; whereas Rho, Rab and Rac are geranylgeranylated21. 
Ras and Rho GTPases link extracellular stimuli to downstream signalling 
molecules such as mitogen-activated protein kinases (MAPK) including 
extracellular signal-regulated kinases (ERK), the c-Jun N-terminal kinase (JNK) 
and the P38 MAPK302. In general ERK is activated by mitogenic factors, while JNK 
and P38 are activated by stress inducing agents or pro-inflammatory cytokines. 
The dependence of these pathways on isoprenylated signal proteins offer a 
potential mechanism of action for statins in lymphoid cells and may explain the 
potential immunosuppressive actions of these compounds. 
The aim of this chapter was to explore the potential mechanisms of the 
immunosuppressive effects of statins by examining the effect of HMG-CoA 
reductase inhibition by fluvastatin on Ras-dependent ERK activation and P38 
activation in human lymphocytes in vitro. 
I hypothesised that fluvastatin would reduce the prenylation of small GTPases 
such as Ras and Rac and therefore affect activation of downstream signalling 
molecules such as ERK and P38. 
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4.2 Results 
4.2.1 U937 Membrane preparations (Figure 4.1) 
To assess the effect of fluvastatin on prenylation and membrane association of 
small G-protein signalling molecules, U937 cells were treated overnight with 2ol-lM 
fluvastatin or 2ol-lM fluvastatin plus 1mM mevalonate. They were then separated 
into their cytosolic and membrane components by ultracentrifugation and Western 
blots performed. 
Figure 4.1 showed the levels of Ras in the membrane compartment were reduced 
by treatment with fluvastatin (panel 1 lane 2) and rescued by mevalonate (lane 3). 
The reduction in prenylation of Ras by HMG-CoA reductase inhibitor removed the 
membrane anchor and caused the unprenylated Ras to remain in the cytosol (lane 
5). A similar result was obtained with Rac (panel 3), but did not show the rescue 
by mevalonate or movement to the cytosol as well. The samples were re run on a 
higher resolution gel (12% polyacrylamide with MOPS buffer), to separate the 
prenylated form of Ras from the unprenylated form and to observe the band shift 
effect (panel 2). The negative control (lane 1) showed more Ras in the smaller 
form (prenylated form) and less in the larger form (unprenylated). However, 
fluvastatin treatment (lane 2) showed less of the smaller prenylated form and more 
of the unprenylated larger form, which had moved into the cytosolic fraction (lane 
4). Lyn is a member of the src family kinase, which has a palmitoylated membrane 
anchor rather than a prenylated anchor, so was used as an equal loading control 
for the membrane fraction. Shp-1 has a cytosolic location in unstimulated cells 
and was therefore used as the loading control for the cytosolic fraction. 
4.2.2 Measurement of FcyRI levels on U937 cells by FACS 
(Figure 4.2) 
U937 cells were treated overnight with lol-lM fluvastatin or lol-lM fluvastatin plus 
1mM mevalonate. FcyRI was measured by FACS using an anti-human FcyRI 
antibody and FITC conjugated anti-mouse Ig to determine whether fluvastatin 
page 110 
dayter 4: Ejlcet (if fill vasta till 011 yrcl1ylati(1)f alid 5i!J71alli'~1 
---- --- - - ----- - ------ - ------
(]) (]) 
.S .S ~ .S .S ~ 
~ ~ 0 ~ ~ 0 
-+-> -+->,,9 -+-> -+-> 0 ~ ~ C\l ~ ~~ 
- 5 5 ~ - 5 5 ~ 0 0 ~ ~ ~ S .l:J ~ ~ S ~ ~~ 0 ~ ~~ 0 0 0 ::t 0 ::t (]) 0 0""'" (]) 0 0""'" > > I ('1 ('1 + I ('1 ('1+ 
Ras 
Ras 
Rae 
Lyn 
Shp-l 
Membrane Cytosol 
Figure 4.1 Fluvastatin reduced Ras and Rae levels in the membrane of U937 cells. 
U937 cells were treated overnight with 2of.!M fluvastatin with or without lmM 
mevalonate and separated into their cytosolic and membrane components by 
ultracentrifugation. Fluvastatin treatment reduced the levels of Ras and Rac in the 
membrane and consequently increased them in the cytosol (panell and 3). A band 
shift in Ras was demonstrated in panel 2 with fluvastatin treated cells containing 
higher levels of unprenylated Ras in both membrane and cytosolic fractions. Lyn 
and Shp-l were used as loading controls. This was representative of 3 
experiments. 
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affected Fc receptor numbers. Autofluorescence was controlled for by addition of 
secondary antibody only. Mean fluorescence intensity was measured and FcyRI 
levels were not affected by either treatment (Figure 4.2). 
4.2.3 Ras activity 
4.2.3.1 Ras activity assay in U937 cells (Figure 4.3) 
Ras is a prenylated G protein signalling molecule which cycles between an inactive 
GDP-bound state and an active GTP-bound state and couples CD3 to the ERK 
proliferative pathway in T cells 20. U937 cells were treated overnight with 20~M 
fluvastatin or 20~M fluvastatin plus 1mM mevalonate to assess the effect of 
fluvastatin on reducing prenylation of Ras and therefore affecting its activity. Cells 
were stimulated by cross-linked IgG. Ras activity was measured by kit from 
Upstate Biotech and phosphotyrosine levels were measured by western blot using 
the supernatant from the Ras assay. Figure 4.3 showed a reduction in Ras activity 
when treated with fluvastatin (top panel lane 4 reduced compared to lane 2) and 
full recovery when rescued with mevalonate (lane 6). The same also applied to 
tyrosine phosphorylation (bottom panel) of proteins in the supernatant, with a 
partial rescue by mevalonate. 
4.2.3.2 Ras activity assay in human primary T cells (Figure 4.4) 
To confirm the effect of fluvastatin on the prenylation of Ras was not confined to a 
cell line, I repeated the Ras activity experiments in T cells extracted from normal 
volunteers. I also further investigated the effect of reduced Ras prenylation by 
addition of farnesyl and geranylgeranyl transferase inhibitors. 
T cells were treated for 72 hours with 20 ~M fluvastatin, with or without 
mevalonate (in the final 18 hours), 10 ~M FTI and/or 10 ~M GGTI inhibitor and 
stimulated by crosslinked anti-human CD3 antibody. Ras activity was measured 
by kit and phospho ERK levels were measured by western blot using the 
supernatant from the ras assay. Figure 44 showed reduced Ras activation by 
addition offluvastatin and FTI and GGTI together, but not FTI or GGTI 
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Figure 4.2 Fluvastatin treatment did not affect FcrRI levels on U937 cells. 
U937 cells were treated overnight with lOf..lM fluvastatin or lOf..lM fluvastatin plus 
ImM mevalonate. FcgRI levels were measured by FACS. (A) FACS overlay graph 
and (B) mean fluorescence intensity values showed FcyRI levels were not affected 
by either treatment. 
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Figure 4.3 Ras activity and tyrosine phosphorylation was reduced byfiuvastatin 
and rescued by mevalonate in the U937 cell line. 
U937 cells were treated overnight with 2oJ.!M fluvastatin or 2oJ.!M fluvastatin plus 
ImM mevalonate and cross linked with IgG. Ras activity was measured (top panel) 
and was reduce by fluvastatin treatment and rescued by mevalonate. The 
supernatant from the ras assay was western blotted and probed with anti-
phosphotyrosine antibody. Similarly, tyrosine phosphorylation was reduced by 
fluvastatin and some protein's tyrosine phosphorylation was rescued by 
mevalonate. This was representative of 2 experiments. 
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Figure 4.4 Ras activation and ERK phosphorylation was reduced in human 
primary T cells by fluvastatin 
Human T cells were extracted from a normal volunteer and stimulated via CD3 
and treated for 72 hours. (A) Ras activation was reduced by addition of fluvastatin 
(lane 3) and a combination of FrI I and GGTI-286, (lane 7) but not by each 
transferase inhibitor alone (lane 5 and 6). (B) ERK phosphorylation was also 
reduced by addition of fluvastatin (lane 3) but not by transferase inhibitors (lane 5-
7). ERK phosphorylation could also be rescued by the addition of mevalonate (lane 
4). (C) Pan ERK confirmed comparable gel loading. This blot was representative 
of two experiments. 
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individually. Ras is normally farnesylated, therefore should be unaffected by GGT 
inhibitors but is alternatively geranylgeranylated when treated with FfI 
inhibitors21• Consistent with this, addition of both inhibitors resulted in some 
reduction of Ras activation. ERK phosphorylation was correspondingly reduced by 
addition of fluvastatin but was unaffected by the addition of FfI, GGTI or both 
inhibitors together. ERK could also be rescued by mevalonate unlike Ras 
suggesting an alternative pathway might be involved304,305. 
4.2.4 Rac activity assay with human primary T cells (Figure 
4.5) 
Rac is the isoprenylated protein that couples CD3 to the P38 stress pathway. I 
therefore investigated the effect of fluvastatin and prenyl inhibitors on Rac and 
P38. The same samples from section 4.2.3.2 were assayed for Rac activity by a Rac 
specific kit and Phospho P38 levels were measured by western blot using the 
supernatant from the ras assay. Figure 4.5 showed reduced Rac activation by 
addition of fluvastatin and GGTI but not Ffl. Rac is normally 
geranylgeranylated306, therefore would be unaffected by FT inhibitors. Consistent 
with this, addition of both inhibitors resulted in some reduction of Rac activation. 
P38 phosphorylation was correspondingly reduced by addition of fluvastatin but 
was unaffected by the addition of FfI, GGTI or both inhibitors together. P38 could 
also be rescued by mevalonate unlike Rac suggesting an alternative pathway might 
be involved307. 
4.2.5 Erk Phosphorylation 
4.2.5.1 ERK phosphorylation in primary human T cells (Figure 4.6) 
I investigated the Ras-ERK pathway in primary human T cells further by 
examining a time course of CD3 stimulation. CD3 ligation resulted in the 
sustained activation of both ERK1 and ERK2 at all time points examined (Figure 
4.6). The inclusion of 2o/-lM fluvastatin to the assay significantly reduced ERK 
activation in response to CD3 ligation at 24 hours, while at 48 hours and 72 hours 
ERK activation was almost entirely abolished. Addition of Mevalonate 18 hours 
---- -------""-~ 
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Figure 4-5 Rac activation and P38 phosphorylation was reduced by fluvastatin. 
The same samples from figure 4.2.3.2 were assayed for Rac activity in the same 
way as Ras. (A) Rac activation was reduced by addition of fluvastatin (lane 3) and 
by GGTI (lane 7), but not by FfI (lane 5). (B) P38 phosphorylation was also 
reduced by addition of fluvastatin (lane 3) but not by transferase inhibitors (lane 5-
7). P38 phosphorylation could also be rescued by the addition of mevalonate (lane 
4). (C) Pan ERK confirmed comparable gel loading. 
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Figure 4.6 ERK phosphorylation stimulated via CD3 was reduced by fluvastatin 
in primary human T cells over a time course of 72 hours. 
Human T cells were extracted from a normal volunteer and stimulated via CD3 
over a time course of 72 hours. (A) A small reduction in ERK phosphorylation was 
apparent in fluvastatin treatment at 24 hours (lane 7), however a greater reduction 
was observed at 48 and 72 hours (lane 8 and 9). Mevalonate rescued ERK 
phosphorylation at all time points (lane 10-12). (B) Pan ERK confirmed equal gel 
loading. This blot was representative of two experiments. 
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prior to cell lysis completely reversed the effects of fluvastatin at all time points 
examined. This was consistent with the inhibitory effects of fluvastatin being 
mediated by reduced isoprenoid synthesis. 
4.2.5.2 ERK phosphorylation in U937 monocyte cell line (Figure 
4.7) 
I further investigated the Ras-ERK pathway in the human monocyte cell line U937. 
FcyR were aggregated with IgG at 37°C for 3,10 and 30 minutes and control U937 
cells were incubated with cross-linking anti-human IgG alone. FcyR aggregation 
caused dual phosphorylation of both P44 and P42 ERK (Figure 4.7). No increase 
in phosphorylation of either kinase was seen in controls. Pre-treatment with 10JlM 
fluvastatin for 48 hours reduced Fcy R mediated activation of ERK and at all time 
points. 
4.2.6 p3S phosphorylation 
4.2.6. 7 p38 phosphorylation in primary human T cells (Figure 4.8) 
The Rac/Rho-P38 pathway plays a role in lymphocyte activation and cytoskeletal 
regulation302• Therefore P38 activation was assessed using a phospho-specific P38 
MAP Kinase (Thr180/Tyr182) antibody. CD3ligation resulted in a transient rise 
in P38 phosphorylation with highest levels observed at 10 and 30 minutes (Figure 
4.8), returning to baseline by 120 minutes. This activation pattern contrasts to the 
sustained activation observed for ERK (Figure 4.6). As a result of this short time 
course of P38 activation it was necessary to culture cells with fluvastatin prior to 
CD3ligation. Thus, cells were incubated with lol-tM fluvastatin for 48 hours and 
then plated onto anti-CD3 coated plates for 0, 10, 30 and 120 minutes. Figure 4.8 
demonstrated that pre-treatment of cells with fluvastatin entirely uncoupled CD3 
from the P38 pathway at all time points examined. Addition of mevalonate to the 
cells for 18 hours prior to CD3 ligation partially restored CD3 coupling to P38 
activation. Analysis of ERK activation in the same celllysates (Fig 4.8 (C)) 
indicated that the ERK pathway was also uncoupled by fluvastatin over this short 
time course of stimulation though the addition of mevalonate was able to restore 
~------------------------------ ---
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Figure 4.7 Fluvastatin blocks Fcyreceptor activation ofERK 
U937 cells were cultured for 48 h in control medium or in 10 /-LM fluvastatin. FcyR 
were aggregated with human IgG followed by crosslinking goat anti-human IgG at 
37°C for the times indicated (FcyR XL). Control cells were incubated with goat 
anti-human IgG alone (no XL control). Fluvastatin treatment reduced phospho 
ERK levels. This blot was reperesentative of 3 individual experiments 
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Figure 4.8 P38 phosphorylation in Tcells stimulated via CD3 was reduced by 
addition of fluvastatin and rescued by mevalonate. 
Human T cells were extracted from a normal volunteer and stimulated via CD3 
over a time course of 2 hours. (A) P38 phosphorylation was apparent at 10 and 30 
min but had diminished by 120 min (lane 2-4). Fluvastatin treatment reduced this 
phosphorylation (lane 6-8) and mevalonate rescued it (lane 10-12). (B) Pan P38 
confirmed equal gel loading. (C) ERK phosphorylation was reduced at these 
smaller time points by being first incubated with fluvastatin before being 
stimulated. This blot is representative of two experiments. 
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ERK activation entirely. This differing sensitivity to mevalonate rescue may reflect 
differences in the rate of turnover of different small G-proteins. Unfortunately, my 
attempts to assess activation of Rac/Rho family members, which lie upstream of 
P38, in response to CD3 ligation proved unsuccessful due to a lack of assay 
sensitivity. 
4.2.6.2 P3S phosphorylation in U937 monocyte cell line (Figure 
4.9) 
I further investigated the Rac-P38 pathway in the human monocyte cell line U937. 
FcyR were aggregated with IgG at 37°C for 3,10 and 30 minutes and control U937 
cells were incubated with cross-linking anti-human IgG alone. FcyR aggregation 
caused phosphorylation of P38 (Figure 4.9). No increase in phosphorylation was 
seen in controls. Pre-treatment with 10llM fluvastatin for 48 hours reduced FcyR 
mediated activation of P38 and at all time points. 
4.3 Discussion 
Several studies have suggested that statins have immunosuppressive actions152, 308 
including reduction in the severity and frequency of acute allograft rejection 
episodes. Fluvastatin has potential benefits in transplant patients receiving 
calcineurin inhibitors (CNI) since the metabolism of fluvastatin is not inhibited by 
the CNI, CyA or tacrolimus255, 309, 310. Thus, fluvastatin was investigated both for 
its impact on rejection and cardiovascular events in renal transplant recipients. 
Statins have been shown to have a number of pleiotropic effects, specifically 
inhibition of proliferation of vascular smooth muscle cells and macrophage 
function. These effects are independent of cholesterol and are reversible by 
mevalonate, geranylgeranyl or farnesyl311 implicating a role for isoprenylated 
proteins in this process. Many small GTPases, involved in cell proliferation 
pathways, require isoprenylation to enable membrane localisation. I have used 
specific inhibitors of geranylgeranyl and farnesyl transferase to attempt to dissect 
out the pathways involved in cell proliferation. I targeted ERK and P38, two 
MAPK pathways known to playa central role in the proliferation and activation of 
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Figure 4.9 Fluvastatin blocks Fcrreceptor activation of P38 
U937 cells were cultured for 48 h in control medium or in 10 f.!M fluvastatin. FcyR 
were aggregated with human IgG followed by crosslinking goat anti-human IgG at 
37°C for the times indicated (FcyR XL). Control cells were incubated with goat 
anti-human IgG alone (no XL control). Fluvastatin treatment reduced phospho 
P38 levels. This blot was reperesentative of 2 individual experiments. 
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lymphocytes312 both of which are reliant on small isoprenylated GTPases for 
activation; ERK on Ras and P38 on rho/rac. 
ERK activation by anti-CD3 cross-linking is evident within minutes and persists 
for up to 72 hours. This effect is abrogated at 24 hours in fluvastatin treated cells 
(figure 4.6) and abolished at 48 and 72 hours. Activation is completely restored by 
inclusion of both statin and mevalonate ("mevalonate rescue") consistent with the 
effects being mediated by isoprenoids. Figure 4.6 also shows two molecular weight 
subfractions of phospho ERK (P44 ERKl and P42 ERK2), the larger of which is 
less abundant. In keeping with the known dependence of ERK on upstream Ras 
activation, CD3 stimulation results in increased p21 Ras expression that is 
significantly reduced by fluvastatin pre-treatment (Figure 4-4). In these 
experiments, 20 /-LM fluvastatin was used because this provided clearer results, 
although a similar pattern was seen with 5 /-LM fluvastatin. 
Another pathway involved in lymphocyte function is the P38 MAP kinase pathway, 
downstream of the rho/rac family of GTPases. I found that fluvastatin 
significantly reduced phospho P38 production in response to CD3 stimulation. 
Mevalonate rescue was less clearly demonstrated for P38 MAP kinase. This is 
likely to reflect differences in the susceptibility of different pathways to mevalonate 
rescue, reflecting the different G protein turnover rates between Ras and Rac/Rho. 
The time course of changes in the phosphorylation of P38 was much shorter than 
ERK, lasting a few hours rather than several days. The observation that the 
inhibitory effects of statins take many hours to develop is consistent with 
intracellular depletion of substrate; the time course of mevalonate rescue 
consistent with re-synthesis of substrate. Thus, the limited recovery may reflect 
the short time-course of activation of P38 in T cells. 
Overall, the data demonstrated that exposure to fluvastatin in vitro is associated 
with reduction in ERK and P38 activity, consistent with inhibition of 
isoprenylation of G proteins involved in signal transduction. The time scale of the 
observed effects suggested that depletion of substrate is important and may 
explain the limited effects observed in vivo (chapter 3), at least in stable patients. 
It may be that under circumstances where there was more active disease, and 
faster cell turnover, such as during acute allograft rejection 308 that substrate 
-~------ -----------------------
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supply is limited. It remains to be seen whether changes in signal transduction can 
be seen in vivo in lymphocytes and other immune-mediator cells, and in other cell 
types (e.g. vascular smooth muscle cells) involved in atherosclerosis. The 
availability of specific inhibitors of geranylgeranyl and farnesyl transferase, some 
of the latter are in clinical trials, offers a novel approach. The combination of these 
agents with statins may allow the combination of depletion of isoprenoids and 
inhibition of enzymatic isoprenylation, with numerous potential applications 
including immunosuppression. 
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chayter 5: Effects of stauns on liytd rafts. 
5.1 Introduction 
Chapter 4 explored the effect of reduced prenylation of small GTPase molecules on 
signalling pathways. However, an alternative explanation for the pleiotropic 
effects of statins is due to disruption, or depletion, of cholesterol rich membrane 
micro-domains (membrane rafts)66, 279. The reduced density of rafts limits the 
function of receptors localised to these domains. 
NKG2D inhibitory receptors are excluded from lipid rafts and prevent formation of 
activation signalling complexes. Therefore reduction of lipid rafts by statins 
maintain NK cells in a non cytotoxic states6. 
FcyR are activated when clustered at the cell surface by IC, and signal through an 
immunoreceptor tyrosine based activation motif (ITAM)6s. Aggregated FcR are 
recruited to cholesterol and sphingolipid rich plasma membrane rafts as a 
platform for signal transduction66, 67, 69, resulting in phosphorylation of tyrosine 
residues within associated ITAMs and recruitment of cytoplasmic signalling 
molecules including Syk tyrosine kinase, PI3-kinase complex, PLC-y and LAT 
(Linker for Activation ofT-cells). Importantly, LAT is targeted to rafts by 
palmitoylation rather than isoprenylation. Disruption of lipid rafts by statins 
would therefore interfere with FCyR signalling pathways. 
Since tyrosine kinase activation is independent of prenylated proteins, I 
hypothesised that statins may limit Fcy Rand NK inhibitory receptor signalling 
and function by disrupting membrane rafts. The aim of this chapter was to 
examine the disruption of formation of lipid rafts by cholesterol depletion whether 
by statin or M~CD. I examined the effect offluvastatin in a dose dependent 
manner on rafts in the U937 human monocyte cell line, primary human 
lymphocytes, and NK92MI cells. I also examined the effect of FTI and GGTI to 
assess the effect of prenylation on raft disruption as well as the effect of apoptosis. 
Raft disruption may provide a further mechanism by which statins may exert their 
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immunomodulatory effects. This mechanism is likely to apply to other immune 
receptors that signal through membrane rafts, including the T cell and B cell 
receptors. 
5.2 Results 
5.2.1 Raft fractions 
5.2.1.1 Protein measurement of raft fractions (Figure 5.1) 
Resting U937 cells and U937 cells treated with 10/-1M fluvastatin were subjected to 
sucrose density centrifugation to isolate rafts. Ten 400/-11 fractions were collected 
and total protein content measured by Bradford's assay (Figure S.l). Fluvastatin 
reduced the total protein levels in the raft fractions (3-S). 
5.2. 1.2 Western blot of raft fractions (Figure 5.2) 
As a marker of cellular membrane raft integrity I assessed the distribution of LAT, 
a 36kD phosphoprotein that is palmitoylated and localised to rafts independent of 
receptor engagement69. I also examined the distribution of the src tyrosine kinase, 
Lyn which is myristoylated313 and associates with rafts. Proteins were resolved by 
SDS-PAGE and western blotting of sucrose gradient fractions. Fractions 8-10 
represent Triton X-100 soluble proteins, while fractions 3-S correspond to low-
density lipid rafts. In resting U937 cells, both LAT and Lyn were present within 
the Triton X-100 soluble fractions and the raft fractions (Figure S.2, panel 1 and 3) 
but pre-treatment with lOI1M fluvastatin for 48 hours caused a substantial 
reduction in raft associated LAT and Lyn (Figure S.2, panel 2 and 4). The 
transferrin receptor is excluded from lipid rafts and was unaffected by fluvastatin 
treatment (Figure S.2 panels.and 6). 
5.2.2 FACS of cell surface receptors on U937 cells (Figure 5.3) 
To determine whether changes in receptor expression could account for the 
inhibitory effects of statins, flow cytometry was used to examine U937 cell 
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Figure 5.1 Measurement of proteins within sucrose density gradient of U937 
cells. 
U937 cells treated with and without lO)lM fluvastatin were subjected to sucrose 
density centrifugation and the protein content from 40o)l1 fractions measured by 
Bradford's assay. Protein levels were expressed as percentage of total protein. 
Rafts were expected to be around fraction 4 and fluvastatin reduced the total 
protein content within this fraction. 
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Figure 5.2 Fluvastatin disrupts plasma membrane rafts in resting U937s 
Fluvastatin treated and untreated resting U937 cells were lysed in 1% Triton X - lOO 
MNE buffer and subjected to sucrose gradient centrifugation. Fractions of 450fll 
were taken from the top, numbered 1-10 and western blotted for LAT, Lyn and 
TfR. This was representative of 3 experiments. 
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expression levels of Fcy RI, Fcy RII, Fcy RIII and cell binding of FITC conjugated 
IgG (Table 1). Cells were found to express FcyRI and FcyRII but not FcyRIII. 
Following treatment with 10JlM fluvastatin or 10JlM simvastatin for 48 hours, the 
expression of FcyRI, FcyRII and binding of IgG-FITC were not altered. Therefore, 
the inhibitory effects of statins on Fcy R signalling were not due to reduced cell 
surface receptor expression. Expression of the human transferrin receptor, used 
as a control, was similarly unchanged (Figure 5.3). 
5.2.3 Induction of Apoptosis in U937 cells 
I investigated whether fluvastatin or simvastatin were capable of inducing 
significant necrosis or apoptosis in U937 cells to exclude these as explanations for 
the disruption of lipid rafts. Trypan blue staining of cells following statin 
treatment over the full dose range showed greater than 99% cell viability. 
Apoptosis was assessed by two methods: morphological examination and caspase 
activity. 
5.2.3.7 Morphological examination 
Morphological examination of stained U937 cells following statin treatment was 
performed in triplicate by counting a minimum of 500 cells per slide. The ability 
of statins to induce apoptosis of U937 cells was weak and appeared to be dose 
dependent with 4.6% of cells showing apoptotic nuclei after treatment with 
10JlM fluvastatin. The corresponding figure for treatment with 5JlM simvastatin 
was 7.6%. 
5.2.3.2 Caspase activity 
I also used an assay for caspase activity as a marker of apoptosis and this showed 
consistent results at 5.6% and 6.2% respectively following 10JlM fluvastatin and 
5JlM simvastatin. 
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Figure 5.3 Relative Fcy receptor expression and IgG-FITC binding of U937 cells. 
Receptor expression was determined by flow cytometry. Statins or transferase 
inhibitors did not affect receptor levels. This was representative of 2 experiments. 
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5.2.4 Effect of a range of statin concentrations on rafts 
5.2.4.1 U937 (Figure 5.4) 
U937 cells were treated with a range of concentrations offluvastatin for 48 hours. 
Disruption of cell rafts by fluvastatin appeared to be dose dependent with 
concentrations above 0.511M reducing levels of both LAT and Lyn in raft fractions, 
with maximal reduction observed at concentrations of 511M and above (Figure 5-4). 
5.2.4.2 Primary human Leukocytes (Figure 5.5) 
Primary human leukocytes obtained from a normal volunteer were also treated 
with a range of fluvastatin concentrations for 48 hours. Although it is not clear 
from the Western blot (Figure 5.5 A) that primary cells behaved the same as 
U937s, after densitometry (Figure 5.5 B) and the ratio of rafts to total cell protein 
calculated, a similar pattern emerged. 
5.2.4.3 NK92MI (Figure 5.6) 
NK92MI cells were treated with a range of concentrations of fluvastatin or 
simvastatin for 48 hours. Disruption of cell rafts by either statin appeared to be 
dose dependent with concentrations above 511M reduced levels of LAT and Fyn 
with fluvastatin and LAT and Lyn with simvastatin in raft fractions (Figure 5.6) 
5.2.5 Effect of Fll, GGll and mevalonate rescue on rafts 
5.2.5.1 U937 (Figure 5.7) 
To investigate whether raft disruption was a result of HMG-CoA reductase 
inhibition, I examined the effect of mevalonate rescue. U937 cells or were 
incubated for 48 hours in lOI1M fluvastatin to maximally deplete raft fractions of 
LAT and Lyn (Figure 5.7). Addition of 1mM mevalonate for 12 hours prior to raft 
fractionation reconstituted levels of Lyn and LAT to resting cell levels. 
Significantly, incubation of U 937 cells with a combination of 10 11M FTI and 10 11M 
-------------- ------------------- ------------------------------~----" 
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Figure 5.4 A range offiuvastatin concentrations disrupts rafts in U937 cells. 
Pooled raft fractions from resting U937 cells treated with increasing 
concentrations of fluvastatin were western blotted and probed for LAT and Lyn 
(upper panels). Lower panels compare expression levels in whole celllysates. This 
was representative of 2 experiments. 
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Figure 5.5 A range of fiuvastatin concentrations disrupts rafts in primary 
human leukocytes. 
Pooled raft fractions from resting primary human leukocytes treated with 
increasing concentrations of fluvastatin were western blotted and probed for LAT 
Densitometry allowed calculation of the ratio of raft LAT levels to whole cell LAT 
levels to give a comparable reduction in raft levels as U937 cells. 
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Figure 5.6 A range offluvastatin and simvastaun concentrations disrupts rafts 
in NK92MI cells. 
Pooled raft fractions from resting NK92MI cells treated with increasing 
concentrations of fluvastatin or simvastatin were western blotted and probed for 
Lyn, Fyn and LAT (panels on right). Panels on the left compare expression levels 
in whole celllysates. 
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Figure 5.7 Disruption of rafts by fiuvastatin in U937 cells was rescued by lmM 
mevalonate and unaffected by FTI and GGTI. 
Pooled raft fractions from U937 cells treated for 48 hours with 10flM fluvastatin, 
or 10flM fluvastatin with 1mM mevalonate added in the final 12 hours, were 
western blotted for LAT and Lyn. The disruption to raft levels by fluvastatin was 
rescued by the addition of mevalonate. Treatment with 10flM FTI and 10flM GGTI 
had no effect on raft levels. This was representative of 2 experiments. 
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GGTI had no measurable effect on either LAT or Lyn raft content. Taken together, 
these data imply that inhibition of cholesterol synthesis by fluvastatin and not 
isoprenoid synthesis is responsible for membrane raft disruption. 
5.2.5.2 Primary human leukocytes (Figure 5.8) 
Primary human leukocytes were also incubated for 48 hours in 10JlM fluvastatin 
and rescued with 12 hours of 1mM mevalonate (Figure 5.8), which was comparable 
with U937. 
5.2.5.3 NK92MI (Figure 5.9) 
NK92MI cells were treated in the same way as U937 cells, again with comparable 
results (Figure 5.9). 
5.2.6 Effect of Methyl beta cyclodextrin on rafts (Figures 5.10 
and 5.11) 
Methyl-p-cyclodextrin (MPCD) is a cyclic oligosaccharide consisting of 7 
glucopyranose units, which form a rigid doughnut shape (Figure 5.10). 
Hydrophobic molecules are incorporated into the cavity by displacing water, 
rendering the molecule water-soluble. When the water-soluble complex is diluted 
in a much larger volume of aqueous solvent, the process is reversed, thereby 
releasing the molecule of interest into the solution. MPCD is efficient in 
solubilizing cholesterol. At high concentrations (5-100mM), can remove 
cholesterol at phenomenal rates (300-400%/hour). At lower concentrations, 
MPCD can serve as cholesterol shuttles, transporting cell membrane cholesterol to 
serum lipoproteins314• 
NK92MI cells were treated with low (0.5mM) and high (lOmM) concentrations of 
MPCD for 1 hour to assess the effect of cholesterol influx and efflux on rafts. My 
hypothesis was that cholesterol movement into the membrane might increase raft 
levels while movement out of the membrane would decrease raft levels. 
Cholesterol influx with the lower concentration of MPCD did not increase Lyn, Fyn 
-------------------~~ ~---~.--------------------------------------------~-----~~~---------~-------- -"--"~~---
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Figure S.8 Disruption of rafts by fluvastatin in primary human leukocytes was 
rescued by lmM mevalonate. 
Pooled raft fractions from primary human leukocytes treated for 48 hours with 
lO/-LM fluvastatin, or lO/-LM fluvastatin with 1mM mevalonate added in the final 12 
hours, were western blotted for LAT and Lyn. The disruption to raft levels by 
fluvastatin was rescued by the addition of mevalonate. 
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Figure 5.9 FTI and GGTI do not affect rafts and mevalonate rescues statin 
disruption of rafts 
Pooled raft fractions from resting NK92MI cells treated with GGTI plus FfI, 
fluvastatin or simvastatin were western blotted and probed for LAT, Lyn and Fyn 
(panels on right). Panels on the left compare expression levels in whole cell 
lysates. 
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Figure 5.10 The chemical structure (A) and the toroidal shape (B) o/the f3-
cyclodextrin molecule. 
7 U-l,4 -linked glucopyranose units form a cone with a hydrophilic outer surface 
and a lipophilic cavity in the centre. 
page J40 
drl)Jlcr 5: Effects (if StfltillS Oil [iyid r4ts 
---. - ----- .----- - - -~"-~"---.------ -------------
or LAT levels and therefore had no effect on raft levels. However cholesterol efflux 
with the higher concentration of MPCD reduced the levels of Lyn, Fyn and LAT 
and therefore rafts (Figure 5.11). 
5.3 Discussion 
The mechanisms by which statins exert their effects remains controversial and 
may be in part independent of changes in serum cholesterol183, 300. Current 
favoured explanations of their mechanism of action have focused on inhibition of 
isoprenoid biosynthesis. This chapter suggests that inhibition of receptor-
mediated cellular responses by statins may also be due to blockade of cholesterol 
biosynthesis and subsequent disruption of plasma membrane lipid raft function. 
Membrane rafts are critical to initiation of signal transduction by many ITAM 
bearing immune receptors, including Fcy R and the Band T cell antigen 
receptors279, 315. Following ligation, receptors translocate into rafts where they co-
localise with signal transduction molecules, such as src kinases, adapter proteins 
and PLC-y. Since raft structure and function depends on cholesterol, disruption of 
rafts provides a potential novel mechanism to explain the actions of statins on 
FcyR signalling. Previous studies have shown that chemical extraction of 
membrane cholesterol with methyl-p cyclodextrin disrupts lipid rafts and 
associated receptor mediated signal transduction279, 315. In this model system I 
found that changes in membrane raft content following treatment of cells with 
statin did not reflect either total cellular or cell supernatant cholesterol levels, and 
therefore inhibition of cholesterol biosynthesis may reduce cholesterol within 
specific cellular compartments independently of externally available cholesterol. I 
showed that reductions in the lipid raft associated signalling proteins LAT, Fyn 
and Lyn was reduced in a dose dependent manner by low levels of statin (O.5/J.M) 
that are representative of in vivo concentrations. Disruption of membrane rafts 
was not seen following treatment of cells with inhibitors of prenylation, supporting 
the hypothesis that the effect of statins are independent of prenylated proteins. 
Cell surface receptors numbers were unaltered by statins, therefore the inhibitory 
effects of statins on Fcy R signalling were not due to reduced cell surface receptor 
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Figure 5.11 High concentration of Mj3CD disrupts rafts in NK92MI cells. 
Pooled raft fractions from resting NK92MI cells treated with MPCD were western 
blotted and probed for LAT, Lyn and Fyn (panels on right). Panels on the left 
compare expression levels in whole celllysates. 
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expreSSIOn. The degree of apoptosis induced by statins was minimal and could not 
account for the changes seen in signal transduction in the whole cell population. 
Fluvastatin has been reported to enhance apoptosis in vascular smooth muscle 
cells but only in the presence of exogenous IL-l~316. 
Since other multichain immune recognition receptors (e.g. BCR, TCR) signal 
through membrane rafts, this mechanism is likely to have broad significance in the 
immune system and elsewhere317. 
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chapter 6: FUnctiOnal effects of statins on monocytes 
6.1 Introduction 
The inflammatory nature of atherosclerotic lesions is well established128• These 
lesions contain high levels of immune complexes, including oxidised low density 
lipoprotein immune complexes (oxLDL-IC), and macrophages318• Monocyte-
macrophage Fc receptor activation by immune complexes triggers the production 
of inflammatory cytokines, metalloproteinases319 and superoxide generation, an 
effect that may be inhibited by statins294, 320, 321• However, although IC-mediated 
cell activation has been implicated in the pathogenesis of atherosclerosis, a role for 
statins in the inhibition of Fcy R mediated inflammatory responses had not been 
investigated, nor had the potential effects of statins on other aspects of 
mononuclear cell function. 
The aim of this chapter was to establish the effect of statins on FcR IC activation in 
monocytes. I examined the effect of statins on tyrosine phosphorylation plus Erk 
and P38 signalling pathways (as confirmed in T cells in chapter 4). I then 
examined the effect of statins on functional responses in the U 937 human 
monocyte cellline281 by measuring immune complex trafficking and degradation, 
cytokine release and MMP-l production. Since tyrosine kinase activation is 
independent of prenylated proteins, I hypothesised that statins may limit Fcy R 
signalling and function by disrupting membrane rafts (as shown in chapter 5) and 
therefore reducing release of the inflammatory cytokines and MMP-l, which are 
found in atherosclerotic lesions. Thus inhibition of prenylation, and more likely 
disruption of membrane rafts, in monocytes may contribute to the anti-
atherosclerotic effects of statins. 
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6.2 Results 
6.2.1 Statins impair Fcy receptor initiated tyrosine 
phosphorylation 
6.2. 1. 1 Fluvastatin impairs Fc r receptor initiated tyrosine 
phosphorylation (Figure 6. 1) 
Aggregation of FcyR on U937 cells caused transient tyrosine phosphorylation that 
peaked at 1-2 minutes and normalised by 10 minutes. Pre-treatment for 48 hours 
with fluvastatin (1of.lM) reduced maximal tyrosine phosphorylation by 60% 
without altering the pattern of phosphorylation (Figure 6.1). 
6.2.1.2 Dose dependent inhibition of tyrosine phosphorylation by 
fluvastatin (Figure 6.2) 
U937 cells were cultured for 48 hours in the presence of increasing concentrations 
offluvastatin and FcyR crosslinked for 1.5 min. Inhibition of tyrosine 
phosphorylation was dose dependant (Figure 6.2 A and 6.2 B) and maximal at 5-
20f.lM. 
6.2. 1.3 Time dependant inhibition of tyrosine phosphorylation by 
fluvastatin (Figure 6.3) 
Inhibition of FcyR responses was also time dependent and required pre-incubation 
for 48 hours with 1of.lM fluvastatin, with little inhibition observed after 24 hours 
(Figure 6.3). To determine whether fluvastatin inhibits FcyR responses via 
inhibition of HMG-CoA reductase, mevalonate was added to fluvastatin treated 
cells for the final 12 hours ("mevalonate rescue"). Thus, 1mM mevalonate entirely 
reversed the effects of fluvastatin on tyrosine phosphorylation. 
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Figure 6.1 Characterisation of tyrosine phosphorylation inhibition by 
fluvastatin. 
Anti-pTyr 
U937 cells were cultured for 48 h in control medium or fluvastatin. FcyR were 
crosslinked with human IgG and goat anti-human IgG at 37°C. Tyrosine 
phosphorylated proteins were detected by western blotting with anti-
phosphotyrosine antibody. Fluvastatin treatment reduced levels of tyrosine 
phosphorylation. 
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Figure 6.2 Dose dependent inhibition of tyrosine phosphorylation by fluvastatin. 
(A) U937 cells were cultured for 48 hours in the presence of increasing 
concentrations of fluvastatin. FcyR were crosslinked for 1.5 min and western 
blotted with anti-phosphotyrosine antibody. (B) Blots from three independent 
experiments were assessed for levels of tyrosine phosphorylation by quantitative 
densitometry. Data are expressed as the mean (± SE). 
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Figure 6.3 Time dependant inhibition of tyrosine phosphorylation by j7.uvastatin. 
U937 cells were cultured with lO/-lM fluvastatin for the times indicated. In the last 
lane 1mM mevalonate was added for the final 12 hours. FcyR were crosslinked and 
western blotted with anti phosphotyrosine antibody. 
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6.2. 1.4 FTI and GGTI have no effect on tyrosine phosphorylation 
(Figure 6.4) 
Tyrosine phosphorylation was unaffected by a combination of FTI and GGTI. 
Figure 6-4 compared the ineffectiveness of transferase inhibitors with the 
inhibition by fluvastatin. 
6.2.2 Statins impair Fcy receptor initiated signalling pathways 
Downstream signalling pathways P38 and Erk were also inhibited by statins in the 
same manner as tyrosine phosphorylation. 
6.2.2. 1 Dose dependent inhibition of signalling pathways by 
f/uvastatin (Figure 6.5) 
U937 cells were cultured for 48 hours in the presence of increasing concentrations 
offluvastatin and FcyR crosslinked for 1.5 min. Inhibition ofP38 and Erk 
pathways by fluvastatin were dose dependent (Figure 6.5). 
6.2.2.2 Dose dependent inhibition of signalling pathways by 
simvastatin (Figure 6.6) 
Inhibition of the P38 and Erk pathways by simvastatin were also dose dependent 
(Figure 6.6). 
6.2.2.3 Time dependant inhibition of signalling pathways by 
f/uvastatin (Figure 6.7) 
Inhibition of FcyR responses to P38 was also time dependent and required pre-
incubation for 48 hours with lOJlM fluvastatin, with little inhibition observed after 
24 hours (Figure 6.7). 
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Figure 6.4 No inhibition of tyrosine phosphorylation by FI'I and GGTI 
U937 cells were cultured for 48 hours in lO/-LM FfI and lO/-LM GGTI. FcyR were 
crosslinked for 1.5 min and western blotted with anti-phosphotyrosine antibody. 
Fluvastatin was used as an inhibition positive control for comparison. 
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Figure 6.5 Dose dependent inhibition of signalling pathways by fluvastatin. 
U937 cells were cultured for 48 hours in the presence of increasing concentrations 
of fluvastatin. FcyR were crosslinked for 1.5 min and western blotted. ERK and 
P38 phosphorylation was reduced dose dependently. This was representative of 2 
experiments. 
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Figure 6.6 Dose dependent inhibition of signalling pathways by simvastatin. 
U937 cells were cultured for 48 hours in the presence of increasing concentrations 
of simvastatin. FcyR were crosslinked for 2 min and western blotted. 
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Figure 6.7 Time dependant inhibition of tyrosine phosphory [anon by fiuvastatin. 
U937 cells were cultured with lO/-LM fluvastatin for the times indicated. FcyR were 
crosslinked for 1.5 min and western blotted. Pan ERK was used as a loading 
control. This was representative of 2 experiments. 
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6.2.2.4 FTI and GGTI have no effect on signalling pathways 
(Figure 6.8) 
P38 and Erk signalling pathways were unaffected by a combination of FfI and 
GGTI (Figure 6.8). To determine whether fluvastatin inhibits FcyR responses via 
inhibition of HMG-CoA reductase, mevalonate was added to fluvastatin treated 
cells for the final 24 hours. 1mM mevalonate entirely reversed the effects of 
fluvastatin on P38 and Erk signalling pathways. 
6.2.3 Statins inhibit immune complex trafficking and 
degradation 
6.2.3. 1 10 pM fluvastatin (Figure 6.9) 
Internalisation of immune complexes by U937 cells was partially inhibited by 
10)..tM fluvastatin with an approximate 25% reduction in cell-associated 
radioactivity 15 minutes after crosslinking when compared with control cells 
(Figure 6.9 A). A similar reduction in internalised counts was seen at all time 
points examined. In contrast, fluvastatin treatment almost entirely abolished 
immune complex trafficking (Figure 6.9 B). Thus, in control cells approximately 
20% of total internalised radiolabelled immune complexes were degraded within 1 
hour of receptor aggregation compared with less than 5% in fluvastatin treated 
cells. 
6.2.3.2 Fluvastatin concentration gradient (Figure 6.10) 
Concentrations of fluvastatin as low as 0.51lM significantly inhibited 
internalisation and trafficking with maximal effect at concentrations greater than 
51lM (Figure 6.10). 
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Figure 6.8 No inhibition of signalling pathways by FIT and GGTI 
U937 cells were cultured for 48 hours in lOflM FTI and lOflM GGTI. FcyR were 
crosslinked for the times indicated and western blotted. Fluvastatin was used as 
an inhibition positive control for comparison (lanes 3-5). In the lanes 7-9, lmM 
mevalonate was added for the final 24 hours and reversed the effects of fluvastatin. 
FTI and GGTI together had no effect on the Erk signalling pathway and very little 
effect on the P38 signalling pathway. 
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Figure 6.9. FcrR Immune complex internalisation and trafficking was reduced 
by fiuvastatin. 
U937 cells treated with 10f,tM fluvastatin were coated in human IgG and 
crosslinked with 1251 labelled anti-human IgG for the times indicated. (A) Surface 
bound radiolabelled immune complexes were removed by an acidified PBS (pH 
2.0) wash, to leave internalised complexes. (B) Trichloroacetic acid soluble counts 
in the supernatant were measured and represented immune complexes which had 
been degraded and trafficked out of the cell. In A and B counts were expressed as 
percentages of total counts (±SD) and were representative of 3 experiments. 
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Figure 6.10 Fluvastatin inhibits immune complex trafficking and degradation in 
a dose dependant manner. 
U937 cells were treated with a range of fluvastatin concentrations and crosslinked 
as above. (A) Represents internalised complexes and (B) represents complexes 
which had been degraded and trafficked out of the cell. (C) Trichloroacetic acid 
soluble counts (±SD) from the one hour time point were plotted against fluvastatin 
concentrations to show the reduction in trafficking with increasing concentration. 
This was representative of 2 experiments. 
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6.2.3.3 Simvastatin concentration gradient (Figure 6. 11) 
Concentrations of simvastatin as low as O.5~M also significantly inhibited 
internalisation and trafficking in U937 cells (Figure 6.11). 
6.2.3.4 Fluvastatin time course with mevalonate rescue (Figure 
6.12) 
Internalisation and trafficking was unaffected by short incubation times with 
fluvastatin. At least 48 hours were required to reduce internalisation and 
trafficking. The inhibition was completely reversed by addition of 1mM 
mevalonate 12 hours prior to assays (Figure 6.12). 
6.2.3.5 FTI and GGTI (Figure 6.13) 
Internalisation and trafficking was unaffected by farnesyl transferase and 
geranylgeranyl transferase inhibitors (Figure 6.13). 
6.2.4 Statins block FcyR mediated release of inflammatory 
molecules 
Fcy R mediated release of inflammatory mediators, specifically matrix 
metalloproteinase-1 (MMP-1) and pro-inflammatory cytokines, may contribute to 
the progression of atherosclerotic plaques. I therefore investigated the release of 
MMP-1 and the inflammatory cytokine, IL-6, by U937 cells in response to 
sustained FcyR activation, using heat aggregated insoluble IgG immune complexes 
(HA-IgG)322, 32 3. 
6.2.4.1 Statins inhibit MMP-1 production (Figure 6.14) 
U937 cells constitutively produced low levels of MMP-l. Incubation for 24 hours 
with 10o~g/ml HA-IgG, but not with monomeric IgG, resulted in a large increase 
in MMP-1 release (Figure 6.14). Treatment of cells with 1o~M fluvastatin or 1ol-lM 
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Figure 6.11 Simvastann inhibits immune complex trafficking and degradation in 
a dose dependant manner. 
U937 cells were treated with a range of simvastatin concentrations and crosslinked 
as above. (A) Represents internalised complexes and (B) represents complexes 
which had been degraded and trafficked out of the cell. (C) Trichloroacetic acid 
soluble counts (±SD) from the two hour time point were plotted against 
simvastatin concentrations to show the reduction in trafficking with increasing 
concentration. This was representative of 3 experiments. 
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Figure 6.12 Fluvastatin inhibits immune complex trafficking and degradation in 
a time dependant manner. 
U937 cells were treated with 10flM fluvastatin for various times and crosslinked as 
above. (A) Represents internalised complexes and (B) highlights the five minute 
time point to show the reduction of internalisation with increasing time in 
fluvastatin as well as rescue by mevalonate. (C) Represents complexes which had 
been degraded and trafficked out of the cell. (D) Highlights the trichloroacetic acid 
soluble counts (±SD) from the 90 minute time point to show the reduction in 
trafficking with increasing time in fluvastatin as well as rescue by mevalonate. 
This was an average of 2 experiments. 
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Figure 6.13 FTI and GGTI do not affect immune complex trafficking and 
degredation. 
FTItGGTl 
FTl+GGTI 
U937 cells were treated with farnesyl transferase and/or geranylgeranyl 
transferase inhibitors for 48 hours and crosslinked as before. (A) Represents 
internalised complexes and (B) compares the five minute time point to highlight 
the unaffected internalisation. (C) Represents complexes which had been 
degraded and trafficked out of the cell. (D) Compares the trichloroacetic acid 
soluble counts (±SD) from the 120 minute time point to show the unaffected 
trafficking. This was the average of 3 experiments 
page 161 
7.0 
6.0 
~ 5.0 
a.. 
:!: 4.0 
:!: 
E 3.0 
-~2.0 
1.0 
0.0 
o 
L.. 
....... 
e 
o () 
c/il~)ter 6: FllIlCti01l(1/ (,!fee ts 4 statil ls 01/ III01/0cytcs 
10 Unstimulated . HA-lgG I 
e +Q) e +Q) l-e ....... e ....... 
....... .- Ol....... Ol (9 ~ ro e ~ ro e In 
en ....... 0 en ....... 0 v 
ol enOl ol en- + 
> ol > > ol ol ~ > Q) E > > l-
tt=: ~E EQ) LL 
'+- en en E 
Figure 6.14 Statins block Fey receptor mediated release of MMP-1. 
U937 cells treated for 48 hours and mevalonate for the final 12 hours were 
stimulated with and without lool-lg/ml HA-IgG for 24 hours. Supernatants 
collected were analysed for MMP-1 release by ELISA. This was the average of 2 
experiments (performed in duplicate). 
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simvastatin for 48 hours reduced constitutive MMP-1 release and abolished the 
FcyR stimulated MMP-1 response. MMP-1 responses were restored by 1mM 
mevalonate rescue. 
6.2.4.2 Statins inhibit inflammatory cytokine production 
6.2.4.2.1 Statins and a combination of Farnesyl and geranylgeranyl 
transferase inhibitors, reduce cytokine production (Figure 
6.15) 
U937 cells were also found to release increased levels of IL-6, IL-8 and IL-10 in 
response to HA-IgG, an effect that was abrogated by pre-treatment with 10)lM 
fluvastatin or 10)lM simvastatin. IL-6, IL-8 and IL-10 responses were also 
restored by 1mM mevalonate rescue (Figure 6.15). 
6.2.4.3 Erk and p38 inhibitors (Figure 6.16) 
As I demonstrated that statins largely abolished coupling of FcyR to the MAPKs, 
ERK and P38, the dependence of MMP-1 and IL-6 release on these kinases was 
assessed pharmacologically. Inhibition of the ERK cascade with the MEK 
inhibitor, 50)lM PD98059, entirely abolished both MMP-1 and IL-6 release from 
U937 cells. In contrast, inhibition ofP38 with 5)lM SB203580 was found to block 
IL-6 production but had no effect on MMP-1 release (Figure 6.16). 
6.3 Discussion 
Fcy R mediate several critical functions within the immune system including 
clearance and disposal of immune complexes, antigen presentation and release of 
inflammatory mediators. Since atherosclerotic lesions contain macrophages and 
large amounts of immune complexes such as oxLDL-IC, I was interested to assess 
the effects of statins on FcyR function using a human monocyte cell line. FcyR-
mediated tyrosine phosphorylation was attenuated by fluvastatin and simvastatin 
at therapeutically comparable concentrations without any alteration in the number 
of cell surface receptors. Similarly, fluvastatin and simvastatin were observed to 
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Figure 6.15 Statins block FCrreceptor mediated release of inflammatory 
cytokines. 
U937 cells treated for 48 hours and mevalonate for the final 12 hours were 
stimulated with and without 100flg/ml HA-IgG for 24 hours. Supernatants 
collected were analysed for IL-6, IL-8 and IL-10 release by cytometric bead array 
kit. This was representative of 2 experiments. 
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Figure 6.16 ERK inhibitors block release a/both MMP-1 and IL-6 whereas P38 
inhibitors have no effect on MMP-1 release. 
U937 cells were treated with ERK inhibitor (SOIlM PD980S9) or P38 inhibitor 
(SIlM SB203S80) for 24 hours during stimulation with HA-IgG. Inhibition of the 
ERK cascade with ERK inhibitor abolished both MMP-l and IL-6 release. 
Inhibition of P38 pathway with P38 inhibitor was found to block IL-6 production 
but had no effect on MMP-l release. This was representative of 2 experiments. 
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cause a large reduction in FcyR-mediated immune complex trafficking and 
degradation. Inhibition of immune complex internalisation was also seen but was 
less profound. These effects of statins are of importance as macrophage FcyR-
internalised IC can be targeted for degradation and MHC class II antigen 
presentation to T -cells. The presence of activated CD4+ T -cells and abundant 
expression of MHC class II antigens within atherosclerotic lesions suggest that 
specific cellular immune responses, as well as non-specific inflammatory 
responses, contribute to atherosclerosis324, 325. 
Statins have previously been reported to inhibit production of inflammatory 
mediators (including MCP-1, MMP-9, TNF-a and IL-8) by monocytes153, 320, 321. 
Inhibition by fluvastatin and simvastatin of Fcy R -coupled release of the 
inflammatory mediators, IL-6, IL-8, IL-10 and MMP-1, and associated inhibition 
of the MAP kinases ERK and P38, which lie upstream in this pathway of cytokine 
release, was observed. Classically, coupling of receptors to ERK activation is 
thought to lie downstream of the farnesylated small GTPase, Ras while P38 is 
thought to lie downstream of geranylgeranylated Rho family GTPases30l. 
However, data suggest that FcyR coupling to ERK is independent of Ras326, 327. 
Specific isoprenyl transferase inhibitors had little or no effect on tyrosine 
phosphorylation and the ERK pathway, and associated immune complex 
trafficking and degradation. It is not known whether this is because a Ras 
independent pathway is involved in trafficking and degradation and prenyl 
inhibitors would therefore not have an effect or whether it is cholesterol reduction 
by statins that disrupts rafts and associated signalling pathways. As prenyl 
inhibitors had some effect on cytokine release, these are likely to be a Ras 
dependent pathway, which is disrupted by both prenyl inhibition and cholesterol 
in rafts. Further investigation is required to determine whether statin mediated 
inhibition of Fcy R coupling to these pathways depends on a block in isoprenylation 
to disruption of membrane raft function through blockade of cholesterol synthesis. 
Release ofMMP-1 from U937 cells in response to oxLDL-IC has previously been 
reported 319. Thus, the observation that fluvastatin or simvastatin abolishes MMP-
1 release in response to FcyR stimulation is of particular interest as monocyte 
MMP-1 has been implicated in the destabilisation of atherosclerotic plaques and 
subsequent acute coronary events. Inhibition of MMP-1 release could contribute 
~------- ---------------- - ----------------------------------~~------------------""------------~--"-"-----~---
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to the reported plaque stabilising properties of statins. The finding that fluvastatin 
decreased Fcy R mediated IL-6 production in monocytes is particularly pertinent in 
light of recent clinical data demonstrating that statin therapy results in a 
significant reduction in systemic IL-6 levels in patients with cardiovascular 
disease328 • 
In conclusion, accumulating evidence indicates a multi-factorial mode of action for 
statins in the successful reduction of morbidity and mortality in cardiovascular 
disease. Thus, in addition to lowering LDL-cholesterollevels, statins block 
leukocyte recruitment to atherosclerotic lesions, inhibit monocyte antigen 
processing and production of inflammatory mediators and inhibit release of matrix 
proteases implicated in plaque rupture. To exert these pleiotropic effects statins 
appear to use multiple mechanisms including inhibition of cholesterol (and 
cholesterol rich signalling domains) and isoprenoid synthesis. Perhaps by exerting 
their effects at multiple levels, statins may limit disease progression without 
inhibiting essential cellular or immunological functions. Overall, the data supports 
a potential role for Fc receptors and Ie in the pathophysiology of atherosclerosis, 
and identify a potential effect of statins on membrane rafts that may affect other 
transmembrane receptors and offer novel therapeutic targets in cardiovascular 
disease. 
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7.1 Introduction 
The cell type for which there is most in vivo evidence of statin effect is the natural 
killer (NK) cell. This is a specialised lymphocyte that targets virus-infected and 
malignant cells that do not express MHC class I molecules on the cell surface. 
MHC class I molecules are the ligand for inhibitory receptors on NK cells; thus loss 
of MHC class renders target cells susceptible to the killing machinery and 
activating receptors of NK cells93, 329. Previously, it was thought that NK cells were 
predominantly under inhibitory regulation, but it is now known that activation 
receptors are necessary for cytotoxicity102, 33°. Recent studies have also shown that 
NK cell killing is dependent on membrane rafts, where activation receptors are 
localised, thus offering an explanation for the apparent sensitivity of NK cells to 
statin therapy56, 280, 297, 331• 
The aim of this chapter was to investigate the effects of statins on modification of 
membrane rafts and isoprenylation on T cell and NK cell function. I examined the 
effect of statins on functional responses in primary human T cells by measuring 
CD3 stimulated proliferation. I then examined the effect of statins on functional 
responses in the NK92MI human NK cell line by measuring chromium release in a 
cytotoxicity assay. MPCD and prenyltransferase inhibitors were also utilised to 
determine whether statins affect mainly raft integrity or prenylation of small G 
proteins in NK cells. I hypothesised that statins would interrupt signalling 
pathways by mainly raft disruption to reduce cytotoxicity of NK cells and reduce 
proliferation of T cells. 
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7.2 Results 
7.2.1 T cell proliferation (Figure 7.1) 
Lymphocytes were extracted from normal volunteers and CD3 stimulated T cell 
proliferation measured by tritiated thymidine incorporation (Figure 7.1). 
Mevalonate added in the final 18 hours failed to rescue proliferation. However, 
mevalonate added at the same time as fluvastatin prevented the inhibitory 
response of the fluvastatin. FTI and GGTI had no effect on T cell proliferation. 
7.2.2 Natural killer cells 
I sought to elaborate the relative importance of rafts and isoprenylation in vitro, 
using the immortalised NK cell line - NK-92MI. NK-92MI is an interleukin-2 
independent natural killer cell line derived the NK92 cell line by transfection. NK-
92 cell line was derived from peripheral blood mononuclear cells from a 50-year-
old Caucasian male with rapidly progressive non-Hodgkins's lymphoma. 
7.2.2.1 NK cell surface receptors 
PCR and F ACS were performed to measure some of the known surface receptors of 
NK cells to ensure comparability of the cell line to primary NK cells. 
7.2.2.1.1 PCR (Figure 7.2) 
RNA from NK-92MI and U937 cells were extracted using Trizol and reverse 
transcribed using the SuperScripttm First-Strand Synthesis System for RT-PCR. 
PCR was performed with various settings optimised for each set of primers (Figure 
7.2). NK cells contain mRNA for the classic receptor FCyRIll. 
7.2.2.1.2 FACS (Figure 7.3) 
NK-92MI and U937 cells were incubated with various antibodies and FACS used to 
measure receptor protein on the cell surface (Figure 7.3). This confirmed that the 
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Figure 7.1 Mevalonate rescue ofT cell proliferation. 
T cells obtained from 4 normal volunteers were stimulated by anti-CD3 ab and the 
tritiated thymidine incorporated, measured. Mevalonate added at the start (72 
hours) prevented fiuvastatin exerting an effect. Mevalonate added in the final 18 
hours failed to rescue proliferation. FTI and GGTI had no effect on T cell 
proliferation. This was representative of 2 experiments. 
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Figure 7.2 peR of NK cell receptors. 
RNA was extracted using Trizol and reverse transcribed using the SuperScripttm 
First-Strand Synthesis System for RT-PCR. PCR was performed with various 
settings optimised for each set of primers. U 937 cells were used as a PCR control. 
NK cells contain mRNA for: FcyRI, FcyRIIA, FeyRIIB, FcyRIII, Fea/!-lR and the 
gamma chain. 
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Figure 7-3 FACS ofNK cell receptors 
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NK-92MI and U937 cells were incubated with various antibodies and FACS used to 
measure receptor protein on the cell surface. Mean fluorescence intensities were 
plotted. NK cells do not express the classical FcyRIn on their surface. This was 
the average of 2 experiments. 
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NK-92MI cell line does not express FcyRIll on its surface even though message is 
made. 
7.2.2.2 NK Proliferation 
NK-92 cells were assessed for effects on proliferation by "AlamarBlue" assay. 
7.2.2.2.1 Statin concentration gradient (Figure 7.4) 
NK-92MI cells were treated with various concentrations offluvastatin or 
simvastatin (Figure 7-4). Proliferation was reduced slightly with increasing 
concentrations of statin. 
7.2.2.2.2 Mevalonate rescue (Figure 7.5) 
NK-92MI cells were treated with lOJ.!M fluvastatin or simvastatin with ImM 
mevalonate added at 24,48 and 72 hour time points (Figure 7.5). Mevalonate 
added at the same time as statin prevented any inhibition of proliferation. 
Mevalonate added 24 hours and 48 hours after statin treatment did not rescue the 
limited inhibition by statin 
7.2.2.2.3 FTI and GGTI (Figure 7.6) 
NK-92MI cells were treated with various concentrations ofFfI and/or GGTls, but 
had no effect on proliferation (Figure 7.6). 
7.2.2.3 NK Cytotoxicity 
Chromium release assay was performed to assess the effects of cholesterol 
disruption on NK lysis of 51 Chromium labelled Ks62 target cells. A ratio of 5 NK 
cells to 1 target cell was used. 
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Figure 7.4 Statins minimally reduce proliferation of NK-92MI cells in a dose 
dependent manner. 
NK-92MI cells were treated with increasing concentrations of fluvastatin or 
simvastatin for 48 hours. Higher concentrations of each statin reduced 
proliferation slightly. This was an average of 2 experiments performed in 
replicates if 4. 
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Figure 7.5 Mevalonate rescues inhibition ofNKproliferation by stanns. 
NK-92MI cells were treated with lO).lM fluvastatin or simvastatin for 72 hours with 
ImM mevalonate added at various time points. Mevalonate added at the same 
time as statin prevented any inhibition of proliferation. This was representative of 
2 experiments performed in replicates of 6. 
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Figure 7-6 FIT and/or GGTI does not affect NK proliferation. 
NK-92MI cells were treated with FrI and GGTI in increasing concentrations for 48 
hours with no effect. This was the average of 2 experiments performed in 
replicates of 5. 
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7.2.2.3.1 Statin concentration gradient (Figure 7.7) 
Pre-incubation of NK-92MI cells with either fluvastatin or simvastatin reduced NK 
killing of K-562 cells in a dose dependent manner (Figure 7.7). Simvastatin was 
more potent than fluvastatin; both compounds caused 50% inhibition of 
cytotoxicity at concentrations of 5-10 flM. 
7.2.2.3.2 Mevalonate rescue (Figure 7.8) 
The effects of statin could be fully reversed by pre-incubation of cells with 
mevalonate (Figure 3). A minimum of 24 hours pre-incubation was required for 
full reversal of statin effects; shorter incubations had limited, time-dependent 
effects (data not shown). (Figure 7.8) 
7.2.2.3.3 FTI and GGTI (Figure 7.9) 
NK -92MI cells were treated with various concentrations of FTI and/or GGTIs, but 
had no effect on cytotoxicity (Figure 7.9) 
7.2.2.3.4 M~CD (Figure 7.10) 
The relationship with membrane cholesterol was investigated further by 
incubation with M~CD. At high concentrations this facilitates the depletion of 
membrane cholesterol, associated with reduced NK cell cytotoxicity (Figure 7.10 
A). In the presence of cholesterol in the culture media, however, low 
concentrations increase internalisation of extracellular cholesterol that is likely to 
explain the increase in NK cell cytotoxicity. The biphasic response of NK cells to 
M~CD was reduced by omission of serum from the culture medium (Figure 7.10 
B). 
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Figure 7-7 Statins reduce NK cytotoxicity in NK-92MI cells in a dose dependent 
manner. 
NK-92 cells were treated with increasing concentrations of fluvastatin or 
simvastatin for 48 hours. Cell numbers were adjusted to account for proliferation 
difference and cytotoxicity assay performed in replicates of 6. This was 
representative of 2 experiments. 
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Figure 7-8 Mevalonate rescues statin inhibition ofNK cytotoxicity. 
NK cells were incubated with lo~M fluvastatin or simvastatin with mevalonate 
added at various time points. The effect of statin was fully reversed by pre-
incubation of cells with mevalonate. A minimum of 24 hours pre-incubation was 
required for full reversal of statin effects; shorter three hour incubations had no 
effect. This was representative of 2 experiments performed in replicates of 6. 
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Figure 7.9 FTI and CCTI does not affect NK cytotoxicity in NK-92MI cells. 
NK-92MI cells were treated with increasing concentrations of FTI and GGTI for 48 
hours with no effect. This was the average of 2 experiments performed in 
replicates of 6. 
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Figure 7.10 High doses ofMfJCD reduced cytotoxicity ofNK-92MI cells and low 
doses increased cytotoxicity when cultured in media containing cholesterol. 
NK-92MI cells were treated with various concentrations of MBCD in culture media 
with or without FCS for one hour. At high concentrations membrane cholesterol 
was depleted resulting in reduced NK cytotoxicity. The presence of cholesterol in 
the culture media, however, increased internalisation of extracellular cholesterol at 
low concentrations of MBCD and probably caused the increase in NK cell 
cytotoxicity (A). The increase at low MBCD concentrations was abolished by 
omission of serum (and therefore extracellular cholesterol) from the culture 
medium (B). 
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7.3 Discussion 
The effects of statins have been proposed to be independent of changes in 
circulating cholesterol and to be due to reduction of isoprenoid intermediates in 
the cholesterol biosynthetic pathway280, 300. Isoprenoids play key roles in various 
aspects of cellular function, specifically the transport and incorporation of lipid 
insoluble peptides into the cell membrane46, 332, 333. Many of these peptides - for 
example, small G-proteins such as Ras - are involved in membrane signalling and 
are concentrated within membrane rafts40, 56, 297, 333. These signal platforms are 
dependent on the production of intracellular cholesterol and the recycling of 
extracellular cholesterol. The prevailing view - that inhibition of isoprenylation 
explains the pleiotropic effects of statins - is reliant on studies where the inhibitory 
effects of statins were replaced by the addition of mevalonate, farnesyl 
pyrophosphate or geranylgeranyl pyrophosphate. However, mevalonate will 
restore synthesis of all components of the mevalonate pathway distal to HMG-CoA 
reductase including cholesterol and, since some of the reactions in this pathway 
are potentially bi-directional, addition of isoprenoids may have a similar effect. 
Although statins are known to deplete membrane rafts331, 334 the notion that this 
may explain the pleiotropic effects of statins has received little attention. The 
alternative hypothesis - that modification of lipid rafts is the central effect - has 
found favour amongst nutritionalists to explain the immunomodulatory effects of 
lipid modifying agents, such as fish oils297. 
A unifying hypothesis would be that membrane and plasma cholesterol (and the 
density of membrane rafts) may change in parallel. Thus, a treatment that lowers 
circulating cholesterol is likely to reduce membrane cholesterol and, 
correspondingly, cell functions that are dependent on membrane cholesterol (and 
cholesterol rafts). The data provides some preliminary support for this hypothesis. 
Potential mechanisms were investigated in a series of in vitro studies using an 
immortalised NK cell line. Depletion of membrane cholesterol using M~CD at 
high concentrations resulted in reduced NK cell cytotoxicity. Lower 
concentrations produced a small, reproducible and unexpected increase in NK cell 
killing. A possible explanation for this is that M~CD increases internalisation of 
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cholesterol at low concentrations314 due to its three dimensional structure, and the 
effect was not seen in the absence of extracellular cholesterol. Exposure to statins 
had a similar effect that could not be reproduced by inhibitors of farnesyl and 
geranylgeranyl transferase332. Again, this is consistent with an effect mediated by 
reduction in membrane cholesterol rather than isoprenylation297. Western 
blotting of whole cell membrane and membrane raft fractions were used to 
determine whether depletion of raft cholesterol was likely (Chapter 5, Figure 5.6 
and 5.11). Both statin and M~CD treated cells showed reduced quantities of signal 
peptides known to be localised in rafts - specifically LAT and Lyn - consistent with 
reduction in rafts and raft-associated proteins. 
NK cells may provide an accessible cell type and the relationship between lipids 
and immune cell function297-299 may be applicable to all cells. 
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chayler 8: General discussion 
The beneficial effects of statin therapy in the treatment of cardiovascular disease 
are well documented177, 179, 193, 203. Although these are likely to be mediated in a 
large part by the reduction in cholesterol, there is increasing evidence to suggest 
that inhibition of inflammatory mechanisms may also be important. Some of the 
beneficial effects of statins have been proposed to be independent of changes in 
circulating cholesterol and to be due to reduction of isoprenoid intermediates in 
the cholesterol biosynthetic pathway280,300. Isoprenoids (and isoprenylation) play 
key roles in various aspects of cellular function, specifically membrane 
translocation of lipid insoluble peptides into the cell membrane46, 332, 333. Many of 
these peptides, for example Ras and Rho families of GTPases, are involved in 
membrane signalling and are concentrated within membrane rafts40, 56, 297, 333. 
These signal platforms are dependent on the production of intracellular cholesterol 
and the recycling of extracellular cholesterol. The common view, that inhibition of 
isoprenylation explains the pleiotropic effects of statins, is reliant on studies where 
the inhibitory effects of statins were replaced by the addition of mevalonate, 
farnesyl pyrophosphate or geranylgeranyl pyrophosphate. However, mevalonate 
will restore synthesis of all components of the mevalonate pathway distal to HMG-
eoA reductase including cholesterol and, since some of the reactions in this 
pathway are potentially bi-directional, addition of isoprenoids may have a similar 
effect. 
An alternative hypothesis would be that membrane and plasma cholesterol (and 
the density of membrane rafts) may change in parallel. Thus, a treatment that 
lowers circulating cholesterol is likely to reduce membrane cholesterol and, 
correspondingly, cell functions that are dependent on membrane cholesterol (and 
cholesterol rafts). This thesis provides some preliminary support for this 
hypothesis and is in keeping with the findings from meta-analysis of clinical 
studies suggesting that the benefit of statin therapy on cardiovascular outcomes is 
primarily due to the direct effect of lowering serum cholesterol and hence cell 
membrane cholestero1335. 
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This thesis hypothesised that the pleiotropic effects of statins would reduce 
lymphocyte functions of T cell proliferation and NK cytotoxicity in vivo and in 
vitro and reduce monocyte functions of cytokine release and Ie trafficking and 
degradation. It also aimed to determine the mechanism of immunosuppressive 
and anti-inflammatory actions of statins by identifying the signalling pathways 
involved and the mode of disruption whether membrane raft depletion or prenyl 
inhibition. 
The in vivo studies of chapter 3 confirmed the benefits of statins in lowering 
cholesterol and raising HDL. Even in the normal volunteer study, with lipid levels 
much lower than the majority of patients in clinical trials a significant reduction in 
LDL cholesterol and increase in HDL cholesterol was observed. In vivo, T cell 
proliferation was reduced in the cardiovascular patients study and statistically 
insignificantly in the normal volunteer study. The absence of an effect on T cell 
proliferation is consistent with the absence of infection rates in large-scale trials177, 
179,193, 203. Alternatively it could reflect the insensitivity of the assay system or the 
fact that T cell proliferation is such an important biological response that it may 
bypass inhibition of a single signalling mechanism. 
Natural killer cell function is, however, more sensitive to in vivo statin use250, 285. 
A clear reduction in NK cytotoxicity was observed in the normal volunteers, which 
was reversed by withdrawal from statin therapy. A similar reduction was also 
obtained in the cardiovascular patients. The changes in cell function paralleled 
those changes in LDL-cholesterol, reflecting the influence of statin therapy. As 
with lymphocyte proliferation, there may be differences in sensitivity of the assay 
making it is easier to detect a reduction in NK cell killing than in lymphocyte 
proliferation. Alternatively, NK cell activation and killing may be more susceptible 
to blockade of statin dependent signalling pathways, whether they be dependent 
on isoprenoids or membrane rafts. Sanni et al56 suggest that NKG2A inhibitory 
receptors are excluded from lipid rafts and therefore prevents formation of 
activation signalling complexes. As activating signals require membrane rafts, 
disruption of lipid rafts by statins would therefore allow inhibitory receptors to 
dominate and maintain NK cells in a non-cytotoxic state. The dependence on 
membrane rafts for activating signals may explain why the ex vivo NK cytotoxicity 
assay was so sensitive to statin treatment. 
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After showing that statins reduce NK cell cytotoxicity in vivo, the possibility that 
this may reflect an underlying relationship between cholesterol synthesis, 
membrane cholesterol and cell function was then considered297. In the NK study, 
we found that statin treated patients did not have lower NK cell cytotoxicity than 
non-statin treated patients but that the overall relationship was with total 
cholesterol (Chapter 3.10; Table 3.2). The patient selection for this study was not 
focused on one particular group but was deliberately wide-ranging to provide a 
spectrum of age, underlying disease and drug therapy to allow comparison of 
potential influences. The analysis was preliminary and power calculations were 
not performed, as these were pilot studies. The information gained will require 
further investigation and be used to power larger, more homogeneous clinical 
studies. However, the findings concur with the normal volunteer study where 
there was a close relationship between reduction in NK cell cytotoxicity and lipid 
levels in normal subjects receiving statins. The meta-analysis by Baigent et al277 
also confirms these findings. The authors concluded that the risk reductions were 
proportional to the absolute reductions in LDL cholesterol. Thus, rather than 
being due to the pleiotropic effects of statin treatment, this change may be a 
consequence of changes in cholesterol levels, both in the circulation and in the cell 
membrane. 
The potential mechanisms were investigated in a series of in vitro studies using an 
immortalised NK cell line. Depletion of membrane cholesterol using MpCD at 
high concentrations resulted in reduced NK cell cytotoxicity. Exposure to statins 
had a similar effect that could not be reproduced by inhibitors of farnesyl and 
geranylgeranyl transferase332• Again, this is consistent with an effect mediated by 
reduction in membrane cholesterol rather than isoprenylation297• Western 
blotting of whole cells and membrane raft fractions were used to determine 
whether depletion of raft cholesterol was likely. Both statin and MPCD treated 
cells showed reduced quantities of signal peptides known to be localised in rafts 
(i.e. LAT and Lyn) consistent with reduction in rafts and raft-associated proteins. 
Although these were small-scale, pilot studies that recruited normal subjects and 
patients over a wide age range, a range of drug therapy and underlying pathology, 
it poses questions about the relationship between circulating lipids and membrane 
lipids, and the wider effects on cell membrane structure and signalling. NK cells 
-----------------------------_._-------- --------------
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may simply provide an accessible cell type and the relationship between lipids and 
immune cell function298, 314 may be applicable to all cells. 
Monocyte Fcy R mediate several critical functions within the immune system 
including clearance and disposal of immune complexes, antigen presentation, and 
release of inflammatory mediators, that may be involved in atherosclerosis336. 
Chapter 6 demonstrates that fluvastatin causes a large reduction in FcyR-mediated 
immune complex trafficking and degradation and, to a lesser extent, IC 
internalisation. FcyR-mediated tyrosine phosphorylation was attenuated by 
fluvastatin at therapeutic concentrations without altering the number of receptors. 
These effects are important as macrophage FcyR-internalised IC can be degraded 
and MHC class II antigen presented to T-cells. The presence of activated CD4+ T-
cells and increased MHC class II expression within atherosclerotic lesions suggest 
that specific cellular immune responses, as well as non-specific inflammatory 
responses, contribute to atherosclerosis325 and then thus be inhibited by statins. 
Statins have previously been reported to inhibit production of inflammatory 
mediators (including MCP-i, MMP-9, TNF-a and IL-8) by monocytes153, 320, 321. 
The FcyR-coupled release ofthe inflammatory mediators, IL-6 and MMP-i, and 
associated inhibition of the MAP kinases ERK and P38, which lie upstream in this 
pathway of cytokine release were inhibited by fluvastatin and simvastatin. 
Coupling of receptors to ERK activation lies downstream of the farnesylated small 
GTPase, Ras whilst P38 is downstream of geranyl-geranylated Rho family 
GTPases301. However, recent data suggest that FcyR coupling to ERK is 
independent of Ras326 and further investigation is required to determine whether 
statin mediated inhibition of Fcy R coupling to these pathways depends on a block 
in isoprenylation or to disruption of membrane raft function through blockade of 
cholesterol synthesis. 
Release ofMMP-i from U937 cells in response to oxLDL-IC has previously been 
reported319. Thus, the observation that fluvastatin abolishes MMP-i release in 
response to FcyR stimulation is of particular interest as monocyte MMP-i has been 
implicated in the destabilisation of atherosclerotic plaques and subsequent 
coronary events. The finding that fluvastatin decreased FcyR mediated IL-6 
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production in monocytes is pertinent in light of recent data that statins reduced 
systemic IL-6 levels in patients with cardiovascular disease328. 
Membrane rafts are critical to initiation of signal transduction by many ITAM 
bearing immune receptors, including Fcy R and the Band T cell antigen 
receptors279, 315. Following ligation, receptors translocate into rafts where they co-
localise with signal transduction molecules, such as src kinases, adapter proteins 
and PLC-y. Since raft structure and function depends on cholesterol, disruption of 
rafts provides a potential novel mechanism to explain the actions of statins on 
FcyR signalling. Raft dependent FcyR mediated signaling is inhibited in a time 
and dose dependent manner by low levels of fluvastatin (O.5~M) that are 
representative of in vivo concentrations337, with parallel reductions in the lipid raft 
associated signaling proteins LAT and Lyn. Disruption of membrane rafts was not 
seen following treatment of cells with inhibitors of prenylation, supporting the 
hypothesis that this effect of fluvastatin is independent of prenylated proteins. 
Since other multichain immune recognition receptors (e.g. BCR, TCR) signal 
through membrane rafts this mechanism is likely to have broad significance in the 
immune system and elsewhere317. 
Accumulating evidence indicates a multifactorial mode of action for statins in the 
reduction of morbidity and mortality from cardiovascular disease. Thus, in 
addition to lowering LDL-cholesterollevels, statins block leukocyte recruitment to 
atherosclerotic lesions, reduce NK functions, inhibit monocyte antigen processing 
and production of inflammatory mediators and inhibit release of matrix proteases 
implicated in plaque rupture. Multiple mechanisms are likely to underlie these 
diverse effects including inhibition of cholesterol and isoprenoid synthesis, and 
disruption of cholesterol rich signalling domains. Statins may confer 
cardiovascular benefit without inhibiting essential cellular or immunological 
functions. NK cells have been implicated in atherosclerosis and are known to 
target cells that do not express HLA class I on the cell surface, including cells that 
have been infected by viruses285, 295. Whether this effect on NK cells contributes to 
the overall beneficial effects of statin therapy in cardiovascular disease is not clear 
and will require further investigation. However, the mechanism by which statins 
inhibit NK cell killing is likely to provide an insight into the signalling mechanisms 
disrupted by statin therapy and that contribute to their pleiotropic effects in other 
-~"-----------~~.~------- ---~------------~----------------~----~-------~--------
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cell types86, 239. The data also support a potential role for Fc receptors and Ie in 
the pathophysiology of atherosclerosis, and identify a novel effect of fluvastatin on 
membrane raft function that may also be relevant for other transmembrane 
receptors in cardiovascular and other diseases. 
This thesis had some limitations. Some western blots and cytokine assays were 
performed twice resulting in small n values. It would have been preferable to 
perform multiple repeats to measure intra and inter assay co-efficients of 
variations for each assay to increase their reproducibility. However, intra assay 
variabilities were small and large variabilities of some inter assay values prevented 
meaningful statistics being performed, although the patterns emerged were 
comparable. 
Work I would like to perform in the future includes development of the 
measurement of membrane lipid rafts in vivo. Although the initial studies 
(Figures 3.7 and 3.8) were statistically insignificant, improvement of the raft 
extraction technique and larger numbers would improve the statistical outcome. 
Large scale clinical studies on groups of patients with differing lipid lowering 
treatments could be used to determine whether reduction of serum cholesterol is 
responsible for disruption of lipids in membrane rafts rather than intracellular 
biosynthesis. NK cells could be used as a model to relate the quantity and quality 
of lipid rafts, reduced by various lipid lowering treatments, to clinical outcomes or 
risk of disease. This work could therefore identify a mechanism for the 
conclusions of Baigent et a12 77• 
8.1 Conclusions 
In conclusion, this thesis has demonstrated that statins have a multitude of 
applications and effects. The pleiotropism of statins due to reduced prenylation 
was observed in vitro by western blot in multiple signalling pathways and 
confirmed with the use of FT and GGT inhibitors in these pathways. However, the 
lack of functional effect of FT and GGTIs indicated that prenylation has a lesser 
impact on the functions of immune effector cells than cholesterol depletion of 
rafts. The link between plasma cholesterol and raft functions may have wide 
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varying implications. The comparable results obtained with M~CD indicated that 
the reduction of cholesterol in the membrane by statins was disrupting rafts and 
therefore disrupting signalling pathways to a greater extent than prenylation 
inhibition. It is however likely to be a combination of both processes that 
contributes to the pleiotropic effect of statins. 
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